Clustering O O
of O O
missense O O
mutations O O
in O O
the O O
ataxia B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
telangiectasia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O O
in O O
a O O
sporadic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
T I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cell I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
leukaemia I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Ataxia B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
telangiectasia I I_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
is O O
a O O
recessive B B_DISEASE/B_GENE
multi I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
system I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
caused O O
by O O
mutations O O
in O O
the O O
ATM O O
gene O O
at O O
11q22 O O
- O O
q23 O O
( O O
ref O O
. O O
3 O O
) O O
. O O

The O O
risk O O
of O O
cancer B B_DISEASE
, O O
especially O O
lymphoid B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neoplasias I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
is O O
substantially O O
elevated O O
in O O
A B B_DISEASE/B_MEASURE
- I I_DISEASE/I_MEASURE
T I I_DISEASE/I_MEASURE
patients O O
and O O
has O O
long O O
been O O
associated O O
with O O
chromosomal O O
instability O O
. O O

By O O
analysing O O
tumour B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O O
from O O
patients O O
with O O
sporadic B B_DISEASE/B_GENE
T I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
cell I I_DISEASE/I_GENE
prolymphocytic I I_DISEASE/I_GENE
leukaemia I I_DISEASE/I_GENE
( O O
T B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
PLL I I_DISEASE/I_LOCATION
) O O
, O O
a O O
rare O O
clonal B B_DISEASE
malignancy I I_DISEASE
with O O
similarities O O
to O O
a O O
mature B B_DISEASE/B_MEASURE
T I I_DISEASE/I_MEASURE
- I I_DISEASE/I_MEASURE
cell I I_DISEASE/I_MEASURE
leukaemia I I_DISEASE/I_MEASURE
seen O O
in O O
A B B_PERSON/B_BIO
- I I_PERSON/I_BIO
T I I_PERSON/I_BIO
, O O
we O O
demonstrate O O
a O O
high O O
frequency O O
of O O
ATM O O
mutations O O
in O O
T B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
PLL I I_DISEASE/I_PERSON
. O O

In O O
marked O O
contrast O O
to O O
the O O
ATM O O
mutation O O
pattern O O
in O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
most O O
frequent O O
nucleotide O O
changes O O
in O O
this O O
leukaemia B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
missense O O
mutations O O
. O O

These O O
clustered O O
in O O
the O O
region O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
corresponding O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
to O O
the O O
kinase O B_GENE/B_LOCATION
domain O I_GENE/I_LOCATION
, O O
which O O
is O O
highly O O
conserved O O
in O O
ATM O B_GENE/B_DISEASE
- O O
related O O
proteins O B_LOCATION/B_DISEASE
in O O
mouse O B_SPECIES[BIO]/B_DISEASE
, O O
yeast O B_SPECIES[BIO]
and O O
Drosophila O B_SPECIES[BIO]/B_PERSON
. O O

The O O
resulting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
acid O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substitutions O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
predicted O O
to O O
interfere O O
with O O
ATP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
binding O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
or O O
substrate O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Two O O
of O O
seventeen O O
mutated O O
T B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
PLL I B_DISEASE/I_GENE
samples O O
had O O
a O O
previously O O
reported O O
A B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele O O
. O O

In O O
contrast O O
, O O
no O O
mutations O O
were O O
detected O O
in O O
the O O
p53 O O
gene O O
, O O
suggesting O O
that O O
this O O
tumour B B_DISEASE/B_GENE
suppressor O O
is O O
not O O
frequently O O
altered O O
in O O
this O O
leukaemia B B_DISEASE/B_PERSON
. O O

Occasional O O
missense O O
mutations O O
in O O
ATM O O
were O O
also O O
found O O
in O O
tumour B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O O
from O O
patients O O
with O O
B B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
cell I I_DISEASE/I_GENE
non I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Hodgkins I I_DISEASE/I_GENE
lymphomas I I_DISEASE/I_GENE
( O O
B B B_DISEASE
- I I_DISEASE
NHL I I_DISEASE
) O O
and O O
a O O
B B B_DISEASE
- I I_DISEASE
NHL I I_DISEASE
cell O O
line O O
. O O

The O O
evidence O O
of O O
a O O
significant O O
proportion O O
of O O
loss O O
- O O
of O O
- O O
function O O
mutations O O
and O O
a O O
complete O O
absence O O
of O O
the O O
normal O O
copy O O
of O O
ATM O O
in O O
the O O
majority O O
of O O
mutated O O
tumours B B_DISEASE/B_BIO
establishes O O
somatic O O
inactivation O O
of O O
this O O
gene O O
in O O
the O O
pathogenesis O O
of O O
sporadic B B_DISEASE
T I I_DISEASE
- I I_DISEASE
PLL I I_DISEASE
and O O
suggests O O
that O O
ATM O O
acts O O
as O O
a O O
tumour B B_DISEASE
suppressor O O
. O O

As O O
constitutional O O
DNA O O
was O O
not O O
available O O
, O O
a O O
putative O O
hereditary O O
predisposition O O
to O O
T B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
PLL I I_DISEASE/I_LOCATION
will O O
require O O
further O O
investigation O O
. O O
. O O

Myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein O O
kinase O O
is O O
involved O O
in O O
the O O
modulation O O
of O O
the O O
Ca2 O O
+ O O
homeostasis O O
in O O
skeletal O O
muscle O O
cells O O
. O O

Myotonic B B_DISEASE/B_LOCATION
dystrophy I I_DISEASE/I_LOCATION
( O O
DM B B_LOCATION/B_ORGANIZATION
) O O
, O O
the O O
most O O
prevalent O O
muscular B B_DISEASE
disorder I I_DISEASE
in O O
adults O O
, O O
is O O
caused O O
by O O
( O O
CTG O O
) O O
n O O
- O O
repeat O O
expansion O O
in O O
a O O
gene O O
encoding O O
a O O
protein O O
kinase O O
( O O
DM B B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
kinase O O
; O O
DMPK O O
) O O
and O O
involves O O
changes O O
in O O
cytoarchitecture O O
and O O
ion O O
homeostasis O O
. O O

To O O
obtain O O
clues O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
normal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DMPK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ion O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
homeostasis O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
we O O
have O O
compared O O
the O O
resting O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca2 O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O O
i O O
, O O
the O O
amplitude O B_MEASURE/B_LOCATION
and O O
shape O B_MEASURE
of O O
depolarization O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
induced O O
Ca2 O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transients O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
content O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
ATP O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
driven O O
ion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pumps O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
skeletal O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
wild O B_BIO/B_GENE
- O O
type O B_TIME[MEASURE]/B_BIO
and O O
DMPK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
/ O O
- O O
] O B_SPECIES[BIO]/B_GENE
knockout O I_SPECIES[BIO]/I_GENE
mice O I_SPECIES[BIO]/I_GENE
. O O

In O O
vitro O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
differentiated O O
DMPK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
/ O O
- O O
] O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
myotubes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O O
a O O
higher O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resting O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
[ O O
Ca2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
] O O
i O O
than O O
do O O
wild O B_PERSON/B_BIO
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
myotubes O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
because O O
of O O
an O O
altered O O
open O B_MEASURE
probability O I_MEASURE
of O O
voltage O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
dependent O B_MEASURE/B_DISEASE
l O I_MEASURE/I_DISEASE
- O O
type O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Ca2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O O
Na O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channels O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
mutant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
myotubes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O O
smaller O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
slower O B_MEASURE
Ca2 O I_MEASURE
+ O O
responses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upon O O
triggering O O
by O O
acetylcholine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
high O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
external O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
K O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
we O O
observed O O
that O O
these O O
Ca2 O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O O
transients O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O O
result O O
from O O
an O O
influx O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
extracellular O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca2 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O O
the O O
l O B_PROTEIN[GENE]/B_DISEASE
- O O
type O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
Ca2 O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
+ O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
channel O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Neither O O
the O O
content O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O O
the O O
activity O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
Na O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ O O
K O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ATPase O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
sarcoplasmic O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Ca2 O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
ATPase O B_ENZYME[GENE]
are O O
affected O O
by O O
DMPK O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
absence O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

In O O
conclusion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
DMPK O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
involved O O
in O O
modulating O O
the O O
initial O B_MEASURE/B_LOCATION
events O I_MEASURE/I_LOCATION
of O O
excitation O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
contraction O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
coupling O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O O
skeletal O B_BODY_PART_OR_ORGAN_COMPONENT
muscle O I_BODY_PART_OR_ORGAN_COMPONENT
. O O
. O O

Constitutional O O
RB1 O O
- O O
gene O O
mutations O O
in O O
patients O O
with O O
isolated O O
unilateral B B_DISEASE/B_GENE
retinoblastoma I I_DISEASE/I_GENE
. O O

In O O
most O O
patients O O
with O O
isolated O O
unilateral B B_DISEASE/B_GENE
retinoblastoma I I_DISEASE/I_GENE
, O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
development O O
is O O
initiated O O
by O O
somatic O O
inactivation O O
of O O
both O O
alleles O O
of O O
the O O
RB1 O O
gene O O
. O O

However O O
, O O
some O O
of O O
these O O
patients O O
can O O
transmit O O
retinoblastoma B B_DISEASE/B_GENE
predisposition O O
to O O
their O O
offspring O O
. O O

To O O
determine O O
the O O
frequency O O
and O O
nature O O
of O O
constitutional O O
RB1 O O
- O O
gene O O
mutations O O
in O O
patients O O
with O O
isolated O O
unilateral B B_DISEASE
retinoblastoma I I_DISEASE
, O O
we O O
analyzed O O
DNA O O
from O O
peripheral O O
blood O O
and O O
from O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O O
. O O

The O O
analysis O O
of O O
tumors B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
54 O O
( O O
71 O O
% O O
) O O
of O O
76 O O
informative O O
patients O O
showed O O
loss O O
of O O
constitutional O O
heterozygosity O O
( O O
LOH O O
) O O
at O O
intragenic O O
loci O O
. O O

Three O B_NUMBER[MEASURE]
of O O
13 O B_PERSON
uninformative O I_PERSON
patients O I_PERSON
had O O
constitutional O B_DISEASE
deletions O I_DISEASE
. O O

For O O
39 O O
randomly O O
selected O O
tumors B B_DISEASE/B_PERSON
, O O
SSCP O O
, O O
hetero O O
- O O
duplex O O
analysis O O
, O O
sequencing O O
, O O
and O O
Southern O O
blot O O
analysis O O
were O O
used O O
to O O
identify O O
mutations O O
. O O

Mutations O O
were O O
detected O O
in O O
21 O O
( O O
91 O O
% O O
) O O
of O O
23 O O
tumors B B_DISEASE/B_PERSON
with O O
LOH O O
. O O

In O O
6 O O
( O O
38 O O
% O O
) O O
of O O
16 O O
tumors B B_DISEASE/B_PERSON
without O O
LOH O O
, O O
one O O
mutation O O
was O O
detected O O
, O O
and O O
in O O
9 O O
( O O
56 O O
% O O
) O O
of O O
the O O
tumors B B_DISEASE/B_MEASURE
without O O
LOH O O
, O O
both O O
mutations O O
were O O
found O O
. O O

Thus O O
, O O
a O O
total O O
of O O
45 O O
mutations O O
were O O
identified O O
in O O
tumors B B_MEASURE
of O O
36 O O
patients O O
. O O

Thirty O B_NUMBER[MEASURE]
- O O
nine O B_NUMBER[MEASURE]
of O O
the O O
mutations O B_DISEASE/B_GENE
- O O
including O O
34 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
small O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
2 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
large O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
structural O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
alterations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
and O O
hypermethylation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
3 O B_DISEASE/B_GENE
tumors O B_DISEASE/I_GENE
- O O
were O O
not O O
detected O O
in O O
the O O
corresponding O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
peripheral O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
blood O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

In O O
6 O B_MEASURE
( O O
17 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
of O O
the O O
36 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
, O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
was O O
detected O O
in O O
constitutional O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
1 O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
is O O
known O O
to O O
be O O
associated O O
with O O
reduced O O
expressivity O B_DISEASE/B_ORGANISM_FUNCTION
. O O

The O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
constitutional O B_DISEASE
mutation O I_DISEASE
was O O
not O O
associated O O
with O O
an O O
early O B_DISEASE_ADJECTIVE[DISEASE]
age O I_DISEASE_ADJECTIVE[DISEASE]
at O O
treatment O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O O

In O O
1 O B_MEASURE/B_PERSON
patient O I_MEASURE/I_PERSON
, O O
somatic O B_DISEASE/B_GENE
mosaicism O I_DISEASE/I_GENE
was O O
demonstrated O O
by O O
molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
RNA O B_GENE/B_BIO
from O O
peripheral O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O O

In O O
2 O O
patients O O
without O O
a O O
detectable O O
mutation O O
in O O
peripheral O O
blood O O
, O O
mosaicism O O
was O O
suggested O O
because O O
1 O O
of O O
the O O
patients O O
showed O O
multifocal O O
tumors B B_DISEASE
and O O
the O O
other O O
later O O
developed O O
bilateral B B_DISEASE
retinoblastoma I I_DISEASE
. O O

In O O
conclusion O O
, O O
our O O
results O O
emphasize O O
that O O
the O O
manifestation O O
and O O
transmissibility O O
of O O
retinoblastoma B B_DISEASE/B_GENE
depend O O
on O O
the O O
nature O O
of O O
the O O
first O O
mutation O O
, O O
its O O
time O O
in O O
development O O
, O O
and O O
the O O
number O O
and O O
types O O
of O O
cells O O
that O O
are O O
affected O O
. O O
. O O

Hereditary B B_DISEASE
deficiency I I_DISEASE
of I I_DISEASE
the I I_DISEASE
fifth I I_DISEASE
component I I_DISEASE
of I I_DISEASE
complement I I_DISEASE
in O O
man O O
. O O

I O B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
immunochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O O
and O O
family O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
first O O
recognized O O
human O O
kindred O O
with O O
hereditary B B_DISEASE/B_GENE
deficiency I I_DISEASE/I_GENE
of I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
fifth I I_DISEASE/I_GENE
component I I_DISEASE/I_GENE
of I I_DISEASE/I_GENE
complement I I_DISEASE/I_GENE
( O O
C5 O O
) O O
is O O
described O O
. O O

The O O
proband O O
, O O
a O O
20 O O
- O O
year O O
- O O
old O O
black O O
female O O
with O O
systemic B B_DISEASE/B_LOCATION
lupus I I_DISEASE/I_LOCATION
erythematosus I I_DISEASE/I_LOCATION
since O O
age O O
11 O O
, O O
lacked O O
serum O O
hemolytic O O
complement O O
activity O O
, O O
even O O
during O O
remission O O
. O O

C5 O B_DISEASE/B_GENE
was O O
undetectable O B_DISEASE_ADJECTIVE[DISEASE]
in O O
her O O
serum O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O O
both O O
immunodiffusion O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O O
hemolytic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Other O B_PERSON
complement O I_PERSON
components O I_PERSON
were O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O O
remission O B_DISEASE
of O O
lupus O B_DISEASE/B_LOCATION
, O O
but O O
C1 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
C4 O B_PROTEIN[GENE]
, O O
C2 O B_PROTEIN[GENE]
, O O
and O O
C3 O B_PROTEIN[GENE]
levels O I_PROTEIN[GENE]
fell O O
during O O
exacerbations O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

A O O
younger O B_PERSON/B_NUMBER[MEASURE]
half O B_PERSON/I_NUMBER[MEASURE]
- O O
sister O B_PERSON/B_BIO
, O O
who O O
had O O
no O O
underlying O B_DISEASE/B_PERSON
disease O I_DISEASE/I_PERSON
, O O
was O O
also O O
found O O
to O O
lack O O
immunochemically O O
detectable O B_DISEASE_ADJECTIVE[DISEASE]
C5 O I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
hemolytic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
she O O
exhibited O O
1 O B_MEASURE/B_LOCATION
- O O
2 O B_SEQUENCE[MEASURE]
% O I_SEQUENCE[MEASURE]
of O O
the O O
normal O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
serum O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
C5 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
level O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O O
normal O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
complement O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
components O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O O

C5 O O
levels O O
of O O
other O O
family O O
members O O
were O O
either O O
normal O O
or O O
approximately O O
half O O
- O O
normal O O
, O O
consistent O O
with O O
autosomal O O
codominant O O
inheritance O O
of O O
the O O
gene O O
determining O O
C5 B B_DISEASE/B_GENE
deficiency I I_DISEASE/I_GENE
. O O

Normal O O
hemolytic O O
titers O O
were O O
restored O O
to O O
both O O
homozygous O O
C5 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
deficient I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
C5D B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
sera O O
by O O
addition O O
of O O
highly O O
purified O O
human O O
C5 O O
. O O

In O O
specific O O
C5 O O
titrations O O
, O O
however O O
, O O
it O O
was O O
noted O O
that O O
when O O
limited O O
amounts O O
of O O
C5 O O
were O O
assayed O O
in O O
the O O
presence O O
of O O
low O O
dilutions O O
of O O
either O O
C5D B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
serum O O
, O O
curving O O
rather O O
than O O
linear O O
dose O O
- O O
response O O
plots O O
were O O
consistently O O
obtained O O
, O O
suggesting O O
some O O
inhibitory O O
effect O O
. O O

Further O O
studies O O
suggested O O
that O O
low O O
dilutions O O
of O O
C5D B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
serum O O
contain O O
a O O
factor O O
( O O
or O O
factors O O
) O O
interfering O O
at O O
some O O
step O O
in O O
the O O
hemolytic O O
assay O O
of O O
C5 O O
, O O
rather O O
than O O
a O O
true O O
C5 O O
inhibitor O O
or O O
inactivator O O
. O O

Of O O
clinical O O
interest O O
are O O
( O O
a O O
) O O
the O O
documentation O O
of O O
membranous O O
glomerulonephritis B B_DISEASE
, O O
vasculitis B B_DISEASE
, O O
and O O
arthritis B B_DISEASE
in O O
an O O
individual O O
lacking O O
C5 O O
( O O
and O O
its O O
biologic O O
functions O O
) O O
, O O
and O O
( O O
b O O
) O O
a O O
remarkable O O
propensity O O
to O O
bacterial B B_DISEASE_ADJECTIVE[DISEASE]
infections I I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
proband O O
, O O
even O O
during O O
periods O O
of O O
low O O
- O O
dose O O
or O O
alternate O O
- O O
day O O
corticosteroid O O
therapy O O
. O O

Other O O
observations O O
indicate O O
that O O
the O O
C5D B B_DISEASE_ADJECTIVE[DISEASE]
state O O
is O O
compatible O O
with O O
normal O O
coagulation O O
function O O
and O O
the O O
capacity O O
to O O
mount O O
a O O
neutrophilic O O
leukocytosis O O
during O O
pyogenic B B_DISEASE
infection I I_DISEASE
. O O
. O O

Susceptibility O O
to O O
ankylosing B B_DISEASE
spondylitis I I_DISEASE
in O O
twins O O
: O O
the O O
role O O
of O O
genes O O
, O O
HLA O O
, O O
and O O
the O O
environment O O
. O O

OBJECTIVE O O
To O O
determine O O
the O O
relative O O
effects O O
of O O
genetic O O
and O O
environmental O O
factors O O
in O O
susceptibility O O
to O O
ankylosing B B_DISEASE
spondylitis I I_DISEASE
( O O
AS B B_DISEASE/B_LOCATION
) O O
. O O

METHODS O O
Twins O O
with O O
AS B B_DISEASE/B_LOCATION
were O O
identified O O
from O O
the O O
Royal O O
National O O
Hospital O O
for O O
Rheumatic B B_DISEASE/B_PERSON
Diseases I I_DISEASE/I_PERSON
database O O
. O O

Clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
radiographic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examinations O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
performed O O
to O O
establish O O
diagnoses O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
disease O B_DISEASE_ADJECTIVE[DISEASE]
severity O I_DISEASE_ADJECTIVE[DISEASE]
was O O
assessed O O
using O O
a O O
combination O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
validated O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scoring O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
systems O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

HLA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
typing O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
HLA O B_GENE
- O O
B27 O B_PROTEIN[GENE]
, O O
HLA O B_GENE
- O O
B60 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
HLA O B_GENE/B_LOCATION
- O O
DR1 O B_PROTEIN[GENE]
was O O
performed O O
by O O
polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
sequence O B_LOCATION/B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
primers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
zygosity O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
was O O
assessed O O
using O O
microsatellite O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
markers O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Genetic O O
and O O
environmental O O
variance O O
components O O
were O O
assessed O O
with O O
the O O
program O O
Mx O O
, O O
using O O
data O O
from O O
this O O
and O O
previous O O
studies O O
of O O
twins O O
with O O
AS B B_DISEASE/B_LOCATION
. O O

RESULTS O B_NUMBER[MEASURE]/B_SPORT[ENT]
Six O I_NUMBER[MEASURE]/I_SPORT[ENT]
of O O
8 O B_MEASURE
monozygotic O I_MEASURE
( O O
MZ O B_PROTEIN[GENE]/B_LOCATION
) O O
twin O B_PERSON/B_LOCATION
pairs O I_PERSON/I_LOCATION
were O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concordant O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
compared O O
with O O
4 O B_NUMBER[MEASURE]
of O O
15 O B_GENE/B_DISEASE
B27 O B_GENE/I_DISEASE
- O O
positive O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dizygotic O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
DZ O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
twin O B_PERSON/B_LOCATION
pairs O I_PERSON/I_LOCATION
( O O
27 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
4 O B_NUMBER[MEASURE]
of O O
32 O B_MEASURE
DZ O I_MEASURE
twin O I_MEASURE
pairs O I_MEASURE
overall O I_MEASURE
( O O
12 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
. O O

Nonsignificant O B_MEASURE
increases O I_MEASURE
in O O
similarity O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
regard O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
age O B_MEASURE/B_DISEASE
at O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
onset O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O O
all O O
of O O
the O O
disease O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
severity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
scores O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assessed O O
were O O
noted O O
in O O
disease O B_DISEASE/B_GENE
- O O
concordant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
MZ O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
twins O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
compared O O
with O O
concordant O B_PERSON/B_MEASURE
DZ O I_PERSON/I_MEASURE
twins O I_PERSON/I_MEASURE
. O O

HLA O B_GENE
- O O
B27 O B_PROTEIN[GENE]
and O O
B60 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
associated O O
with O O
the O O
disease O B_DISEASE/B_GENE
in O O
probands O B_PERSON/B_BIO
, O O
and O O
the O O
rate O B_MEASURE
of O O
disease O B_DISEASE/B_LOCATION
concordance O I_DISEASE/I_LOCATION
was O O
significantly O O
increased O O
among O O
DZ O B_PERSON/B_BIO
twin O I_PERSON/I_BIO
pairs O I_PERSON/I_BIO
in O O
which O O
the O O
co O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
twin O B_PERSON/B_MEASURE
was O O
positive O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
both O O
B27 O B_GENE
and O O
DR1 O B_PROTEIN[GENE]
. O O

Additive O B_PERSON
genetic O I_PERSON
effects O I_PERSON
were O O
estimated O O
to O O
contribute O O
97 O B_PERSON/B_MEASURE
% O I_PERSON/I_MEASURE
of O O
the O O
population O B_MEASURE/B_DISEASE
variance O I_MEASURE/I_DISEASE
. O O

CONCLUSION O O
Susceptibility O O
to O O
AS B B_DISEASE/B_LOCATION
is O O
largely O O
genetically O O
determined O O
, O O
and O O
the O O
environmental O O
trigger O O
for O O
the O O
disease O O
is O O
probably O O
ubiquitous O O
. O O

HLA O O
- O O
B27 O O
accounts O O
for O O
a O O
minority O O
of O O
the O O
overall O O
genetic O O
susceptibility O O
to O O
AS B B_DISEASE/B_LOCATION
. O O

Cell O B_TIME[MEASURE]/B_PERSON
cycle O I_TIME[MEASURE]/I_PERSON
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colocalization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BARD1 O B_GENE/B_LOCATION
and O O
BRCA1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
discrete O B_DISEASE
nuclear O I_DISEASE
domains O I_DISEASE
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
BRCA1 O O
gene O O
predispose O O
women O O
to O O
early O O
- O O
onset O O
breast B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
ovarian I I_DISEASE/I_LOCATION
cancer I I_DISEASE/I_LOCATION
by O O
compromising O O
the O O
genes O O
presumptive O O
function O O
as O O
a O O
tumor B B_DISEASE
suppressor O O
. O O

Although O O
the O O
biochemical O B_LOCATION
properties O I_LOCATION
of O O
BRCA1 O B_GENE/B_BIO
polypeptides O I_GENE/I_BIO
are O O
not O O
understood O O
, O O
their O O
expression O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
subcellular O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggest O O
a O O
role O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O O
cycle O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

When O O
resting O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O O
induced O O
to O O
proliferate O O
, O O
the O O
steady O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
state O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
BRCA1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
increase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
late O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
G1 O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
reach O O
a O O
maximum O B_MEASURE/B_LOCATION
during O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O O

Moreover O O
, O O
in O O
S O B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
BRCA1 O B_GENE/B_BIO
polypeptides O I_GENE/I_BIO
are O O
hyperphosphorylated O O
and O O
accumulate O O
into O O
discrete O B_MEASURE/B_LOCATION
subnuclear O I_MEASURE/I_LOCATION
foci O I_MEASURE/I_LOCATION
termed O O
" O O
BRCA1 O B_LOCATION
nuclear O I_LOCATION
dots O I_LOCATION
. O O

" O O
BRCA1 O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
associates O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
with O O
a O O
structurally O O
related O O
protein O B_BIO/B_GENE
termed O O
BARD1 O B_GENE
. O O

Here O O
we O O
show O O
that O O
the O O
steady O B_MEASURE/B_GENE
- O O
state O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
levels O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
BARD1 O B_GENE
, O O
unlike O O
those O O
of O O
BRCA1 O B_GENE/B_DISEASE
, O O
remain O O
relatively O O
constant O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
during O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cycle O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
progression O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O O

However O O
, O O
immunostaining O O
revealed O O
that O O
BARD1 O B_GENE/B_DISEASE
resides O O
within O O
BRCA1 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dots O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
during O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
cell O B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cycle O B_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O O
but O O
not O O
during O O
the O O
G1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Nevertheless O O
, O O
BARD1 O B_GENE/B_PERSON
polypeptides O I_GENE/I_PERSON
are O O
found O O
exclusively O O
in O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
fractions O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
both O O
G1 O B_MEASURE/B_LOCATION
- O O
and O O
S O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Therefore O O
, O O
progression O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
S O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
phase O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O O
accompanied O O
by O O
the O O
aggregation O B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
nuclear O B_GENE
BARD1 O I_GENE
polypeptides O I_GENE
into O O
BRCA1 O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dots O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

This O O
cell O O
cycle O O
- O O
dependent O O
colocalization O O
of O O
BARD1 O O
and O O
BRCA1 O O
indicates O O
a O O
role O O
for O O
BARD1 O O
in O O
BRCA1 O O
- O O
mediated O O
tumor B B_DISEASE/B_GENE
suppression O O
. O O

Ethnic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
differences O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
the O O
HFE O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
codon O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
282 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Cys O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O O
Tyr O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
polymorphism O B_GENE
. O O

Recent O O
studies O O
have O O
shown O O
that O O
hereditary B B_DISEASE
hemochromatosis I I_DISEASE
( O O
HH B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
likely O O
to O O
be O O
caused O O
by O O
homozygosity O O
for O O
a O O
Cys282Tyr O O
mutation O O
in O O
the O O
HFE O O
gene O O
located O O
4 O O
. O O

5 O B_DISEASE_ADJECTIVE[DISEASE]
Mb O I_DISEASE_ADJECTIVE[DISEASE]
telomeric O I_DISEASE_ADJECTIVE[DISEASE]
to O O
HLA O B_PROTEIN[GENE]/B_LOCATION
- O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Population O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
polymorphism O B_GENE/B_BIO
are O O
facilitated O O
by O O
the O O
fact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O O
the O O
Cys282Tyr O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
creates O O
a O O
Rsal O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
restriction O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
site O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

We O O
have O O
studied O O
the O O
codon O B_GENE
282 O I_GENE
( O O
Cys O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O O
Tyr O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
polymorphism O B_GENE
in O O
different O B_BIO/B_DISEASE
ethnic O I_BIO/I_DISEASE
groups O I_BIO/I_DISEASE
. O O

In O O
agreement O B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
previous O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
observations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
the O O
Tyr O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allele O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appeared O O
to O O
be O O
rare O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
or O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
Asiatic O B_NUMBER[MEASURE]/B_PERSON
( O O
Indian O B_PERSON/B_LOCATION
, O O
Chinese O B_LOCATION/B_PERSON
) O O
populations O B_LOCATION/B_PERSON
. O O

The O O
highest O B_MEASURE/B_PERSON
allele O I_MEASURE/I_PERSON
frequency O I_MEASURE/I_PERSON
( O O
7 O B_MEASURE
. O O
5 O B_MEASURE
% O I_MEASURE
) O O
was O O
found O O
in O O
Swedes O B_LOCATION/B_PERSON
. O O

Saamis O B_PERSON/B_LOCATION
( O O
2 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
Mordvinians O B_PERSON/B_LOCATION
( O O
1 O B_MEASURE
. O O
8 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
had O O
significantly O O
lower O B_MEASURE
frequencies O I_MEASURE
of O O
the O O
Tyr O B_DISEASE/B_GENE
allele O I_DISEASE/I_GENE
. O O

Comparisons O O
with O O
allele O O
frequencies O O
based O O
on O O
prevalence O O
estimates O O
of O O
HH B B_DISEASE/B_GENE
showed O O
some O O
disagreements O O
with O O
the O O
RFLP O O
data O O
, O O
particularly O O
in O O
Finns O O
. O O

The O O
newly O O
described O O
HFE O O
marker O O
provides O O
a O O
new O O
approach O O
to O O
the O O
screening O O
of O O
HH B B_DISEASE/B_PERSON
as O O
well O O
as O O
studies O O
of O O
the O O
relationship O O
between O O
the O O
HFE O O
Tyr O O
allele O O
and O O
different O O
disorders O O
including O O
cancer B B_DISEASE

Autosomal B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dominant I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
neurohypophyseal I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
diabetes I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
insipidus I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
associated O O
with O O
a O O
missense O O
mutation O O
encoding O O
Gly23 O O
- O O
- O O
> O O
Val O O
in O O
neurophysin O O
II O O
. O O

Autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
neurohypophyseal I I_DISEASE/I_GENE
diabetes I I_DISEASE/I_GENE
insipidus I I_DISEASE/I_GENE
( O O
ADNDI B B_DISEASE
) O O
is O O
an O O
inherited B B_DISEASE
disease I I_DISEASE
caused O O
by O O
progressive O O
degeneration O O
of O O
the O O
magnocellular O O
neurons O O
of O O
the O O
hypothalamus O O
leading O O
to O O
decreased O O
ability O O
to O O
produce O O
the O O
hormone O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
. O O

Affected O O
individuals O O
are O O
not O O
symptomatic O O
at O O
birth O O
, O O
but O O
usually O O
develop O O
diabetes B B_DISEASE_ADJECTIVE[DISEASE]
insipidus I I_DISEASE_ADJECTIVE[DISEASE]
at O O
1 O O
- O O
6 O O
yr O O
of O O
age O O
. O O

The O O
genetic O O
locus O O
of O O
the O O
disease O O
is O O
the O O
AVP O O
- O O
neurophysin O O
II O O
( O O
NPII O O
) O O
gene O O
, O O
and O O
mutations O O
that O O
cause O O
ADNDI B B_DISEASE/B_GENE
have O O
been O O
found O O
in O O
both O O
the O O
signal O O
peptide O O
of O O
the O O
prepro O O
- O O
AVP O O
- O O
NPII O O
precursor O O
and O O
within O O
NPII O O
itself O O
. O O

An O O
affected O O
girl O B_PERSON
who O O
presented O O
at O O
9 O B_TIME[MEASURE]/B_LOCATION
months O I_TIME[MEASURE]/I_LOCATION
of O O
age O B_TIME[MEASURE]/B_PERSON
and O O
her O O
similarly O O
affected O B_PERSON/B_DISEASE
younger O I_PERSON/I_DISEASE
brother O I_PERSON/I_DISEASE
and O O
father O B_PERSON
were O O
all O O
found O O
to O O
have O O
a O O
novel O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
missense O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
G1758 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
- O O
> O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
T O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
) O O
encoding O O
the O O
amino O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
substitution O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Gly23 O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
> O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Val O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
within O O
NPII O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
restriction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endonuclease O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

A O O
T1 O B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O O
weighted O O
magnetic O B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging O I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
fathers O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pituitary O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
gland O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
demonstrates O O
an O O
attenuated O B_DISEASE
posterior O I_DISEASE
pituitary O I_DISEASE
bright O I_DISEASE
spot O I_DISEASE
. O O

This O O
mutation O O
may O O
be O O
valuable O O
for O O
developing O O
models O O
of O O
dominantly B B_DISEASE
inherited I I_DISEASE
neurodegeneration I I_DISEASE
, O O
as O O
the O O
early O O
age O O
of O O
onset O O
of O O
symptoms O O
suggests O O
that O O
this O O
mutation O O
may O O
be O O
particularly O O
deleterious O O
to O O
the O O
magnocellular O O
neuron O O
. O O
. O O

Frequent O O
inactivation O O
of O O
PTEN O O
/ O O
MMAC1 O O
in O O
primary O O
prostate B B_DISEASE
cancer I I_DISEASE
. O O

Sporadic B B_DISEASE
prostate I I_DISEASE
carcinoma I I_DISEASE
is O O
the O O
most O O
common O O
male B B_DISEASE
cancer I I_DISEASE
in O O
the O O
Western O O
world O O
, O O
yet O O
many O O
of O O
the O O
major O O
genetic O O
events O O
involved O O
in O O
the O O
progression O O
of O O
this O O
often O O
fatal O O
cancer B B_DISEASE
remain O O
to O O
be O O
elucidated O O
. O O

Numerous O O
cytogenetic O O
and O O
allelotype O O
studies O O
have O O
reported O O
frequent O O
loss O O
of O O
heterozygosity O O
on O O
chromosomal O O
arm O O
10q O O
in O O
sporadic B B_DISEASE
prostate I I_DISEASE
cancer I I_DISEASE
. O O

Deletion O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mapping O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
unambiguously O O
identified O O
a O O
region O B_LOCATION/B_MEASURE
of O O
chromosome O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
10q23 O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O O
be O O
the O O
minimal O B_LOCATION/B_PERSON
area O I_LOCATION/I_PERSON
of O O
loss O B_DISEASE
. O O

A O O
new O O
tumor B B_DISEASE/B_GENE
suppressor O O
gene O O
, O O
PTEN O O
/ O O
MMAC1 O O
, O O
was O O
isolated O O
recently O O
at O O
this O O
region O O
of O O
chromosome O O
10q23 O O
and O O
found O O
to O O
be O O
inactivated O O
by O O
mutation O O
in O O
three O O
prostate B B_DISEASE
cancer I I_DISEASE
cell O O
lines O O
. O O

We O O
screened O O
80 O O
prostate B B_DISEASE/B_PERSON
tumors I I_DISEASE/I_PERSON
by O O
microsatellite O O
analysis O O
and O O
found O O
chromosome O O
10q23 O O
to O O
be O O
deleted O O
in O O
23 O O
cases O O
. O O

We O O
then O O
proceeded O O
with O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
entire O B_LOCATION/B_ORGANIZATION
PTEN O I_LOCATION/I_ORGANIZATION
/ O O
MMAC1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
tested O O
for O O
homozygous O B_DISEASE
deletion O I_DISEASE
with O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intragenic O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
23 O B_PERSON/B_TIME[MEASURE]
cases O I_PERSON/I_TIME[MEASURE]
with O O
10q23 O B_DISEASE_ADJECTIVE[DISEASE]
loss O I_DISEASE_ADJECTIVE[DISEASE]
of O O
heterozygosity O B_GENE/B_DISEASE
. O O

The O O
identification O O
of O O
the O O
second O O
mutational O O
event O O
in O O
10 O O
( O O
43 O O
% O O
) O O
tumors B B_DISEASE/B_PERSON
establishes O O
PTEN O O
/ O O
MMAC1 O O
as O O
a O O
main O O
inactivation O O
target O O
of O O
10q O O
loss O O
in O O
sporadic B B_DISEASE/B_GENE
prostate I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
. O O
. O O

Risk O O
reversals O O
in O O
predictive O O
testing O O
for O O
Huntington B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
. O O

The O O
first O O
predictive O O
testing O O
for O O
Huntington B B_DISEASE
disease I I_DISEASE
( O O
HD B B_DISEASE/B_PROTEIN[GENE]
) O O
was O O
based O O
on O O
analysis O O
of O O
linked O O
polymorphic O O
DNA O O
markers O O
to O O
estimate O O
the O O
likelihood O O
of O O
inheriting O O
the O O
mutation O O
for O O
HD B B_DISEASE/B_PROTEIN[GENE]
. O O

Limits O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
accuracy O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O O
recombination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O O
the O O
DNA O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
markers O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
pedigree O B_MEASURE/B_PERSON
structure O I_MEASURE/I_PERSON
, O O
and O O
whether O O
DNA O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
available O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
family O B_PERSON/B_MEASURE
members O I_PERSON/I_MEASURE
. O O

With O O
direct O O
tests O O
for O O
the O O
HD B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O O
, O O
we O O
have O O
assessed O O
the O O
accuracy O O
of O O
results O O
obtained O O
by O O
linkage O O
approaches O O
when O O
requested O O
to O O
do O O
so O O
by O O
the O O
test O O
individuals O O
. O O

For O O
six O B_PERSON/B_MEASURE
such O I_PERSON/I_MEASURE
individuals O I_PERSON/I_MEASURE
, O O
there O O
was O O
significant O B_DISEASE_ADJECTIVE[DISEASE]
disparity O I_DISEASE_ADJECTIVE[DISEASE]
between O O
the O O
tests O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
went O O
from O O
a O O
decreased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
an O O
increased O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O O
while O O
in O O
another O O
three O B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O O
risk O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
was O O
decreased O O
. O O

Knowledge O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
potential O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
these O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O O
impact O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
risk O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversals O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
both O O
patients O B_PERSON
and O O
the O O
counseling O B_PERSON/B_ORGANIZATION
team O I_PERSON/I_ORGANIZATION
can O O
assist O O
in O O
the O O
development O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
strategies O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
the O O
prevention O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
where O O
necessary O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
management O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O O
a O O
risk O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversal O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
any O O
predictive O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O

A O O
novel O O
common O O
missense O O
mutation O O
G301C O O
in O O
the O O
N O O
- O O
acetylgalactosamine O O
- O O
6 O O
- O O
sulfate O O
sulfatase O O
gene O O
in O O
mucopolysaccharidosis B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
IVA I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

Mucopolysaccharidosis B B_DISEASE/B_PROTEIN[GENE]
IVA I B_DISEASE/I_PROTEIN[GENE]
( O O
MPS B B_LOCATION/B_PERSON
IVA I I_LOCATION/I_PERSON
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
lysosomal I I_DISEASE/I_GENE
storage I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
caused O O
by O O
a O O
genetic B B_DISEASE_ADJECTIVE[DISEASE]
defect I I_DISEASE_ADJECTIVE[DISEASE]
in O O
N O O
- O O
acetylgalactosamine O O
- O O
6 O O
- O O
sulfate O O
sulfatase O O
( O O
GALNS O O
) O O
. O O

In O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O O
we O O
have O O
found O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
common O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
Caucasians O B_PERSON/B_LOCATION
and O O
Japanese O B_LOCATION/B_PERSON
, O O
respectively O O
. O O

To O O
characterize O O
the O O
mutational O O
spectrum O O
in O O
various O O
ethnic O O
groups O O
, O O
mutations O O
in O O
the O O
GALNS O O
gene O O
in O O
Colombian O O
MPS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
were O O
investigated O O
, O O
and O O
genetic O O
backgrounds O O
were O O
extensively O O
analyzed O O
to O O
identify O O
racial O O
origin O O
, O O
based O O
on O O
mitochondrial O O
DNA O O
( O O
mtDNA O O
) O O
lineages O O
. O O

Three O O
novel O O
missense O O
mutations O O
never O O
identified O O
previously O O
in O O
other O O
populations O O
and O O
found O O
in O O
16 O O
out O O
of O O
19 O O
Colombian O O
MPS B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
IVA I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
unrelated O O
alleles O O
account O O
for O O
84 O O
. O O

2 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
alleles O B_PERSON/B_LOCATION
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O O

The O O
G301C O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
S162F O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
account O O
for O O
68 O B_NUMBER[MEASURE]/B_PERSON
. O O

4 O B_SEQUENCE[MEASURE]/B_PERSON
% O I_SEQUENCE[MEASURE]/I_PERSON
and O O
10 O B_MEASURE/B_LOCATION
. O O

5 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
mutations O B_PERSON/B_LOCATION
, O O
respectively O O
, O O
whereas O O
the O O
remaining O O
F69V O B_MEASURE
is O O
limited O O
to O O
a O O
single O B_SEQUENCE[MEASURE]/B_PERSON
allele O I_SEQUENCE[MEASURE]/I_PERSON
. O O

The O O
skewed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
G301C O B_DISEASE/B_GENE
in O O
only O B_PERSON/B_BIO
Colombian O B_PERSON/I_BIO
patients O B_PERSON/I_BIO
and O O
haplotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
restriction O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fragment O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
length O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
GALNS O B_PERSON/B_BIO
gene O I_PERSON/I_BIO
suggest O O
that O O
G301C O B_DISEASE/B_PERSON
originated O O
from O O
a O O
common O B_BIO/B_GENE
ancestor O B_BIO/I_GENE
. O O

Investigation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
background O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O O
means O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mtDNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineages O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
all O O
our O O
patients O B_PERSON/B_BIO
are O O
probably O O
of O O
native O B_DISEASE/B_GENE
American O B_DISEASE/I_GENE
descent O B_DISEASE/I_GENE

Low O O
frequency O O
of O O
BRCA1 O O
germline O O
mutations O O
in O O
45 O O
German O O
breast B B_DISEASE/B_PERSON
/ I I_DISEASE/I_PERSON
ovarian I I_DISEASE/I_PERSON
cancer I I_DISEASE/I_PERSON
families O O
. O O

In O O
this O O
study O O
we O O
investigated O O
45 O O
German O O
breast B B_DISEASE
/ I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
families O O
for O O
germline O O
mutations O O
in O O
the O O
BRCA1 O O
gene O O
. O O

We O O
identified O O
four O O
germline O O
mutations O O
in O O
three O O
breast B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
families O O
and O O
in O O
one O O
breast B B_DISEASE
- I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
family O O
. O O
among O O
these O O
were O O
one O O
frameshift O O
mutation O O
, O O
one O O
nonsense O O
mutation O O
, O O
one O O
novel O O
splice O O
site O O
mutation O O
, O O
and O O
one O O
missense O O
mutation O O
. O O

The O O
missense O B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]
was O O
also O O
found O O
in O O
2 O B_NUMBER[MEASURE]/B_BIO
. O O

8 O B_LOCATION/B_PERSON
% O I_LOCATION/I_PERSON
of O O
the O O
general O B_PERSON/B_MEASURE
population O I_PERSON/I_MEASURE
, O O
suggesting O O
that O O
it O O
is O O
not O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
associated O O
. O O

The O O
average O B_MEASURE
age O I_MEASURE
of O O
disease O B_PERSON
onset O I_PERSON
in O O
those O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
harbouring O O
causative O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
was O O
between O O
32 O B_NUMBER[MEASURE]/B_PERSON
. O O

3 O B_MEASURE
and O O
37 O B_NUMBER[MEASURE]/B_LOCATION
. O O

4 O B_MEASURE/B_LOCATION
years O I_MEASURE/I_LOCATION
, O O
whereas O O
the O O
family O B_PERSON
harbouring O O
the O O
missense O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
had O O
an O O
average O B_TIME[MEASURE]/B_PERSON
age O I_TIME[MEASURE]/I_PERSON
of O O
onset O B_TIME[MEASURE]/B_PERSON
of O O
51 O B_TIME[MEASURE]/B_DISEASE
. O O

2 O B_ENT/B_TIME[MEASURE]
years O I_ENT/I_TIME[MEASURE]
. O O

These O O
findings O O
show O O
that O O
BRCA1 O O
is O O
implicated O O
in O O
a O O
small O O
fraction O O
of O O
breast B B_DISEASE/B_GENE
/ I I_DISEASE/I_GENE
ovarian I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
families O O
suggesting O O
the O O
involvement O O
of O O
another O O
susceptibility O O
gene O O
( O O
s O O
) O O

Paternal O O
transmission O O
of O O
congenital B B_DISEASE
myotonic I I_DISEASE
dystrophy I I_DISEASE
. O O

We O O
report O O
a O O
rare O O
case O O
of O O
paternally O O
transmitted O O
congenital B B_DISEASE
myotonic I I_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_DISEASE/B_GENE
) O O
. O O

The O O
proband O O
is O O
a O O
23 O O
year O O
old O O
, O O
mentally B B_PERSON/B_DISEASE
retarded I I_PERSON/I_DISEASE
male O O
who O O
suffers O O
severe O O
muscular B B_DISEASE
weakness I I_DISEASE
. O O

He O O
presented O O
with O O
respiratory O B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
feeding O B_DISEASE
difficulties O I_DISEASE
at O O
birth O B_TIME[MEASURE]/B_PERSON
. O O

His O O
two O O
sibs O O
suffer O O
from O O
childhood O O
onset O O
DM B B_DISEASE
. O O

Their O O
late O O
father O O
had O O
the O O
adult O O
type O O
of O O
DM B B_DISEASE/B_GENE
, O O
with O O
onset O O
around O O
30 O O
years O O
. O O

Only O O
six O O
other O O
cases O O
of O O
paternal O O
transmission O O
of O O
congenital B B_DISEASE
DM I I_DISEASE
have O O
been O O
reported O O
recently O O
. O O

We O O
review O O
the O O
sex O O
related O O
effects O O
on O O
transmission O O
of O O
congenital B B_DISEASE
DM I I_DISEASE
. O O

Decreased O O
fertility O O
of O O
males O O
with O O
adult O O
onset O O
DM B B_DISEASE/B_GENE
and O O
contraction O O
of O O
the O O
repeat O O
upon O O
male O O
transmission O O
contribute O O
to O O
the O O
almost O O
absent O O
occurrence O O
of O O
paternal O O
transmission O O
of O O
congenital B B_DISEASE/B_GENE
DM I I_DISEASE/I_GENE
. O O

Also O O
the O O
fathers O O
of O O
the O O
reported O O
congenitally O O
affected O O
children O O
showed O O
, O O
on O O
average O O
, O O
shorter O O
CTG O O
repeat O O
lengths O O
and O O
hence O O
less O O
severe O O
clinical O O
symptoms O O
than O O
the O O
mothers O O
of O O
children O O
with O O
congenital B B_DISEASE/B_PERSON
DM I I_DISEASE/I_PERSON
. O O

We O O
conclude O O
that O O
paternal O O
transmission O O
of O O
congenital B B_DISEASE
DM I I_DISEASE
is O O
rare O O
and O O
preferentially O O
occurs O O
with O O
onset O O
of O O
DM B B_DISEASE
past O O
30 O O
years O O
in O O
the O O
father O O
. O O
. O O

The O O
RB1 O O
gene O O
mutation O O
in O O
a O O
child O O
with O O
ectopic B B_DISEASE
intracranial I I_DISEASE
retinoblastoma I I_DISEASE
. O O

The O O
RB1 O O
gene O O
mutation O O
was O O
investigated O O
in O O
a O O
child O O
with O O
ectopic B B_DISEASE
intracranial I I_DISEASE
retinoblastoma I I_DISEASE
using O O
DNA O O
obtained O O
from O O
both O O
the O O
pineal B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
retinal I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
tumours I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
the O O
patient O O
. O O

A O O
nonsense O O
mutation O O
in O O
exon O O
17 O O
( O O
codon O O
556 O O
) O O
of O O
the O O
RB1 O O
gene O O
was O O
found O O
to O O
be O O
present O O
homozygously O O
in O O
both O O
the O O
retinal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
the I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pineal I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tumours I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
same O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heterozygously O O
in O O
the O O
DNA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O O
the O O
constitutional O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
patient O B_PERSON/B_BIO
, O O
proving O O
it O O
to O O
be O O
of O O
germline O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
origin O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
initial O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O O
shown O O
to O O
have O O
occurred O O
in O O
the O O
paternally O O
derived O O
RB1 O B_GENE/B_PERSON
allele O I_GENE/I_PERSON
. O O

The O O
mutation O O
is O O
in O O
an O O
area O O
of O O
the O O
gene O O
that O O
encodes O O
the O O
protein O O
- O O
binding O O
region O O
known O O
as O O
the O O
pocket O O
region O O
and O O
has O O
been O O
detected O O
in O O
other O O
cases O O
of O O
retinoblastoma B B_DISEASE
. O O
. O O

Low O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
beta O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hexosaminidase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
healthy O B_PERSON/B_ORGANIZATION
individuals O I_PERSON/I_ORGANIZATION
with O O
apparent O B_DISEASE_ADJECTIVE[DISEASE]
deficiency O I_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
enzyme O B_ENZYME[GENE]
. O O

Appreciable O O
beta O O
hexosaminidase O O
A O O
( O O
hex O O
A O O
) O O
activity O O
has O O
been O O
detected O O
in O O
cultured O O
skin O O
fibroblasts O O
and O O
melanoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O O
from O O
healthy O O
individuals O O
previously O O
reported O O
as O O
having O O
deficiency B B_ENZYME[GENE]/B_DISEASE
of I I_ENZYME[GENE]/I_DISEASE
hex I I_ENZYME[GENE]/I_DISEASE
A I I_ENZYME[GENE]/I_DISEASE
activity O O
indistinguishable O O
from O O
that O O
of O O
patients O O
with O O
Tay B B_DISEASE
- I I_DISEASE
Sachs I I_DISEASE
disease I I_DISEASE
( O O
TSD B B_MEASURE/B_DISEASE
) O O
. O O

Identification O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
quantitation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
hex O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
A O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
, O O
amounting O O
to O O
3 O B_NUMBER[MEASURE]
. O O

5 O B_MEASURE
% O I_MEASURE
- O O
6 O B_MEASURE
. O O

9 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
total O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexosaminidase O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
has O O
been O O
obtained O O
by O O
cellulose O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gel O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electrophoresis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
DEAE O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
cellulose O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ion O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O O
exchange O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chromatography O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
radial O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunodiffusion O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
radioimmunoassay O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Previous O O
family O O
studies O O
suggested O O
that O O
these O O
individuals O O
may O O
be O O
compound O O
heterozygotes O O
for O O
the O O
common O O
mutant O O
TSD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
and O O
a O O
rare O O
( O O
allelic O O
) O O
mutant O O
gene O O
. O O

Thus O O
, O O
the O O
postulated O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rate O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutant O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O O
to O O
code O O
for O O
the O O
expression O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amounts O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
hex O B_GENE/B_SPECIES[BIO]
A O I_GENE/I_SPECIES[BIO]
. O O

Heterozygotes O O
for O O
the O O
rare O O
mutant O O
may O O
be O O
indistinguishable O O
from O O
heterozygotes O O
for O O
the O O
common O O
TSD B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant O O
. O O

However O O
, O O
direct O O
visualization O O
and O O
quantitation O O
of O O
hex O O
A O O
by O O
the O O
methods O O
described O O
may O O
prevent O O
false O O
- O O
positive O O
prenatal O O
diagnosis O O
of O O
TSD B B_DISEASE
in O O
fetuses O O
having O O
the O O
incomplete O O
hex B B_DISEASE/B_GENE
A I I_DISEASE/I_GENE
deficiency I I_DISEASE/I_GENE
of O O
the O O
type O O
described O O
in O O
the O O
four O O
healthy O O
individuals O O

The O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
suppressor O O
gene O O
Smad4 O O
/ O O
Dpc4 O O
is O O
required O O
for O O
gastrulation O O
and O O
later O O
for O O
anterior O O
development O O
of O O
the O O
mouse O O
embryo O O
. O O

Mutations O O
in O O
the O O
SMAD4 O O
/ O O
DPC4 O O
tumor B B_DISEASE/B_GENE
suppressor O O
gene O O
, O O
a O O
key O O
signal O O
transducer O O
in O O
most O O
TGFbeta O O
- O O
related O O
pathways O O
, O O
are O O
involved O O
in O O
50 O O
% O O
of O O
pancreatic B B_DISEASE/B_PERSON
cancers I I_DISEASE/I_PERSON
. O O

Homozygous O B_PERSON
Smad4 O I_PERSON
mutant O I_PERSON
mice O I_PERSON
die O O
before O O
day O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
7 O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O O

5 O B_TIME[MEASURE]/B_EDU[ORGANIZATION]
of O O
embryogenesis O B_LOCATION/B_PERSON
. O O

Mutant O B_PERSON
embryos O I_PERSON
have O O
reduced O O
size O B_DISEASE/B_ORGANISM_FUNCTION
, O O
fail O O
to O O
gastrulate O O
or O O
express O O
a O O
mesodermal O B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
marker O I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
show O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]
visceral O I_DISEASE_ADJECTIVE[DISEASE]
endoderm O I_DISEASE_ADJECTIVE[DISEASE]
development O I_DISEASE_ADJECTIVE[DISEASE]
. O O

Growth B B_DISEASE_ADJECTIVE[DISEASE]
retardation I I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Smad4 O O
- O O
deficient O O
embryos O O
results O O
from O O
reduced O O
cell O O
proliferation O O
rather O O
than O O
increased O O
apoptosis O O
. O O

Aggregation O O
of O O
mutant O O
Smad4 O O
ES O O
cells O O
with O O
wild O O
- O O
type O O
tetraploid O O
morulae O O
rescues O O
the O O
gastrulation B B_DISEASE_ADJECTIVE[DISEASE]
defect I I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O O
indicate O O
that O O
Smad4 O O
is O O
initially O O
required O O
for O O
the O O
differentiation O O
of O O
the O O
visceral O O
endoderm O O
and O O
that O O
the O O
gastrulation B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
epiblast O O
is O O
secondary O O
and O O
non O O
- O O
cell O O
autonomous O O
. O O

Rescued O O
embryos O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
show O O
severe O B_DISEASE/B_GENE
anterior O I_DISEASE/I_GENE
truncations O I_DISEASE/I_GENE
, O O
indicating O O
a O O
second O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
important O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Smad4 O B_GENE
in O O
anterior O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
patterning O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O O
embryogenesis O B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Prevalence O O
of O O
p16 O O
and O O
CDK4 O O
germline O O
mutations O O
in O O
48 O O
melanoma B B_DISEASE
- O O
prone O O
families O O
in O O
France O O
. O O

The O O
French O O
Familial B B_DISEASE/B_LOCATION
Melanoma I I_DISEASE/I_LOCATION
Study O O
Group O O
. O O

Germline O O
mutations O O
in O O
the O O
p16 O O
and O O
CDK4 O O
genes O O
have O O
been O O
reported O O
in O O
a O O
subset O O
of O O
melanoma B B_DISEASE/B_LOCATION
pedigrees O O
, O O
but O O
their O O
prevalence O O
is O O
not O O
well O O
known O O
. O O

We O O
searched O O
for O O
such O O
germline O O
mutations O O
in O O
48 O O
French O O
melanoma B B_DISEASE/B_LOCATION
- O O
prone O O
families O O
selected O O
according O O
to O O
two O O
major O O
criteria O O
families O O
with O O
at O O
least O O
three O O
affected O O
members O O
( O O
n O O
= O O
20 O O
) O O
or O O
families O O
with O O
two O O
affected O O
members O O
, O O
one O O
of O O
them O O
affected O O
before O O
the O O
age O O
of O O
50 O O
( O O
n O O
= O O
28 O O
) O O
, O O
and O O
one O O
additional O O
minor O O
criterion O O
. O O

Sixteen O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
different O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
p16 O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
germline O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
found O O
in O O
21 O B_DISEASE/B_PERSON
families O I_DISEASE/I_PERSON
, O O
while O O
one O B_SEQUENCE[MEASURE]/B_PERSON
germline O I_SEQUENCE[MEASURE]/I_PERSON
mutation O I_SEQUENCE[MEASURE]/I_PERSON
, O O
Arg24His O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
detected O O
in O O
the O O
CDK4 O B_PERSON/B_MEASURE
gene O I_PERSON/I_MEASURE
. O O

The O O
frequency O B_MEASURE
of O O
p16 O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
mutation O I_DISEASE/I_GENE
in O O
our O O
sample O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O O
44 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
is O O
among O O
the O O
highest O B_MEASURE
rates O I_MEASURE
yet O O
reported O O
and O O
the O O
CDK4 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O O
the O O
second O B_SEQUENCE[MEASURE]
mutation O I_SEQUENCE[MEASURE]
detected O O
in O O
this O O
gene O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
worldwide O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

In O O
summary O O
, O O
our O O
results O O
show O O
frequent O O
involvement O O
of O O
the O O
p16 O O
gene O O
in O O
familial B B_DISEASE
melanoma I I_DISEASE
and O O
confirm O O
the O O
role O O
of O O
the O O
CDK4 O O
gene O O
as O O
a O O
melanoma B B_DISEASE
- O O
predisposing O O
gene O O
. O O
. O O

Progression O O
of O O
somatic O O
CTG O O
repeat O O
length O O
heterogeneity O O
in O O
the O O
blood O O
cells O O
of O O
myotonic B B_DISEASE/B_LOCATION
dystrophy I I_DISEASE/I_LOCATION
patients O O
. O O

The O O
genetic O O
basis O O
of O O
myotonic B B_DISEASE/B_GENE
dystrophy I I_DISEASE/I_GENE
( O O
DM B B_LOCATION
) O O
is O O
the O O
expansion O O
of O O
an O O
unstable O O
CTG O O
repeat O O
in O O
the O O
34 O O
UTR O O
of O O
the O O
DM B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
kinase O O
gene O O
on O O
chromosome O O
19 O O
. O O

One O O
of O O
the O O
principal O O
features O O
of O O
the O O
DM B B_DISEASE/B_GENE
mutation O O
is O O
an O O
extraordinarily O O
high O O
level O O
of O O
somatic O O
mosaicism O O
, O O
due O O
to O O
an O O
extremely O O
high O O
degree O O
of O O
somatic O O
instability O O
both O O
within O O
and O O
between O O
different O O
tissues O O
. O O

This O O
instability O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O O
to O O
be O O
biased O O
towards O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expansion O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
continuous O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
throughout O O
the O O
life O B_TIME[MEASURE]/B_LOCATION
of O O
an O O
individual O B_PERSON/B_DISEASE
, O O
features O O
that O O
could O O
be O O
associated O O
with O O
the O O
progressive O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
nature O I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O O
the O O
disease O B_DISEASE
. O O

Although O O
increasing O O
measured O O
allele O B_MEASURE
size O I_MEASURE
between O O
patients O B_PERSON/B_BIO
clearly O O
correlates O O
with O O
an O O
increased O O
severity O B_MEASURE/B_LOCATION
of O O
symptoms O B_DISEASE
and O O
an O O
earlier O B_TIME[MEASURE]/B_DISEASE
age O I_TIME[MEASURE]/I_DISEASE
of O O
onset O B_DISEASE
, O O
this O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O O
not O O
precise O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
measured O B_MEASURE/B_LOCATION
allele O I_MEASURE/I_LOCATION
length O I_MEASURE/I_LOCATION
cannot O I_MEASURE/I_LOCATION
be O O
used O O
as O O
an O O
accurate O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictor O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
age O B_TIME[MEASURE]
of O O
onset O B_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
order O O
to O O
further O O
characterize O O
the O O
dynamics O O
of O O
DM B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
CTG O O
repeat O O
somatic O O
instability O O
, O O
we O O
have O O
studied O O
repeat O O
length O O
changes O O
over O O
time O O
in O O
111 O O
myotonic B B_DISEASE
dystrophy I I_DISEASE
patients O O
with O O
varying O O
clinical O O
severity O O
and O O
CTG O O
repeat O O
size O O
over O O
time O O
intervals O O
of O O
1 O O
- O O
7 O O
years O O
. O O

We O O
have O O
found O O
a O O
direct O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
progression O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
size O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
heterogeneity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
over O O
time O B_TIME[MEASURE]/B_LOCATION
related O O
to O O
initial O B_MEASURE/B_LOCATION
CTG O I_MEASURE/I_LOCATION
repeat O I_MEASURE/I_LOCATION
size O I_MEASURE/I_LOCATION
and O O
the O O
time O B_MEASURE
interval O I_MEASURE
and O O
always O O
biased O O
towards O O
further O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
expansion O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Attempts O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O O
mathematically O O
model O O
the O O
dynamics O B_DISEASE/B_EDU[ORGANIZATION]
have O O
proved O O
only O O
partially O O
successful O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
individual O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
specific O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
/ O O
or O O
environmental O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factors O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
also O O
play O O
a O O
role O B_MEASURE/B_PERSON
in O O
somatic O B_DISEASE/B_EDU[ORGANIZATION]
mosaicism O I_DISEASE/I_EDU[ORGANIZATION]
. O O
. O O

Aspartylglucosaminuria B B_DISEASE
among O O
Palestinian O O
Arabs O O
. O O

Aspartylglucosaminuria B B_DISEASE
( O O
AGU B B_LOCATION/B_ORGANIZATION
) O O
is O O
a O O
rare O O
disorder B B_DISEASE_ADJECTIVE[DISEASE]
of I I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I I_DISEASE_ADJECTIVE[DISEASE]
metabolism I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
the O O
deficiency B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
the I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lysosomal I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartylglucosaminidase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
AGA O O
) O O
. O O

AGU B B_DISEASE
is O O
inherited O O
as O O
an O O
autosomal O O
recessive O O
trait O O
and O O
occurs O O
with O O
a O O
high O O
frequency O O
in O O
Finland O O
because O O
of O O
a O O
founder O O
effect O O
. O O

While O O
very O O
few O O
patients O O
with O O
AGU B B_DISEASE/B_LOCATION
have O O
been O O
reported O O
from O O
non O O
- O O
Finnish O O
origin O O
, O O
we O O
diagnosed O O
the O O
disorder O O
in O O
8 O O
patients O O
originating O O
from O O
3 O O
unrelated O O
families O O
, O O
all O O
Palestinian O O
Arabs O O
from O O
the O O
region O O
of O O
Jerusalem O O
. O O

The O O
clinical O O
diagnosis O O
of O O
AGU B B_DISEASE/B_LOCATION
is O O
often O O
difficult O O
, O O
in O O
particular O O
early O O
in O O
the O O
course O O
of O O
the O O
disease O O
, O O
and O O
most O O
of O O
the O O
patients O O
are O O
diagnosed O O
after O O
the O O
age O O
of O O
5 O O
years O O
. O O

However O O
, O O
since O O
these O O
patients O B_PERSON/B_BIO
excrete O O
early O B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
large O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts O B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
aspartylglucosamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
urine O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
biochemical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
easy O B_DISEASE_ADJECTIVE[DISEASE]
by O O
urine O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O

Detection O O
of O O
heterozygous O O
carriers O O
of O O
the O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
ATM O O
) O O
gene O O
by O O
G2 O O
phase O O
chromosomal O O
radiosensitivity O O
of O O
peripheral O O
blood O O
lymphocytes O O
. O O

In O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
patients O O
, O O
mutations O O
in O O
a O O
single O O
gene O O
, O O
ATM O O
, O O
result O O
in O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
that O O
embraces O O
a O O
variety O O
of O O
clinical O O
features O O
and O O
manifests O O
extreme O O
radiosensitivity O O
and O O
a O O
strong O O
pre O O
- O O
disposition O O
to O O
malignancy B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Heterozygotes O O
for O O
the O O
ATM O O
gene O O
have O O
no O O
clinical O O
expression O O
of O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
may O O
be O O
cancer B B_DISEASE/B_GENE
prone O O
with O O
a O O
moderate O O
increase O O
in O O
in O O
vitro O O
radiosensitivity O O
. O O

We O O
performed O O
a O O
blind O O
chromosomal O O
analysis O O
on O O
G2 O O
- O O
phase O O
lymphocytes O O
from O O
7 O O
unrelated O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
, O O
13 O O
obligate O O
A B B_GENE/B_PERSON
- I I_GENE/I_PERSON
T I I_GENE/I_PERSON
heterozygotes O O
( O O
parents O O
of O O
the O O
patients O O
) O O
, O O
and O O
14 O O
normal O O
controls O O
following O O
X O O
- O O
irradiation O O
with O O
1 O O
Gy O O
in O O
order O O
to O O
evaluate O O
this O O
cytogenetic O O
method O O
as O O
a O O
tool O O
for O O
detection O O
of O O
ATM O O
carriers O O
. O O

Both O O
A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homozygotes O O
and O O
heterozygotes O O
showed O O
significantly O O
increased O O
levels O O
of O O
radiation O O
- O O
induced O O
chromatid O O
damage O O
relative O O
to O O
that O O
of O O
normal O O
controls O O
. O O

These O O
results O O
show O O
that O O
the O O
G2 O O
- O O
phase O O
chromosomal O O
radiosensitivity O O
assay O O
can O O
be O O
used O O
for O O
the O O
detection O O
of O O
A B B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterozygotes O O
. O O

In O O
combination O O
with O O
molecular O O
genetic O O
analyses O O
, O O
this O O
test O O
may O O
be O O
of O O
value O O
in O O
studies O O
of O O
familial B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
sporadic I I_DISEASE/I_LOCATION
cancers I I_DISEASE/I_LOCATION
aimed O O
at O O
determination O O
of O O
the O O
potential O O
involvement O O
of O O
ATM O O
mutations O O
in O O
tumor B B_DISEASE/B_LOCATION
risk O O
or O O
development O O
. O O
. O O

Ataxia B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
telangiectasia I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
identification O O
and O O
detection O O
of O O
founder O O
- O O
effect O O
mutations O O
in O O
the O O
ATM O O
gene O O
in O O
ethnic O O
populations O O
. O O

To O O
facilitate O O
the O O
evaluation O O
of O O
ATM O O
heterozygotes O O
for O O
susceptibility O O
to O O
other O O
diseases O O
, O O
such O O
as O O
breast B B_DISEASE
cancer I I_DISEASE
, O O
we O O
have O O
attempted O O
to O O
define O O
the O O
most O O
common O O
mutations O O
and O O
their O O
frequencies O O
in O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
homozygotes O O
from O O
10 O O
ethnic O O
populations O O
. O O

Both O O
genomic O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
their O O
effects O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O O
cDNA O B_GENE/B_DISEASE
were O O
characterized O O
. O O

Protein O B_GENE/B_MEASURE
- O O
truncation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
testing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
entire O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATM O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O O
92 O B_MEASURE
( O O
66 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
truncating O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
140 O B_GENE/B_BIO
mutant O I_GENE/I_BIO
alleles O I_GENE/I_BIO
screened O O
. O O

The O O
haplotyping O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
patients O B_PERSON/B_BIO
with O O
identical O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
indicates O O
that O O
almost O O
all O O
of O O
these O O
represent O B_PERSON/B_MEASURE
common O I_PERSON/I_MEASURE
ancestry O I_PERSON/I_MEASURE
and O O
that O O
very O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spontaneously O O
recurring O O
ATM O B_DISEASE/B_GENE
mutations O I_DISEASE/I_GENE
exist O O
. O O

Assays O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
requiring O O
minimal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
genomic O B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O O
designed O O
to O O
allow O O
rapid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
common O B_DISEASE_ADJECTIVE[DISEASE]
ethnic O I_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
rapid O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
detected O O
mutations O B_DISEASE
in O O
76 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
of O O
Costa O B_PERSON/B_LOCATION
Rican O I_PERSON/I_LOCATION
patients O I_PERSON/I_LOCATION
( O O
3 O B_MEASURE
) O O
, O O
50 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
Norwegian O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
( O O
1 O B_MEASURE
) O O
, O O
25 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
Polish O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
( O O
4 O B_NUMBER[MEASURE]
) O O
, O O
and O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
Italian O B_PERSON/B_LOCATION
patients O I_PERSON/I_LOCATION
( O O
1 O B_MEASURE
) O O
, O O
as O O
well O O
as O O
in O O
patients O B_PERSON/B_LOCATION
of O O
Amish O B_PERSON/B_LOCATION
/ O O
Mennonite O B_LOCATION/B_PERSON
and O O
Irish O B_PERSON/B_LOCATION
English O I_PERSON/I_LOCATION
backgrounds O I_PERSON/I_LOCATION
. O O

Additional O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
observed O O
in O O
Japanese O B_LOCATION/B_PERSON
, O O
Utah O B_PERSON/B_LOCATION
Mormon O I_PERSON/I_LOCATION
, O O
and O O
African O B_PERSON/B_LOCATION
American O B_PERSON/I_LOCATION
patients O B_PERSON/I_LOCATION
. O O

These O O
assays O O
should O O
facilitate O O
screening O O
for O O
A B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterozygotes O O
in O O
the O O
populations O O
studied O O
. O O
. O O

The O O
von B B_DISEASE/B_GENE
Hippel I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Lindau I I_DISEASE/I_GENE
tumor I I_DISEASE/I_GENE
suppressor O O
gene O O
is O O
required O O
for O O
cell O O
cycle O O
exit O O
upon O O
serum O O
withdrawal O O
. O O

The O O
inactivation O O
of O O
the O O
von B B_DISEASE/B_GENE
Hippel I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Lindau I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
VHL I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
tumor I I_DISEASE/I_GENE
suppressor O O
gene O O
predisposes O O
affected O O
individuals O O
to O O
the O O
human O O
VHL B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
and O O
is O O
associated O O
with O O
sporadic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
RCC B B_LOCATION/B_ORGANIZATION
) O O
and O O
brain B B_DISEASE
hemangioblastomas I I_DISEASE
. O O

VHL O O
- O O
negative O O
786 O O
- O O
0 O O
RCC B B_DISEASE
cells O O
are O O
tumorigenic O O
in O O
nude O O
mice O O
which O O
is O O
suppressed O O
by O O
the O O
reintroduction O O
of O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Remarkably O O
, O O
this O O
occurs O O
without O O
affecting O O
the O O
growth O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
cell O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cycle O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profile O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
these O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
in O O
culture O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O O

The O O
786 O O
- O O
0 O O
cell O O
line O O
, O O
like O O
many O O
cancer B B_DISEASE
cells O O
, O O
fails O O
to O O
exit O O
the O O
cell O O
cycle O O
upon O O
serum O O
withdrawal O O
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
reintroduction O O
of O O
the O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
restores O O
the O O
ability O O
of O O
VHL O O
- O O
negative O O
RCC B B_DISEASE
cancer I I_DISEASE
cells O O
to O O
exit O O
the O O
cell O O
cycle O O
and O O
enter O O
G0 O O
/ O O
quiescence O O
in O O
low O O
serum O O
. O O

Both O O
VHL O O
- O O
positive O O
and O O
VHL O O
- O O
negative O O
RCC B B_DISEASE
cells O O
exit O O
the O O
cell O O
cycle O O
by O O
contact O O
inhibition O O
. O O

The O O
cyclin O O
- O O
dependent O O
kinase O O
inhibitor O O
, O O
p27 O O
, O O
accumulates O O
upon O O
serum O O
withdrawal O O
, O O
only O O
in O O
the O O
presence O O
of O O
VHL B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
a O O
result O O
of O O
the O O
stabilization O O
of O O
the O O
protein O O
. O O

We O O
propose O O
that O O
the O O
loss O O
of O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
results O O
in O O
a O O
specific O O
cellular O O
defect O O
in O O
serum O O
- O O
dependent O O
growth O O
control O O
, O O
which O O
may O O
initiate O O
tumor B B_DISEASE
formation O O
. O O

This O O
is O O
corrected O O
by O O
the O O
reintroduction O O
of O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
implicating O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
first O O
tumor B B_DISEASE/B_GENE
suppressor O O
involved O O
in O O
the O O
regulation O O
of O O
cell O O
cycle O O
exit O O
, O O
which O O
is O O
consistent O O
with O O
its O O
gatekeeper O O
function O O
in O O
the O O
kidney O O
. O O
. O O

Piebaldism B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
with O O
deafness B B_DISEASE
: O O
molecular O O
evidence O O
for O O
an O O
expanded O O
syndrome O O
. O O

In O O
a O O
South O O
African O O
girl O O
of O O
Xhosa O O
stock O O
with O O
severe O O
piebaldism B B_DISEASE
and O O
profound O O
congenital O O
sensorineural B B_DISEASE
deafness I I_DISEASE
we O O
identified O O
a O O
novel O O
missense O O
substitution O O
at O O
a O O
highly O O
conserved O O
residue O O
in O O
the O O
intracellular O O
kinase O O
domain O O
of O O
the O O
KIT O O
proto O O
- O O
oncogene O O
, O O
R796G O O
. O O

Though O O
auditory B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anomalies I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
observed O O
in O O
mice O O
with O O
dominant O O
white O O
spotting O O
( O O
W O O
) O O
due O O
to O O
KIT O O
mutations O O
, O O
deafness B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
typical O O
in O O
human O O
piebaldism B B_DISEASE/B_PERSON
. O O

Thus O O
, O O
the O O
occurrence O O
of O O
sensorineural B B_DISEASE/B_GENE
deafness I I_DISEASE/I_GENE
in O O
this O O
patient O O
extends O O
considerably O O
the O O
phenotypic O O
range O O
of O O
piebaldism B B_DISEASE/B_MEASURE
due O O
to O O
KIT O O
gene O O
mutation O O
in O O
humans O O
and O O
tightens O O
the O O
clinical O O
similarity O O
between O O
piebaldism B B_DISEASE/B_PERSON
and O O
the O O
various O O
forms O O
of O O
Waardenburg B B_DISEASE/B_GENE
syndrome I I_DISEASE/I_GENE
. O O
. O O

Cycloheximide O O
facilitates O O
the O O
identification O O
of O O
aberrant O O
transcripts O O
resulting O O
from O O
a O O
novel O O
splice O O
- O O
site O O
mutation O O
in O O
COL17A1 O O
in O O
a O O
patient O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
. O O

Patients O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
often O O
show O O
decreased O O
expression O O
of O O
type O O
XVII O O
collagen O O
, O O
a O O
transmembrane O O
hemidesmosomal O O
protein O O
encoded O O
by O O
COL17A1 O O
. O O

This O O
report O O
documents O O
a O O
novel O O
splice O O
- O O
site O O
mutation O O
in O O
COL17A1 O O
in O O
a O O
patient O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
, O O
and O O
applies O O
a O O
new O O
methodology O O
to O O
define O O
and O O
characterize O O
the O O
resulting O O
mRNA O O
splice O O
variants O O
. O O

Mutational O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
COL17A1 O B_GENE/B_BIO
identified O O
a O O
maternally O O
inherited O O
G O B_PROTEIN[GENE]/B_LOCATION
- O O
to O O
- O O
T O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
transversion O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
at O O
the O O
- O O
1 O B_LOCATION/B_MEASURE
position O I_LOCATION/I_MEASURE
of O O
exon O B_GENE
32 O I_GENE
. O O

This O O
acceptor O B_NUMBER[MEASURE]/B_GENE
splice O I_NUMBER[MEASURE]/I_GENE
- O O
site O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O O
to O O
the O O
formation O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O O
aberrant O B_GENE/B_DISEASE
transcripts O I_GENE/I_DISEASE
present O I_GENE/I_DISEASE
at O O
extremely O O
low O B_MEASURE/B_LOCATION
levels O I_MEASURE/I_LOCATION
. O O

Based O O
on O O
our O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
stabilized O O
mutant O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
COL17A1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
keratinocytes O B_BIO/B_PERSON
homozygous O I_BIO/I_PERSON
for O O
a O O
frameshift O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
the O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
splice O B_GENE/B_MEASURE
- O O
site O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
on O O
splicing O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
COL17A1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O O
determined O O
using O O
reverse O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
total O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O O
keratinocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
incubated O O
for O O
2 O B_TIME[MEASURE]/B_BIO
. O O

5 O B_MEASURE
h O O
in O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
10 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycloheximide O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O O
ml O B_TIME[MEASURE]/B_PERSON
. O O

Using O O
this O O
approach O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O O
an O O
abnormally O O
spliced O O
transcript O B_GENE/B_LOCATION
was O O
identified O O
that O O
contains O O
an O O
extra O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
264 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bases O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
upstream O O
from O O
exon O B_GENE
32 O I_GENE
, O O
resulting O O
in O O
a O O
premature O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
termination O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
codon O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
27 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
bp O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
downstream O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
from O O
the O O
cryptic O B_GENE/B_TIME[MEASURE]
splice O I_GENE/I_TIME[MEASURE]
site O I_GENE/I_TIME[MEASURE]
. O O

Three O B_NUMBER[MEASURE]/B_PERSON
other O I_NUMBER[MEASURE]/I_PERSON
splice O I_NUMBER[MEASURE]/I_PERSON
variants O I_NUMBER[MEASURE]/I_PERSON
, O O
including O O
one O B_NUMBER[MEASURE]/B_PERSON
derived O O
from O O
the O O
skipping O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
exon O B_GENE
32 O I_GENE
, O O
were O O
also O O
identified O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O O
the O O
usefulness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
cycloheximide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
evaluating O O
the O O
abnormal O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mRNA O B_GENE
due O O
to O O
splice O B_MEASURE/B_GENE
- O O
site O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
because O O
( O O
i O O
) O O
aberrant O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
often O O
generates O O
a O O
premature O B_GENE/B_DISEASE
termination O I_GENE/I_DISEASE
codon O I_GENE/I_DISEASE
, O O
( O O
ii O B_TIME[MEASURE]/B_PROTEIN[GENE]
) O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
premature O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
termination O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
codons O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
can O O
occur O O
at O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O O
undetectable O B_MEASURE
levels O I_MEASURE
due O O
to O O
nonsense O B_GENE
- O O
mediated O O
mRNA O B_DISEASE/B_GENE
decay O I_DISEASE/I_GENE
, O O
and O O
( O O
iii O B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O O
the O O
levels O B_MEASURE/B_GENE
of O O
these O O
transcripts O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O O
be O O
increased O O
by O O
cycloheximide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

A O O
deletion O O
mutation O O
in O O
COL17A1 O O
in O O
five O O
Austrian O O
families O O
with O O
generalized O O
atrophic B B_DISEASE/B_GENE
benign I I_DISEASE/I_GENE
epidermolysis I I_DISEASE/I_GENE
bullosa I I_DISEASE/I_GENE
represents O O
propagation O O
of O O
an O O
ancestral O O
allele O O
. O O

Patients O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
, O O
a O O
usually O O
nonlethal O O
form O O
of O O
junctional B B_DISEASE/B_GENE
epidermolysis I I_DISEASE/I_GENE
bullosa I I_DISEASE/I_GENE
, O O
have O O
generalized O O
blistering B B_DISEASE
, O O
nail B B_DISEASE
dystrophy I I_DISEASE
, O O
patchy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
alopecia I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
dental B B_DISEASE
abnormalities I I_DISEASE
. O O

Skin B B_DISEASE/B_GENE
fragility I I_DISEASE/I_GENE
in O O
most O O
cases O O
is O O
due O O
to O O
mutations O O
in O O
the O O
gene O O
encoding O O
type O O
XVII O O
collagen O O
( O O
COL17A1 O O
) O O
. O O

Recently O O
, O O
we O O
reported O O
five O O
Austrian O O
families O O
with O O
generalized O O
atrophic B B_DISEASE/B_GENE
benign I I_DISEASE/I_GENE
epidermolysis I I_DISEASE/I_GENE
bullosa I I_DISEASE/I_GENE
who O O
share O O
the O O
same O O
COL17A1 O O
mutation O O
. O O

Affected O O
individuals O B_PERSON/B_BIO
in O O
three O B_NUMBER[MEASURE]/B_ENT
families O I_NUMBER[MEASURE]/I_ENT
are O O
homozygous O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O O
4003delTC O B_GENE/B_LOCATION
, O O
whereas O O
those O O
in O O
two O B_NUMBER[MEASURE]/B_PERSON
others O I_NUMBER[MEASURE]/I_PERSON
are O O
compound O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heterozygotes O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

To O O
determine O O
if O O
the O O
occurrence O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
4003delTC O B_DISEASE/B_GENE
in O O
these O O
unrelated O B_PERSON/B_BIO
families O I_PERSON/I_BIO
signifies O O
propagation O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
an O O
ancestral O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allele O B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
a O O
mutational O B_DISEASE/B_MEASURE
hot O I_DISEASE/I_MEASURE
spot O I_DISEASE/I_MEASURE
, O O
haplotypes O B_PERSON/B_MEASURE
were O O
determined O O
for O O
polymorphisms O B_GENE
both O O
within O O
and O O
flanking O O
COL17A1 O B_GENE/B_PERSON
. O O

Five O B_PERSON/B_ENT
intragenic O I_PERSON/I_ENT
polymorphisms O I_PERSON/I_ENT
were O O
chosen O O
based O O
on O O
their O O
informativeness O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

One O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
, O O
not O O
previously O O
reported O O
, O O
was O O
2988 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
C O B_MEASURE/B_GENE
that O O
introduces O O
a O O
new O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
restriction O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Eco0109 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O O
. O O

All O O
the O O
4003delTC O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
showed O O
the O O
same O B_GENE
haplotype O I_GENE
for O O
these O O
five O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
polymorphic O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
markers O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O O

Fourteen O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
microsatellite O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
polymorphisms O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O O
selected O O
based O O
on O O
their O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heterozygosity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
their O O
location O B_LOCATION/B_MEASURE
within O O
10q23 O B_GENE/B_MEASURE
- O O
q25 O B_MEASURE/B_LOCATION
near O O
COL17A1 O B_GENE
. O O

Three O B_NUMBER[MEASURE]/B_ENT
families O I_NUMBER[MEASURE]/I_ENT
shared O O
microsatellite O B_LOCATION
polymorphisms O I_LOCATION
covering O O
at O O
most O O
19 O B_TIME[MEASURE]/B_LOCATION
cM O B_TIME[MEASURE]/I_LOCATION
, O O
whereas O O
the O O
others O B_PERSON/B_SEQUENCE[MEASURE]
shared O O
smaller O B_DISEASE/B_MEASURE
regions O I_DISEASE/I_MEASURE
consistent O I_DISEASE/I_MEASURE
with O O
cross O O
- O O
over O O
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O O
passage O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
this O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_BIO
through O O
several O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
generations O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
indicate O O
that O O
4003delTC O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurs O O
on O O
a O O
single O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
ancestral O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
allele O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O
. O O

The O O
haptoglobin O O
- O O
gene O O
deletion O O
responsible O O
for O O
anhaptoglobinemia B B_DISEASE
. O O

We O O
have O O
found O O
an O O
allelic O O
deletion O O
of O O
the O O
haptoglobin O O
( O O
Hp O O
) O O
gene O O
from O O
an O O
individual O O
with O O
anhaptoglobinemia B B_DISEASE/B_LOCATION
. O O

The O O
Hp O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
consists O O
of O O
coding O B_GENE/B_LOCATION
regions O I_GENE/I_LOCATION
of O O
the O O
alpha O B_PROTEIN[GENE]
chain O I_PROTEIN[GENE]
and O O
beta O B_PROTEIN[GENE]/B_LOCATION
chain O I_PROTEIN[GENE]/I_LOCATION
of O O
the O O
haptoglobin O B_GENE
gene O I_GENE
( O O
Hp O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
and O O
of O O
the O O
alpha O B_PROTEIN[GENE]
chain O I_PROTEIN[GENE]
and O O
beta O B_GENE/B_LOCATION
chain O I_GENE/I_LOCATION
of O O
the O O
haptoglobin O B_GENE/B_DISEASE
- O O
related O O
gene O B_GENE/B_LOCATION
( O O
Hpr O B_GENE/B_LOCATION
) O O
, O O
in O O
tandem O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
the O O
5 O B_GENE/B_MEASURE
side O I_GENE/I_MEASURE
. O O

Southern O O
blot O O
and O O
PCR O O
analyses O O
have O O
indicated O O
that O O
the O O
individual O O
with O O
anhaptoglobinemia B B_DISEASE
was O O
homozygous O O
for O O
the O O
gene O O
deletion O O
and O O
that O O
the O O
gene O O
deletion O O
was O O
included O O
at O O
least O O
from O O
the O O
promoter O O
region O O
of O O
Hp O O
to O O
Hpr O O
alpha O O
but O O
not O O
to O O
Hpr O O
beta O O
( O O
Hpdel O O
) O O
. O O

In O O
addition O O
, O O
we O O
found O O
seven O O
individuals O O
with O O
hypohaptoglobinemia B B_DISEASE
in O O
three O O
families O O
, O O
and O O
the O O
genotypes O O
of O O
six O O
of O O
the O O
seven O O
individuals O O
were O O
found O O
to O O
be O O
Hp2 O O
/ O O
Hpdel O O
. O O

The O O
phenotypes O O
and O O
genotypes O O
in O O
one O O
of O O
these O O
three O O
families O O
showed O O
the O O
father O O
to O O
be O O
hypohaptoglobinemic B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O O
Hp2 O O
) O O
and O O
Hp2 O O
/ O O
Hpdel O O
, O O
the O O
mother O O
to O O
be O O
Hp2 O O
- O O
1 O O
and O O
Hp1 O O
/ O O
Hp2 O O
, O O
one O O
of O O
the O O
two O O
children O O
to O O
be O O
hypohaptoglobinemic B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O O
Hp2 O O
) O O
and O O
Hp2 O O
/ O O
Hpdel O O
, O O
and O O
the O O
other O O
child O O
to O O
be O O
Hp1 O O
and O O
Hp1 O O
/ O O
Hpdel O O
, O O
showing O O
an O O
anomalous O O
inheritance O O
of O O
Hp O O
phenotypes O O
in O O
the O O
child O O
with O O
Hp1 O O
. O O

The O O
Hp2 O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
/ O O
Hpdel O B_PERSON/B_LOCATION
individuals O I_PERSON/I_LOCATION
had O O
an O O
extremely O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
level O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
Hp O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O O
mean O B_MEASURE
+ O I_MEASURE
/ O O
- O O
SD O B_DISEASE/B_MEASURE
= O O
0 O B_MEASURE
. O O
049 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
043 O B_MEASURE
mg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
; O O
n O O
= O O
6 O B_MEASURE
) O O
, O O
compared O O
with O O
the O O
level O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
1 O B_MEASURE/B_LOCATION
. O O
64 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
1 O B_MEASURE
. O O
07 O B_MEASURE/B_PERSON
mg O I_MEASURE/I_PERSON
/ O O
ml O B_MEASURE/B_PERSON
) O O
obtained O O
from O O
52 O B_PERSON
healthy O I_PERSON
volunteers O I_PERSON
having O O
phenotype O B_DISEASE/B_GENE
Hp2 O I_DISEASE/I_GENE
, O O
whereas O O
the O O
serum O B_MEASURE/B_DISEASE
Hp O I_MEASURE/I_DISEASE
level O I_MEASURE/I_DISEASE
of O O
an O O
individual O B_PERSON/B_DISEASE
with O O
Hp1 O B_PROTEIN[GENE]/B_MEASURE
/ O O
Hpdel O B_GENE/B_MEASURE
was O O
0 O B_MEASURE
. O O

50 O B_MEASURE/B_ORGANIZATION
mg O I_MEASURE/I_ORGANIZATION
/ O O
ml O B_TIME[MEASURE]/B_PERSON
, O O
which O O
was O O
approximately O O
half O O
the O O
level O B_MEASURE/B_DISEASE
of O O
Hp O B_GENE/B_BACTERIUM[BIO]
in O O
control O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
sera O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O O
the O O
Hp1 O B_PERSON/B_BIO
phenotype O I_PERSON/I_BIO
( O O
1 O B_MEASURE/B_LOCATION
. O O
26 O B_MEASURE
+ O I_MEASURE
/ O O
- O O
0 O B_MEASURE
. O O
33 O B_MEASURE
mg O I_MEASURE
/ O O
ml O B_MEASURE/B_PERSON
; O O
n O B_OTHER/B_MEASURE
= O O
9 O B_MEASURE
) O O
, O O
showing O O
a O O
gene O B_PERSON/B_MEASURE
- O O
dosage O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
other O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
allele O I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
( O O
Hp2 O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O O
of O O
individuals O B_PERSON/B_BIO
with O O
Hp2 O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
/ O O
Hpdel O B_MEASURE/B_GENE
was O O
found O O
to O O
have O O
, O O
in O O
all O O
exons O B_PERSON/B_LOCATION
, O O
no O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O O
by O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O O

On O O
the O O
basis O O
of O O
the O O
present O O
study O O
, O O
the O O
mechanism O O
of O O
anhaptoglobinemia B B_DISEASE/B_GENE
and O O
the O O
mechanism O O
of O O
anomalous O O
inheritance O O
of O O
Hp O O
phenotypes O O
were O O
well O O
explained O O
. O O

However O O
, O O
the O O
mechanism O O
of O O
hypohaptoglobinemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remains O O
unknown O O

ATM O O
mutations O O
and O O
phenotypes O O
in O O
ataxia B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
telangiectasia I B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
families O O
in O O
the O O
British O O
Isles O O
: O O
expression O O
of O O
mutant O O
ATM O O
and O O
the O O
risk O O
of O O
leukemia B B_DISEASE
, O O
lymphoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
breast B B_DISEASE
cancer I I_DISEASE
. O O

We O O
report O O
the O O
spectrum O O
of O O
59 O O
ATM O O
mutations O O
observed O O
in O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
patients O O
in O O
the O O
British O O
Isles O O
. O O

Of O O
51 O O
ATM O O
mutations O O
identified O O
in O O
families O O
native O O
to O O
the O O
British O O
Isles O O
, O O
11 O O
were O O
founder O O
mutations O O
, O O
and O O
2 O O
of O O
these O O
11 O O
conferred O O
a O O
milder O O
clinical O O
phenotype O O
with O O
respect O O
to O O
both O O
cerebellar B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degeneration I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cellular O O
features O O
. O O

We O O
report O O
, O O
in O O
two O O
A B B_LOCATION/B_MEASURE
- I I_LOCATION/I_MEASURE
T I I_LOCATION/I_MEASURE
families O O
, O O
an O O
ATM O O
mutation O O
( O O
7271T O O
- O O
- O O
> O O
G O O
) O O
that O O
may O O
be O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
in O O
both O O
homozygotes O O
and O O
heterozygotes O O
( O O
relative O O
risk O O
12 O O
. O O
7 O O
; O O
P O O
= O O
. O O
0025 O O
) O O
, O O
although O O
there O O
is O O
a O O
less O O
severe O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O O
in O O
terms O O
of O O
the O O
degree O O
of O O
cerebellar B B_DISEASE/B_GENE
degeneration I I_DISEASE/I_GENE
. O O

This O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
( O O
7271T O B_PROTEIN[GENE]/B_LOCATION
- O O
- O O
> O B_MEASURE/B_DISEASE
G O I_MEASURE/I_DISEASE
) O O
also O O
allows O O
expression O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
full O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
length O B_GENE/B_MEASURE
ATM O I_GENE/I_MEASURE
protein O I_GENE/I_MEASURE
at O O
a O O
level O B_MEASURE/B_LOCATION
comparable O I_MEASURE/I_LOCATION
with O O
that O O
in O O
unaffected O B_PERSON/B_BIO
individuals O I_PERSON/I_BIO
. O O

In O O
addition O O
, O O
we O O
have O O
studied O O
18 O O
A B B_DISEASE/B_MEASURE
- I I_DISEASE/I_MEASURE
T I I_DISEASE/I_MEASURE
patients O O
, O O
in O O
15 O O
families O O
, O O
who O O
developed O O
leukemia B B_DISEASE
, O O
lymphoma B B_DISEASE
, O O
preleukemic O O
T O O
- O O
cell O O
proliferation O O
, O O
or O O
Hodgkin B B_DISEASE
lymphoma I I_DISEASE
, O O
mostly O O
in O O
childhood O O
. O O

A O O
wide O B_MEASURE
variety O I_MEASURE
of O O
ATM O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
types O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
including O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
in O O
- O O
frame O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
deletions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
were O O
seen O O
in O O
these O O
patients O B_PERSON/B_BIO
. O O

We O O
also O O
show O O
that O O
25 O O
% O O
of O O
all O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
carried O O
in O O
- O O
frame O O
deletions O O
or O O
missense O O
mutations O O
, O O
many O O
of O O
which O O
were O O
also O O
associated O O
with O O
expression O O
of O O
mutant O O
ATM O O
protein O O
. O O

The O O
DMPK O O
gene O O
of O O
severely O O
affected O O
myotonic B B_DISEASE/B_GENE
dystrophy I I_DISEASE/I_GENE
patients O O
is O O
hypermethylated O O
proximal O O
to O O
the O O
largely O O
expanded O O
CTG O O
repeat O O
. O O

Using O O
methylation O O
- O O
sensitive O O
restriction O O
enzymes O O
, O O
we O O
characterized O O
the O O
methylation O O
pattern O O
on O O
the O O
5 O O
side O O
of O O
the O O
CTG O O
repeat O O
in O O
the O O
DMPK O O
gene O O
of O O
normal O O
individuals O O
and O O
of O O
patients O O
affected O O
with O O
myotonic B B_DISEASE/B_GENE
dystrophy I I_DISEASE/I_GENE
, O O
showing O O
expansions O O
of O O
the O O
repetitive O O
sequence O O
. O O

The O O
gene O B_GENE/B_LOCATION
segment O I_GENE/I_LOCATION
analyzed O O
corresponds O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
the O O
genomic O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
SacI O I_PROTEIN[GENE]/I_BACTERIUM[BIO]
- O O
HindIII O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragment O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
carrying O O
exons O B_GENE/B_LOCATION
11 O I_GENE/I_LOCATION
- O O
15 O B_MEASURE
. O O

There O O
is O O
constitutive O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
intron O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
12 O B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O O
restriction O B_LOCATION/B_MEASURE
sites O I_LOCATION/I_MEASURE
of O O
SacII O B_PROTEIN[GENE]/B_SPECIES[BIO]
and O O
HhaI O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O O
localized O B_MEASURE/B_LOCATION
1 O I_MEASURE/I_LOCATION
, O O
159 O B_MEASURE
- O O
1 O B_MEASURE
, O O
232 O B_MEASURE
bp O I_MEASURE
upstream O O
of O O
the O O
CTG O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
whereas O O
most O B_NUMBER[MEASURE]/B_PERSON
, O O
if O O
not O O
all O O
, O O
of O O
the O O
other O B_GENE/B_LOCATION
sites O I_GENE/I_LOCATION
of O O
SacII O B_GENE/B_SPECIES[BIO]
, O O
HhaI O B_GENE/B_BACTERIUM[BIO]
, O O
and O O
HpaII O B_GENE/B_BIO
in O O
this O O
region O B_LOCATION/B_PERSON
are O O
unmethylated O O
, O O
in O O
normal O B_PERSON
individuals O I_PERSON
and O O
most O B_NUMBER[MEASURE]/B_LOCATION
of O O
the O O
patients O B_PERSON/B_DISEASE
. O O

In O O
a O O
number O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
young O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O O
severely O O
affected O B_PERSON/B_DISEASE
patients O I_PERSON/I_DISEASE
, O O
however O O
, O O
complete O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
methylation O B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
of O O
these O O
restriction O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
in O O
the O O
mutated O B_GENE/B_PERSON
allele O I_GENE/I_PERSON
. O O

In O O
most O B_NUMBER[MEASURE]/B_PERSON
of O O
these O O
patients O B_PERSON/B_LOCATION
, O O
the O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
the O O
disease O B_DISEASE
was O O
congenital O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O O

Preliminary O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
vivo O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
footprinting O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gave O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
protein O B_GENE/B_BACTERIUM[BIO]
- O O
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contact O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
normal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
genes O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
at O O
an O O
Sp1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
consensus O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O O
site O B_LOCATION/B_MEASURE
upstream O O
of O O
the O O
CTG O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
for O O
a O O
significant O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
this O O
interaction O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
cells O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O O
a O O
hypermethylated O B_DISEASE/B_GENE
DMPK O I_DISEASE/I_GENE
gene O I_DISEASE/I_GENE
. O O
. O O

The O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O O
product O O
complexes O O
with O O
the O O
transferrin O O
receptor O O
and O O
lowers O O
its O O
affinity O O
for O O
ligand O O
binding O O
. O O

We O O
recently O O
reported O O
the O O
positional O O
cloning O O
of O O
a O O
candidate O O
gene O O
for O O
hereditary B B_DISEASE
hemochromatosis I I_DISEASE
called O O
HFE O O
. O O

The O O
gene O B_PERSON/B_ORGANIZATION
product O I_PERSON/I_ORGANIZATION
, O O
a O O
member O B_PERSON/B_MEASURE
of O O
the O O
major O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I O O
- O O
like O B_PROTEIN[GENE]/B_LOCATION
family O I_PROTEIN[GENE]/I_LOCATION
, O O
was O O
found O O
to O O
have O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Cys O B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O O
282 O B_MEASURE/B_LOCATION
- O O
- O O
> O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Tyr O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O O
C282Y O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
in O O
85 O B_NUMBER[MEASURE]
% O I_NUMBER[MEASURE]
of O O
patient O B_PERSON/B_BIO
chromosomes O I_PERSON/I_BIO
. O O

This O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
eliminates O O
the O O
ability O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
HFE O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O O
associate O B_PERSON/B_TIME[MEASURE]
with O O
beta2 O B_PROTEIN[GENE]/B_MEASURE
- O O
microglobulin O B_GENE
( O O
beta2m O B_LOCATION/B_ORGANIZATION
) O O
and O O
prevents O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
surface O B_DISEASE_ADJECTIVE[DISEASE]
expression O I_DISEASE_ADJECTIVE[DISEASE]
. O O

A O O
second O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
has O O
no O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
beta2m O B_GENE/B_DISEASE
association O B_GENE/I_DISEASE
, O O
H63D O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
was O O
found O O
in O O
eight O B_NUMBER[MEASURE]
out O O
of O O
nine O B_NUMBER[MEASURE]
patients O I_NUMBER[MEASURE]
heterozygous O I_NUMBER[MEASURE]
for O O
the O O
C282Y O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

In O O
this O O
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
we O O
demonstrate O O
in O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
293 O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
overexpressing O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_MEASURE/B_LOCATION
or O O
mutant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
HFE O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
proteins O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
that O O
both O O
the O O
wild O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O O
type O B_DISEASE/B_MEASURE
and O O
H63D O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
HFE O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
form O O
stable O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O O
the O O
transferrin O B_GENE/B_BIO
receptor O I_GENE/I_BIO
( O O
TfR O B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

The O O
C282Y O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nearly O O
completely O O
prevents O O
the O O
association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
mutant O B_GENE/B_DISEASE
HFE O I_GENE/I_DISEASE
protein O I_GENE/I_DISEASE
with O O
the O O
TfR O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
cell O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
associated O O
transferrin O B_PROTEIN[GENE]
at O O
37 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
degrees O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
C O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
suggest O O
that O O
the O O
overexpressed O O
wild O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
HFE O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decreases O O
the O O
affinity O B_MEASURE/B_GENE
of O O
the O O
TfR O B_GENE
for O O
transferrin O B_GENE
. O O

The O O
overexpressed O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
H63D O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
protein O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
does O O
not O O
have O O
this O O
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
providing O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
direct O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
a O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequence O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
H63D O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

Addition O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
soluble O B_PROTEIN[GENE]
wild O I_PROTEIN[GENE]
- O O
type O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
HFE O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
/ O O
beta2m O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
heterodimers O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
cultured O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
also O O
decreased O O
the O O
apparent O B_MEASURE
affinity O I_MEASURE
of O O
the O O
TfR O B_GENE
for O O
its O O
ligand O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
under O O
steady O B_DISEASE_ADJECTIVE[DISEASE]
- O O
state O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
conditions O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O O
both O O
in O O
293 O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
in O O
HeLa O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Furthermore O O
, O O
at O O
4 O B_TIME[MEASURE]/B_LOCATION
degrees O I_TIME[MEASURE]/I_LOCATION
C O I_TIME[MEASURE]/I_LOCATION
, O O
the O O
added O O
soluble O B_MEASURE/B_PROTEIN[GENE]
complex O I_MEASURE/I_PROTEIN[GENE]
of O O
HFE O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
beta2m O B_GENE/B_LOCATION
inhibited O O
binding O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
transferrin O B_GENE
to O O
HeLa O B_GENE
cell O I_GENE
TfR O I_GENE
in O O
a O O
concentration O B_MEASURE/B_LOCATION
- O O
dependent O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manner O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O O

Scatchard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
plots O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
of O O
these O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O O
that O O
the O O
added O O
heterodimer O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
substantially O O
reduced O O
the O O
affinity O B_MEASURE/B_GENE
of O O
TfR O B_GENE
for O O
transferrin O B_GENE
. O O

These O O
results O O
establish O O
a O O
molecular O O
link O O
between O O
HFE O O
and O O
a O O
key O O
protein O O
involved O O
in O O
iron O O
transport O O
, O O
the O O
TfR O O
, O O
and O O
raise O O
the O O
possibility O O
that O O
alterations O O
in O O
this O O
regulatory O O
mechanism O O
may O O
play O O
a O O
role O O
in O O
the O O
pathogenesis O O
of O O
hereditary B B_DISEASE
hemochromatosis I I_DISEASE
. O O
. O O

Genomic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
organization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
UBE3A O B_GENE
/ O O
E6 O B_PROTEIN[GENE]/B_LOCATION
- O O
AP O B_GENE/B_DISEASE
gene O I_GENE/I_DISEASE
and O O
related O O
pseudogenes O B_BACTERIUM[BIO]/B_GENE
. O O

The O O
UBE3A O O
gene O O
encodes O O
the O O
E6 O O
- O O
AP O O
ubiquitin O O
- O O
protein O O
ligase O O
and O O
has O O
recently O O
been O O
shown O O
to O O
be O O
mutated O O
in O O
Angelman B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patients O O
who O O
lack O O
15q11 O O
- O O
q13 O O
deletions O O
or O O
chromosome O O
15 O O
paternal O O
uniparental B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
disomy I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

Previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UBE3A O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
has O O
shown O O
a O O
coding O B_LOCATION/B_MEASURE
region O B_LOCATION/I_MEASURE
of O O
approximately O O
2 O B_NUMBER[MEASURE]
. O O

6 O B_GENE/B_MEASURE
kb O I_GENE/I_MEASURE
and O O
a O O
3 O B_TIME[MEASURE]/B_LOCATION
- O O
untranslated O B_GENE/B_LOCATION
region O I_GENE/I_LOCATION
( O O
UTR O B_GENE/B_LOCATION
) O O
of O O
< O B_GENE/B_DISEASE
50 O I_GENE/I_DISEASE
bp O I_GENE/I_DISEASE
, O O
whereas O O
Northern O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
has O O
indicated O O
mRNA O B_MEASURE/B_LOCATION
sizes O I_MEASURE/I_LOCATION
of O O
5 O B_NUMBER[MEASURE]/B_LOCATION
- O O
8 O B_MEASURE
kb O I_MEASURE
. O O

We O O
have O O
analyzed O O
additional O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clones O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
provide O O
evidence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
an O O
additional O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

5 O B_MEASURE/B_LOCATION
kb O I_MEASURE/I_LOCATION
of O O
5 O B_MEASURE/B_LOCATION
- O O
UTR O B_GENE/B_LOCATION
and O O
> O B_MEASURE/B_LOCATION
2 O I_MEASURE/I_LOCATION
kb O I_MEASURE/I_LOCATION
of O O
3 O B_MEASURE/B_LOCATION
- O O
UTR O B_GENE/B_LOCATION
. O O

We O O
have O O
established O O
the O O
genomic O B_LOCATION/B_ORGANIZATION
organization O I_LOCATION/I_ORGANIZATION
of O O
UBE3A O B_GENE
and O O
the O O
sequence O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
intron O B_GENE/B_DISEASE
- O O
exon O B_NUMBER[MEASURE]/B_PERSON
borders O I_NUMBER[MEASURE]/I_PERSON
. O O

We O O
have O O
also O O
mapped O O
two O B_NUMBER[MEASURE]/B_PERSON
highly O O
homologous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processed O O
pseudogenes O B_GENE/B_BACTERIUM[BIO]
, O O
UBE3AP1 O B_GENE
and O O
UBE3AP2 O B_GENE
, O O
to O O
chromosomes O B_MEASURE
2 O I_MEASURE
and O O
21 O B_NUMBER[MEASURE]
, O O
respectively O O
, O O
and O O
determined O O
their O O
genomic O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organization O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O O
form O O
the O O
basis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
studies O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
imprinting O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
UBE3A O B_GENE/B_SPECIES[BIO]
. O O

Mutation O O
spectrum O O
and O O
genotype O O
- O O
phenotype O O
analyses O O
in O O
Cowden B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
and O O
Bannayan B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Zonana I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
, O O
two O O
hamartoma B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndromes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
germline O O
PTEN O O
mutation O O
. O O

The O O
tumour B B_DISEASE/B_GENE
suppressor O O
gene O O
PTEN O O
, O O
which O O
maps O O
to O O
10q23 O O
. O O

3 O O
and O O
encodes O O
a O O
403 O O
amino O O
acid O O
dual O O
specificity O O
phosphatase O O
( O O
protein O O
tyrosine O O
phosphatase O O
; O O
PTPase O O
) O O
, O O
was O O
shown O O
recently O O
to O O
play O O
a O O
broad O O
role O O
in O O
human O O
malignancy B B_DISEASE
. O O

Somatic O O
PTEN O O
deletions O O
and O O
mutations O O
were O O
observed O O
in O O
sporadic B B_DISEASE
breast I I_DISEASE
, I I_DISEASE
brain I I_DISEASE
, I I_DISEASE
prostate I I_DISEASE
and I I_DISEASE
kidney I I_DISEASE
cancer I I_DISEASE
cell O O
lines O O
and O O
in O O
several O O
primary O O
tumours B B_DISEASE/B_LOCATION
such O O
as O O
endometrial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
malignant B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
melanoma I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thyroid B B_DISEASE
tumours I I_DISEASE
. O O

In O O
addition O O
, O O
PTEN O O
was O O
identified O O
as O O
the O O
susceptibility O O
gene O O
for O O
two O O
hamartoma B B_DISEASE
syndromes I I_DISEASE
Cowden B I_DISEASE
disease I I_DISEASE
( O O
CD B B_LOCATION/B_DISEASE
; O O
MIM O O
158350 O O
) O O
and O O
Bannayan B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Zonana I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
BZS I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
or I I_DISEASE/I_GENE
Ruvalcaba I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Riley I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Smith I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
( O O
MIM O O
153480 O O
) O O
. O O

Constitutive O O
DNA O O
from O O
37 O O
CD B B_DISEASE
families O O
and O O
seven O O
BZS B B_DISEASE/B_LOCATION
families O O
was O O
screened O O
for O O
germline O O
PTEN O O
mutations O O
. O O

PTEN O O
mutations O O
were O O
identified O O
in O O
30 O O
of O O
37 O O
( O O
81 O O
% O O
) O O
CD B B_DISEASE
families O O
, O O
including O O
missense O O
and O O
nonsense O O
point O O
mutations O O
, O O
deletions O O
, O O
insertions O O
, O O
a O O
deletion O O
/ O O
insertion O O
and O O
splice O O
site O O
mutations O O
. O O

These O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
scattered O O
over O O
the O O
entire O B_MEASURE/B_LOCATION
length O I_MEASURE/I_LOCATION
of O O
PTEN O B_GENE
, O O
with O O
the O O
exception O B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
first O B_SEQUENCE[MEASURE]
, O O
fourth O B_SEQUENCE[MEASURE]
and O O
last O B_SEQUENCE[MEASURE]/B_ENT
exons O I_SEQUENCE[MEASURE]/I_ENT
. O O

A O O
hot O O
spot O O
for O O
PTEN O O
mutation O O
in O O
CD B B_DISEASE/B_LOCATION
was O O
identified O O
in O O
exon O O
5 O O
that O O
contains O O
the O O
PTPase O O
core O O
motif O O
, O O
with O O
13 O O
of O O
30 O O
( O O
43 O O
% O O
) O O
CD B B_DISEASE/B_GENE
mutations O O
identified O O
in O O
this O O
exon O O
. O O

Seven O B_NUMBER[MEASURE]
of O O
30 O B_NUMBER[MEASURE]/B_PERSON
( O O
23 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
were O O
within O O
the O O
core O B_GENE/B_LOCATION
motif O I_GENE/I_LOCATION
, O O
the O O
majority O B_PERSON/B_MEASURE
( O O
five O B_NUMBER[MEASURE]/B_LOCATION
of O O
seven O B_NUMBER[MEASURE]/B_PERSON
) O O
of O O
which O O
were O O
missense O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
possibly O O
pointing O O
to O O
the O O
functional O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
this O O
region O B_LOCATION
. O O

Germline O O
PTEN O O
mutations O O
were O O
identified O O
in O O
four O O
of O O
seven O O
( O O
57 O O
% O O
) O O
BZS B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
families O O
studied O O
. O O

Interestingly O O
, O O
none O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LOCATION
was O O
observed O O
in O O
the O O
PTPase O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
core O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
motif O I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

It O O
is O O
also O O
worthy O O
of O O
note O O
that O O
a O O
single O O
nonsense O O
point O O
mutation O O
, O O
R233X O O
, O O
was O O
observed O O
in O O
the O O
germline O O
DNA O O
from O O
two O O
unrelated O O
CD B B_DISEASE/B_LOCATION
families O O
and O O
one O O
BZS B B_LOCATION/B_DISEASE
family O O
. O O

Genotype O O
- O O
phenotype O O
studies O O
were O O
not O O
performed O O
on O O
this O O
small O O
group O O
of O O
BZS B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
families O O
. O O

However O O
, O O
genotype O O
- O O
phenotype O O
analysis O O
inthe O O
group O O
of O O
CD B B_DISEASE/B_NUMBER[MEASURE]
families O O
revealed O O
two O O
possible O O
associations O O
worthy O O
of O O
follow O O
- O O
up O O
in O O
independent O O
analyses O O
. O O

The O O
first O O
was O O
an O O
association O O
noted O O
in O O
the O O
group O O
of O O
CD B B_NUMBER[MEASURE]/B_LOCATION
families O O
with O O
breast B B_DISEASE
disease I I_DISEASE
. O O

A O O
correlation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
between O O
the O O
presence O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
a O O
PTEN O B_DISEASE/B_MEASURE
mutation O I_DISEASE/I_MEASURE
and O O
the O O
type O B_MEASURE
of O O
breast O B_DISEASE
involvement O I_DISEASE
( O O
unaffected O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benign O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malignant O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Specifically O O
and O O
more O O
directly O O
, O O
an O O
association O O
was O O
also O O
observed O O
between O O
the O O
presence O O
of O O
a O O
PTEN O O
mutation O O
and O O
malignant B B_DISEASE/B_GENE
breast I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
. O O

Secondly O O
, O O
there O O
appeared O O
to O O
be O O
an O O
interdependent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
association O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
upstream O O
and O O
within O O
the O O
PTPase O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif O I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
core O B_LOCATION
motif O I_LOCATION
containing O O
the O O
majority O B_MEASURE/B_LOCATION
of O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
and O O
the O O
involvement O B_DISEASE/B_GENE
of O O
all O O
major O B_DISEASE/B_LOCATION
organ O B_DISEASE/I_LOCATION
systems O B_DISEASE/I_LOCATION
( O O
central O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
thyroid O B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
breast O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
skin O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
gastrointestinal O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

However O O
, O O
these O O
observations O O
would O O
need O O
to O O
be O O
confirmed O O
by O O
studying O O
a O O
larger O O
number O O
of O O
CD B B_DISEASE/B_LOCATION
families O O
. O O

Molecular O O
defects O O
leading O O
to O O
human O O
complement B B_DISEASE
component I I_DISEASE
C6 I I_DISEASE
deficiency I I_DISEASE
in O O
an O O
African O O
- O O
American O O
family O O
. O O

Complement B B_DISEASE
component I I_DISEASE
C6 I I_DISEASE
deficiency I I_DISEASE
( O O
C6D B B_DISEASE/B_LOCATION
) O O
was O O
diagnosed O O
in O O
a O O
16 O O
- O O
year O O
- O O
old O O
African O O
- O O
American O O
male O O
with O O
meningococcal B B_DISEASE/B_GENE
meningitis I I_DISEASE/I_GENE
. O O

The O O
patients O O
father O O
and O O
two O O
brothers O O
also O O
had O O
C6D B B_DISEASE
, O O
but O O
gave O O
no O O
history O O
of O O
meningitis B B_DISEASE
or O O
other O O
neisserial B B_DISEASE_ADJECTIVE[DISEASE]
infection I I_DISEASE_ADJECTIVE[DISEASE]
. O O

By O O
using O O
exon O B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O O
/ O O
single O B_NUMBER[MEASURE]
- O O
strand O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conformation O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
a O O
screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
nucleotide O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
target O B_GENE/B_BIO
exons O I_GENE/I_BIO
, O O
we O O
determined O O
that O O
the O O
proband O B_PERSON/B_BIO
was O O
a O O
compound O B_PERSON/B_LOCATION
heterozygote O I_PERSON/I_LOCATION
for O O
two O B_DISEASE/B_GENE
C6 O I_DISEASE/I_GENE
gene O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
. O O

The O O
first O O
, O O
1195delC O O
located O O
in O O
exon O O
7 O O
, O O
is O O
a O O
novel O O
mutation O O
, O O
while O O
the O O
second O O
, O O
1936delG O O
in O O
exon O O
12 O O
, O O
has O O
been O O
described O O
before O O
to O O
cause O O
C6D B B_DISEASE/B_GENE
in O O
an O O
unrelated O O
African O O
- O O
American O O
individual O O
. O O

Both O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
result O O
in O O
premature O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
termination O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
codons O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
C6 O B_DISEASE/B_GENE
null O I_DISEASE/I_GENE
alleles O I_DISEASE/I_GENE
. O O

Allele O B_PERSON/B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O O
that O O
the O O
probands O B_PERSON/B_ENT
two O I_PERSON/I_ENT
brothers O I_PERSON/I_ENT
also O O
inherited O O
the O O
1195delC O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
from O O
their O O
heterozygous O B_PERSON
mother O I_PERSON
and O O
the O O
1936delG O B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
from O O
their O O
homozygous O B_PERSON
father O I_PERSON
. O O
. O O

PAX6 O B_PERSON/B_LOCATION
mutations O I_PERSON/I_LOCATION
reviewed O O
. O O

Mutations O O
in O O
PAX6 O O
are O O
responsible O O
for O O
human O O
aniridia B B_DISEASE/B_SPECIES[BIO]
and O O
have O O
also O O
been O O
found O O
in O O
patients O O
with O O
Peters B B_DISEASE
anomaly I I_DISEASE
, O O
with O O
congenital B B_DISEASE
cataracts I I_DISEASE
, O O
with O O
autosomal B B_DISEASE
dominant I I_DISEASE
keratitis I I_DISEASE
, O O
and O O
with O O
isolated B B_DISEASE
foveal I I_DISEASE
hypoplasia I I_DISEASE
. O O

No O O
locus O O
other O O
than O O
chromosome O O
11p13 O O
has O O
been O O
implicated O O
in O O
aniridia B B_DISEASE/B_SPECIES[BIO]
, O O
and O O
PAX6 O O
is O O
clearly O O
the O O
major O O
, O O
if O O
not O O
only O O
, O O
gene O O
responsible O O
. O O

Twenty O B_NUMBER[MEASURE]
- O O
eight O B_NUMBER[MEASURE]
percent O I_NUMBER[MEASURE]
of O O
identified O O
PAX6 O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
are O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
T O B_MEASURE/B_LOCATION
changes O B_MEASURE/I_LOCATION
at O O
CpG O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dinucleotides O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
20 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
are O O
splicing O O
errors O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
more O B_MEASURE/B_PERSON
than O O
30 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
are O O
deletion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
insertion O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

There O O
is O O
a O O
noticeably O O
elevated O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
level O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
the O O
paired O B_GENE/B_BIO
domain O I_GENE/I_BIO
compared O O
with O O
the O O
rest O B_LOCATION/B_MEASURE
of O O
the O O
gene O B_GENE/B_LOCATION
. O O

Increased O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
in O O
the O O
homeodomain O B_GENE/B_BIO
is O O
accounted O O
for O O
by O O
the O O
hypermutable O B_DISEASE_ADJECTIVE[DISEASE]
CpG O I_DISEASE_ADJECTIVE[DISEASE]
dinucleotide O I_DISEASE_ADJECTIVE[DISEASE]
in O O
codon O B_GENE
240 O I_GENE
. O O

Very O O
nearly O O
all O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
appear O O
to O O
cause O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
function O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
mutant O B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
allele O I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O O
and O O
more O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O O
80 O B_NUMBER[MEASURE]/B_LOCATION
% O I_NUMBER[MEASURE]/I_LOCATION
of O O
exonic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitutions O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O O
in O O
nonsense O B_DISEASE/B_GENE
codons O I_DISEASE/I_GENE
. O O

In O O
a O O
gene O B_PERSON/B_GENE
with O O
such O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
extraordinarily O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conservation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
throughout O O
evolution O B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
there O O
are O O
presumed O O
undiscovered O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
missense O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
these O O
are O O
hypothesized O O
to O O
exist O O
in O O
as O O
- O O
yet O O
unidentified O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
phenotypes O I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O O
. O O

Genetic O O
heterogeneity O O
and O O
penetrance O O
analysis O O
of O O
the O O
BRCA1 O O
and O O
BRCA2 O O
genes O O
in O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
cancer I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
families O O
. O O

The O O
Breast B B_PERSON/B_ORGANIZATION
Cancer I B_PERSON/I_ORGANIZATION
Linkage O O
Consortium O O
. O O

The O O
contribution O O
of O O
BRCA1 O O
and O O
BRCA2 O O
to O O
inherited B B_DISEASE/B_GENE
breast I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
was O O
assessed O O
by O O
linkage O O
and O O
mutation O O
analysis O O
in O O
237 O O
families O O
, O O
each O O
with O O
at O O
least O O
four O O
cases O O
of O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
, O O
collected O O
by O O
the O O
Breast B B_DISEASE/B_LOCATION
Cancer I B_DISEASE/I_LOCATION
Linkage O O
Consortium O O
. O O

Families O O
were O O
included O O
without O O
regard O O
to O O
the O O
occurrence O O
of O O
ovarian B B_DISEASE
or I I_DISEASE
other I I_DISEASE
cancers I I_DISEASE
. O O

Overall O O
, O O
disease O B_DISEASE/B_GENE
was O O
linked O O
to O O
BRCA1 O B_GENE/B_DISEASE
in O O
an O O
estimated O O
52 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
, O O
to O O
BRCA2 O B_GENE/B_DISEASE
in O O
32 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
, O O
and O O
to O O
neither O O
gene O B_GENE
in O O
16 O B_PERSON/B_NUMBER[MEASURE]
% O I_PERSON/I_NUMBER[MEASURE]
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
confidence O I_MEASURE/I_LOCATION
interval O I_MEASURE/I_LOCATION
[ O O
CI O B_MEASURE/B_LOCATION
] O O
6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
- O O
28 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
suggesting O O
other O B_DISEASE/B_GENE
predisposition O I_DISEASE/I_GENE
genes O I_DISEASE/I_GENE
. O O

The O O
majority O O
( O O
81 O O
% O O
) O O
of O O
the O O
breast B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
ovarian I I_DISEASE_ADJECTIVE[DISEASE]
cancer I I_DISEASE_ADJECTIVE[DISEASE]
families O O
were O O
due O O
to O O
BRCA1 O O
, O O
with O O
most O O
others O O
( O O
14 O O
% O O
) O O
due O O
to O O
BRCA2 O O
. O O

Conversely O O
, O O
the O O
majority O O
of O O
families O O
with O O
male B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
female I I_DISEASE/I_LOCATION
breast I I_DISEASE/I_LOCATION
cancer I I_DISEASE/I_LOCATION
were O O
due O O
to O O
BRCA2 O O
( O O
76 O O
% O O
) O O
. O O

The O O
largest O O
proportion O O
( O O
67 O O
% O O
) O O
of O O
families O O
due O O
to O O
other O O
genes O O
was O O
found O O
in O O
families O O
with O O
four O O
or O O
five O O
cases O O
of O O
female O O
breast B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
only O O
. O O

These O O
estimates O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O O
not O O
substantially O O
affected O O
either O O
by O O
changing O O
the O O
assumed O O
penetrance O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
BRCA1 O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O O
by O O
including O O
or O O
excluding O O
BRCA1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mutation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

Among O O
those O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O O
disease O B_DISEASE/B_GENE
due O O
to O O
BRCA1 O B_DISEASE/B_GENE
that O O
were O O
tested O O
by O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
standard O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
methods O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O O
detected O O
in O O
the O O
coding O B_GENE
sequence O I_GENE
or O O
splice O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
an O O
estimated O B_MEASURE/B_PERSON
63 O B_MEASURE/I_PERSON
% O B_MEASURE/I_PERSON
( O O
95 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
CI O I_MEASURE/I_LOCATION
51 O I_MEASURE/I_LOCATION
% O I_MEASURE/I_LOCATION
- O O
77 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
. O O

The O O
estimated O O
sensitivity O B_MEASURE
was O O
identical O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O O
other O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
penetrance O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
BRCA2 O B_DISEASE/B_GENE
was O O
estimated O O
by O O
maximizing O O
the O O
LOD O B_MEASURE
score O I_MEASURE
in O O
BRCA2 O B_GENE/B_NUMBER[MEASURE]
- O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
families O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
over O O
all O O
possible O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
penetrance O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
functions O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

The O O
estimated O O
cumulative O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
reached O O
28 O O
% O O
( O O
95 O O
% O O
CI O O
9 O O
% O O
- O O
44 O O
% O O
) O O
by O O
age O O
50 O O
years O O
and O O
84 O O
% O O
( O O
95 O O
% O O
CI O O
43 O O
% O O
- O O
95 O O
% O O
) O O
by O O
age O O
70 O O
years O O
. O O

The O O
corresponding O O
ovarian B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cancer I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
risks O O
were O O
0 O O
. O O

4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
0 O I_MEASURE
% O I_MEASURE
- O O
1 O B_MEASURE
% O I_MEASURE
) O O
by O O
age O B_PERSON
50 O I_PERSON
years O I_PERSON
and O O
27 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
95 O B_MEASURE
% O I_MEASURE
CI O I_MEASURE
0 O I_MEASURE
% O I_MEASURE
- O O
47 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
) O O
by O O
age O B_PERSON
70 O I_PERSON
years O I_PERSON
. O O

The O O
lifetime O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
appears O O
similar O O
to O O
the O O
risk O O
in O O
BRCA1 O O
carriers O O
, O O
but O O
there O O
was O O
some O O
suggestion O O
of O O
a O O
lower O O
risk O O
in O O
BRCA2 O O
carriers O O
< O O
50 O O
years O O
of O O
age O O
. O O

Eye B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
movement I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
correlate O O
with O O
genotype O O
in O O
autosomal O O
dominant O O
cerebellar B B_DISEASE/B_PERSON
ataxia I I_DISEASE/I_PERSON
type I I_DISEASE/I_PERSON
I I I_DISEASE/I_PERSON
. O O

We O O
compared O O
horizontal O O
eye O O
movements O O
( O O
visually O O
guided O O
saccades O O
, O O
antisaccades O O
, O O
and O O
smooth O O
pursuit O O
) O O
in O O
control O O
subjects O O
( O O
n O O
= O O
14 O O
) O O
and O O
patients O O
with O O
three O O
forms O O
of O O
autosomal O O
dominant O O
cerebellar B B_DISEASE/B_GENE
ataxias I I_DISEASE/I_GENE
type I I_DISEASE/I_GENE
I I I_DISEASE/I_GENE
spinocerebellar B I_DISEASE/I_GENE
ataxias I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
and I I_DISEASE/I_GENE
2 I I_DISEASE/I_GENE
( O O
SCA1 B B_DISEASE/B_GENE
, O O
n O O
= O O
11 O O
; O O
SCA2 B B_DISEASE/B_GENE
, O O
n O O
= O O
10 O O
) O O
and O O
SCA3 B B_PERSON
/ O O
Machado B B_MEASURE
- I I_MEASURE
Joseph I I_MEASURE
disease I I_MEASURE
( O O
MJD B B_DISEASE/B_GENE
) O O
( O O
n O O
= O O
16 O O
) O O
. O O

In O O
SCA1 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
saccade O O
amplitude O O
was O O
significantly O O
increased O O
, O O
resulting O O
in O O
hypermetria B B_DISEASE
. O O

The O O
smooth O B_DISEASE/B_MEASURE
pursuit O I_DISEASE/I_MEASURE
gain O I_DISEASE/I_MEASURE
was O O
decreased O O
. O O

In O O
SCA2 B B_DISEASE/B_TIME[MEASURE]
, O O
saccade O O
velocity O O
was O O
markedly O O
decreased O O
. O O

The O O
percentage O B_MEASURE
of O O
errors O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O O
antisaccades O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O O
greatly O O
increased O O
and O O
was O O
significantly O O
correlated O O
with O O
age O B_TIME[MEASURE]/B_DISEASE
at O O
disease O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
onset O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
addition O B_MEASURE/B_LOCATION
, O O
a O O
correlation O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
smooth O B_DISEASE/B_GENE
pursuit O I_DISEASE/I_GENE
gain O I_DISEASE/I_GENE
and O O
the O O
number O B_MEASURE/B_LOCATION
of O O
trinucleotide O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repeats O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
found O O
. O O

In O O
SCA3 B B_PERSON/B_BIO
, O O
gaze B B_DISEASE
- I I_DISEASE
evoked I I_DISEASE
nystagmus I I_DISEASE
was O O
often O O
present O O
as O O
was O O
saccade O O
hypometria O O
and O O
smooth O O
pursuit O O
gain O O
was O O
markedly O O
decreased O O
. O O

Three O O
major O O
criteria O O
, O O
saccade O O
amplitude O O
, O O
saccade O O
velocity O O
, O O
and O O
presence O O
of O O
gaze B B_DISEASE
- I I_DISEASE
evoked I I_DISEASE
nystagmus I I_DISEASE
, O O
permitted O O
the O O
correct O O
assignment O O
of O O
90 O O
% O O
of O O
the O O
SCA1 B B_DISEASE/B_PERSON
, O O
90 O O
% O O
of O O
the O O
SCA2 B B_DISEASE/B_PERSON
, O O
and O O
93 O O
% O O
of O O
the O O
patients O O
with O O
SCA3 B B_DISEASE/B_GENE
to O O
their O O
genetically O O
confirmed O O
patient O O
group O O
and O O
, O O
therefore O O
, O O
may O O
help O O
orient O O
diagnoses O O
of O O
SCA1 B B_DISEASE/B_GENE
, O O
SCA2 B B_DISEASE/B_GENE
, O O
and O O
SCA3 B B_DISEASE/B_PERSON
at O O
early O O
clinical O O
stages O O
of O O
the O O
diseases O O
. O O
. O O

Genetic O O
basis O O
and O O
molecular O O
mechanism O O
for O O
idiopathic B B_DISEASE
ventricular I I_DISEASE
fibrillation I I_DISEASE
. O O

Ventricular B B_DISEASE
fibrillation I I_DISEASE
causes O O
more O O
than O O
300 O O
, O O
000 O O
sudden O O
deaths O O
each O O
year O O
in O O
the O O
USA O O
alone O O
. O O

In O O
approximately O O
5 O O
- O O
12 O O
% O O
of O O
these O O
cases O O
, O O
there O O
are O O
no O O
demonstrable O O
cardiac O O
or O O
non O O
- O O
cardiac O O
causes O O
to O O
account O O
for O O
the O O
episode O O
, O O
which O O
is O O
therefore O O
classified O O
as O O
idiopathic B B_DISEASE/B_ORGANISM_FUNCTION
ventricular I I_DISEASE/I_ORGANISM_FUNCTION
fibrillation I I_DISEASE/I_ORGANISM_FUNCTION
( O O
IVF B B_LOCATION/B_ORGANIZATION
) O O
. O O

A O O
distinct O O
group O O
of O O
IVF B B_DISEASE/B_PERSON
patients O O
has O O
been O O
found O O
to O O
present O O
with O O
a O O
characteristic O O
electrocardiographic O O
pattern O O
. O O

Because O O
of O O
the O O
small O O
size O O
of O O
most O O
pedigrees O O
and O O
the O O
high O O
incidence O O
of O O
sudden B B_DISEASE
death I I_DISEASE
, O O
however O O
, O O
molecular O O
genetic O O
studies O O
of O O
IVF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O O
not O O
yet O O
been O O
done O O
. O O

Because O O
IVF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes O O
cardiac O O
rhythm O O
disturbance O O
, O O
we O O
investigated O O
whether O O
malfunction O O
of O O
ion O O
channels O O
could O O
cause O O
the O O
disorder O O
by O O
studying O O
mutations O O
in O O
the O O
cardiac O O
sodium O O
channel O O
gene O O
SCN5A O O
. O O

We O O
have O O
now O O
identified O O
a O O
missense O O
mutation O O
, O O
a O O
splice O O
- O O
donor O O
mutation O O
, O O
and O O
a O O
frameshift O O
mutation O O
in O O
the O O
coding O O
region O O
of O O
SCN5A O O
in O O
three O O
IVF B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
families O O
. O O

We O O
show O O
that O O
sodium O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
channels O I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
with O O
the O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
recover O O
from O O
inactivation O B_DISEASE
more O O
rapidly O O
than O O
normal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
that O O
the O O
frameshift O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
causes O O
the O O
sodium O B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
channel O B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
to O O
be O O
non O B_DISEASE
- O O
functional O B_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
results O O
indicate O O
that O O
mutations O O
in O O
cardiac O O
ion O O
- O O
channel O O
genes O O
contribute O O
to O O
the O O
risk O O
of O O
developing O O
IVF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O
. O O

Molecular O O
heterogeneity O O
in O O
mucopolysaccharidosis B B_DISEASE/B_LOCATION
IVA I I_DISEASE/I_LOCATION
in O O
Australia O O
and O O
Northern O O
Ireland O O
: O O
nine O O
novel O O
mutations O O
including O O
T312S O O
, O O
a O O
common O O
allele O O
that O O
confers O O
a O O
mild O O
phenotype O O
. O O

Mucopolysaccharidosis B B_DISEASE/B_PROTEIN[GENE]
IVA I B_DISEASE/I_PROTEIN[GENE]
( O O
MPS B B_LOCATION/B_PERSON
IVA I I_LOCATION/I_PERSON
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
lysosomal I I_DISEASE/I_GENE
storage I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
caused O O
by O O
a O O
genetic B B_DISEASE_ADJECTIVE[DISEASE]
defect I I_DISEASE_ADJECTIVE[DISEASE]
in O O
N O O
- O O
acetylgalactosamine O O
- O O
6 O O
- O O
sulfate O O
sulfatase O O
( O O
GALNS O O
) O O
. O O

Previous O O
studies O O
of O O
patients O O
from O O
a O O
British O O
- O O
Irish O O
population O O
showed O O
that O O
the O O
I113F O O
mutation O O
is O O
the O O
most O O
common O O
single O O
mutation O O
among O O
MPS B B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
and O O
produces O O
a O O
severe O O
clinical O O
phenotype O O
. O O

We O O
studied O O
mutations O O
in O O
the O O
GALNS O O
gene O O
from O O
23 O O
additional O O
MPS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
( O O
15 O O
from O O
Australia O O
, O O
8 O O
from O O
Northern O O
Ireland O O
) O O
, O O
with O O
various O O
clinical O O
phenotypes O O
( O O
severe O O
, O O
16 O O
cases O O
; O O
intermediate O O
, O O
4 O O
cases O O
; O O
mild O O
, O O
3 O O
cases O O
) O O
. O O

We O O
found O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
common O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
that O O
together O O
accounted O O
for O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
the O O
44 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
unrelated O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
alleles O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
these O O
patients O B_PERSON/B_BIO
. O O

One O B_SEQUENCE[MEASURE]/B_PERSON
is O O
the O O
T312S O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
a O O
novel O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O O
exclusively O O
in O O
milder O B_PERSON/B_BIO
patients O B_PERSON/I_BIO
. O O

The O O
other O B_SEQUENCE[MEASURE]/B_DISEASE
is O O
the O O
previously O O
described O O
I113F O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O O
produces O O
a O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
I113F O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
T312S O B_DISEASE/B_PROTEIN[GENE]
mutations O B_DISEASE/I_PROTEIN[GENE]
accounted O O
for O O
8 O B_MEASURE
( O O
18 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
and O O
6 O B_MEASURE
( O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
44 O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
unrelated O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alleles O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
respectively O O
. O O

The O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
residual O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
GALNS O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activity O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seen O O
when O O
the O O
T312S O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
overexpressed O O
in O O
mutant O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
provides O O
an O O
explanation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O O
the O O
mild O B_DISEASE_ADJECTIVE[DISEASE]
phenotype O I_DISEASE_ADJECTIVE[DISEASE]
in O O
patients O B_PERSON/B_BIO
with O O
this O O
mutation O B_DISEASE/B_GENE
. O O

The O O
distribution O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O O
relative O B_MEASURE/B_LOCATION
frequencies O I_MEASURE/I_LOCATION
of O O
the O O
I113F O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
T312S O B_DISEASE/B_GENE
mutations O B_DISEASE/I_GENE
in O O
Australia O B_LOCATION/B_PERSON
corresponded O O
to O O
those O O
observed O O
in O O
Northern O B_LOCATION
Ireland O I_LOCATION
and O O
are O O
unique O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O O
these O O
two O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
suggesting O O
that O O
both O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O O
probably O O
introduced O O
to O O
Australia O B_LOCATION
by O O
Irish O B_PERSON/B_LOCATION
migrants O I_PERSON/I_LOCATION
during O O
the O O
19th O B_TIME[MEASURE]/B_LOCATION
century O I_TIME[MEASURE]/I_LOCATION
. O O

Haplotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
6 O B_GENE
RFLPs O I_GENE
provides O O
additional O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O O
the O O
I113F O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
originated O O
from O O
a O O
common O B_PERSON/B_GENE
ancestor O I_PERSON/I_GENE
. O O

The O O
other O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
9 O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
novel O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
identified O O
in O O
these O O
23 O B_PERSON/B_TIME[MEASURE]
patients O I_PERSON/I_TIME[MEASURE]
were O O
each O O
limited O O
to O O
a O O
single O B_MEASURE/B_PERSON
family O I_MEASURE/I_PERSON
. O O

These O O
data O O
provide O O
further O O
evidence O O
for O O
extensive O O
allelic O O
heterogeneity O O
in O O
MPS B B_DISEASE/B_GENE
IVA I B_DISEASE/I_GENE
in O O
British O O
- O O
Irish O O
patients O O
and O O
provide O O
evidence O O
for O O
their O O
transmission O O
to O O
Australia O O
by O O
British O O
- O O
Irish O O
migrants O O
. O O
. O O

Identification O O
of O O
constitutional O O
WT1 O O
mutations O O
, O O
in O O
patients O O
with O O
isolated O O
diffuse B B_DISEASE/B_GENE
mesangial I I_DISEASE/I_GENE
sclerosis I I_DISEASE/I_GENE
, O O
and O O
analysis O O
of O O
genotype O O
/ O O
phenotype O O
correlations O O
by O O
use O O
of O O
a O O
computerized O O
mutation O O
database O O
. O O

Constitutional O O
mutations O O
of O O
the O O
WT1 O O
gene O O
, O O
encoding O O
a O O
zinc O O
- O O
finger O O
transcription O O
factor O O
involved O O
in O O
renal O O
and O O
gonadal O O
development O O
, O O
are O O
found O O
in O O
most O O
patients O O
with O O
Denys B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Drash I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
DDS B B_DISEASE
) O O
, O O
or O O
diffuse B B_DISEASE
mesangial I I_DISEASE
sclerosis I I_DISEASE
( O O
DMS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
associated O O
with O O
pseudohermaphroditism B B_DISEASE/B_BIO
and O O
/ O O
or O O
Wilms B B_DISEASE/B_GENE
tumor I I_DISEASE/I_GENE
( O O
WT B B_PROTEIN[GENE]/B_LOCATION
) O O
. O O

Most O O
mutations O O
in O O
DDS B B_DISEASE/B_PERSON
patients O O
lie O O
in O O
exon O O
8 O O
or O O
exon O O
9 O O
, O O
encoding O O
zinc O O
finger O O
2 O O
or O O
zinc O O
finger O O
3 O O
, O O
respectively O O
, O O
with O O
a O O
hot O O
spot O O
( O O
R394W O O
) O O
in O O
exon O O
9 O O
. O O

We O O
analyzed O O
a O O
series O O
of O O
24 O O
patients O O
, O O
10 O O
with O O
isolated B B_DISEASE/B_GENE
DMS I I_DISEASE/I_GENE
( O O
IDMS B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
10 O O
with O O
DDS B B_DISEASE/B_LOCATION
, O O
and O O
4 O O
with O O
urogenital B B_DISEASE/B_PROTEIN[GENE]
abnormalities I B_DISEASE/I_PROTEIN[GENE]
and O O
/ O O
or O O
WT B B_DISEASE/B_GENE
. O O

We O O
report O O
WT1 O O
heterozygous O O
mutations O O
in O O
16 O O
patients O O
, O O
4 O O
of O O
whom O O
presented O O
with O O
IDMS B B_DISEASE
. O O

One O O
male O O
and O O
two O O
female O O
IDMS B B_DISEASE/B_PERSON
patients O O
with O O
WT1 O O
mutations O O
underwent O O
normal O O
puberty O O
. O O

Two O O
mutations O O
associated O O
with O O
IDMS B B_DISEASE
are O O
different O O
from O O
those O O
described O O
in O O
DDS B B_DISEASE/B_MEASURE
patients O O
. O O

No O O
WT1 O O
mutations O O
were O O
detected O O
in O O
the O O
six O O
other O O
IDMS B B_DISEASE/B_NUMBER[MEASURE]
patients O O
, O O
suggesting O O
genetic O O
heterogeneity O O
of O O
this O O
disease O O
. O O

We O O
analyzed O O
genotype O B_GENE/B_DISEASE
/ O O
phenotype O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
on O O
the O O
basis O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
constitution O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
WT1 O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mutation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
database O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
84 O B_SEQUENCE[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
germ O I_SEQUENCE[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
line O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O O
to O O
compare O O
the O O
distribution O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
type O B_DISEASE/B_MEASURE
of O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O O
according O O
to O O
the O O
different O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
symptoms O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

This O O
demonstrated O O
( O O
1 O O
) O O
the O O
association O O
between O O
mutations O O
in O O
exons O O
8 O O
and O O
9 O O
and O O
DMS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
( O O
2 O O
) O O
among O O
patients O O
with O O
DMS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
higher O O
frequency O O
of O O
exon O O
8 O O
mutations O O
among O O
46 O O
, O O
XY O O
patients O O
with O O
female O O
phenotype O O
than O O
among O O
46 O O
, O O
XY O O
patients O O
with O O
sexual O O
ambiguity O O
or O O
male O O
phenotype O O
; O O
and O O
( O O
3 O O
) O O
statistically O O
significant O O
evidence O O
that O O
mutations O O
in O O
exons O O
8 O O
and O O
9 O O
preferentially O O
affect O O
amino O O
acids O O
with O O
different O O
functions O O
. O O
. O O

The O O
185delAG O B_DISEASE/B_MEASURE
BRCA1 O I_DISEASE/I_MEASURE
mutation O I_DISEASE/I_MEASURE
originated O O
before O O
the O O
dispersion O B_TIME[MEASURE]/B_PERSON
of O O
Jews O B_PERSON/B_LOCATION
in O O
the O O
diaspora O B_LOCATION/B_PERSON
and O O
is O O
not O O
limited O O
to O O
Ashkenazim O B_PERSON/B_LOCATION
. O O

The O O
185delAG O O
mutation O O
in O O
BRCA1 O O
is O O
detected O O
in O O
Ashkenazi O O
Jews O O
both O O
in O O
familial B B_PERSON/B_LOCATION
breast I I_PERSON/I_LOCATION
and I I_PERSON/I_LOCATION
ovarian I I_PERSON/I_LOCATION
cancer I I_PERSON/I_LOCATION
and O O
in O O
the O O
general O O
population O O
. O O

All O O
tested O O
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
carriers O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
share O O
the O O
same O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
allelic O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
at O O
the O O
BRCA1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
this O O
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
also O O
occurs O O
in O O
Iraqi O B_PERSON/B_LOCATION
Jews O I_PERSON/I_LOCATION
with O O
a O O
similar O B_DISEASE/B_PERSON
allelic O I_DISEASE/I_PERSON
pattern O I_DISEASE/I_PERSON
. O O

We O O
extended O O
our O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
other O B_PERSON/B_DISEASE
non O I_PERSON/I_DISEASE
- O O
Ashkenazi O B_PERSON
subsets O I_PERSON
354 O I_PERSON
of O O
Moroccan O B_MEASURE/B_PERSON
origin O I_MEASURE/I_PERSON
, O O
200 O B_MEASURE/B_PERSON
Yemenites O I_MEASURE/I_PERSON
and O O
150 O B_PERSON
Iranian O I_PERSON
Jews O I_PERSON
. O O

Heteroduplex O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complemented O O
by O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
abnormally O O
migrating O O
bands O B_LOCATION/B_GENE
were O O
employed O O
. O O

Four O B_NUMBER[MEASURE]/B_PERSON
of O O
Moroccan O B_PERSON/B_LOCATION
origin O I_PERSON/I_LOCATION
( O O
1 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
and O O
none O B_PERSON/B_NUMBER[MEASURE]
of O O
the O O
Yemenites O B_PERSON/B_LOCATION
or O O
Iranians O B_PERSON/B_LOCATION
was O O
a O O
carrier O B_PERSON/B_MEASURE
of O O
the O O
185delAG O B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]
. O O

BRCA1 O O
allelic O O
patterns O O
were O O
determined O O
for O O
four O O
of O O
these O O
individuals O O
and O O
for O O
12 O O
additional O O
non O O
- O O
Ashkenazi O O
185delAG O O
mutation O O
carriers O O
who O O
had O O
breast B B_DISEASE
/ I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O

Six O B_NUMBER[MEASURE]/B_DISEASE
non O I_NUMBER[MEASURE]/I_DISEASE
- O O
Ashkenazi O B_PERSON
individuals O I_PERSON
shared O O
the O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
haplotype O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
four O B_NUMBER[MEASURE]
had O O
a O O
closely O O
related O O
pattern O B_DISEASE/B_GENE
, O O
and O O
the O O
rest O B_SEQUENCE[MEASURE]/B_LOCATION
( O O
n O B_OTHER/B_LOCATION
= O O
6 O B_MEASURE
) O O
displayed O O
a O O
distinct O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
BRCA1 O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
allelic O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
pattern O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

We O O
conclude O O
that O O
the O O
185delAG O B_DISEASE_ADJECTIVE[DISEASE]
BRCA1 O I_DISEASE_ADJECTIVE[DISEASE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]
occurs O O
in O O
some O O
non O B_LOCATION/B_PERSON
- O O
Ashkenazi O B_PERSON/B_LOCATION
populations O I_PERSON/I_LOCATION
at O O
rates O B_MEASURE/B_LOCATION
comparable O I_MEASURE/I_LOCATION
with O O
that O O
of O O
Ashkenazim O B_PERSON/B_LOCATION
. O O

The O O
majority O B_PERSON/B_LOCATION
of O O
Jewish O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
185delAG O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
carriers O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
have O O
a O O
common O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
allelic O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pattern O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
supporting O O
the O O
founder O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
notion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O O
but O O
dating O O
the O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]
origin O I_DISEASE_ADJECTIVE[DISEASE]
to O O
an O O
earlier O B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
date O I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O O
currently O O
estimated O O
. O O

However O O
, O O
the O O
different O B_DISEASE_ADJECTIVE[DISEASE]
allelic O I_DISEASE_ADJECTIVE[DISEASE]
pattern O I_DISEASE_ADJECTIVE[DISEASE]
at O O
the O O
BRCA1 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
locus O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
even O O
in O O
some O O
Jewish O B_DISEASE/B_PERSON
mutation O I_DISEASE/I_PERSON
carriers O I_DISEASE/I_PERSON
, O O
might O O
suggest O O
that O O
the O O
mutation O B_DISEASE/B_GENE
arose O O
independently O O
. O O
. O O

Crystal O O
structure O O
of O O
the O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
HFE O O
and O O
characterization O O
of O O
its O O
interaction O O
with O O
transferrin O O
receptor O O
. O O

HFE O O
is O O
an O O
MHC O O
- O O
related O O
protein O O
that O O
is O O
mutated O O
in O O
the O O
iron B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
overload I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hereditary B I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hemochromatosis I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

HFE O B_DISEASE/B_PROTEIN[GENE]
binds O O
to O O
transferrin O O
receptor O B_PROTEIN[GENE]/B_DISEASE
( O O
TfR O B_PROTEIN[GENE]/B_LOCATION
) O O
and O O
reduces O O
its O O
affinity O B_MEASURE/B_GENE
for O O
iron O B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
loaded O O
transferrin O B_PROTEIN[GENE]
, O O
implicating O O
HFE O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O O
iron O B_DISEASE
metabolism O I_DISEASE
. O O

The O O
2 O B_TIME[MEASURE]/B_PERSON
. O O

6 O O
A O O
crystal O O
structure O O
of O O
HFE O O
reveals O O
the O O
locations O O
of O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O O
and O O
a O O
patch O O
of O O
histidines O O
that O O
could O O
be O O
involved O O
in O O
pH O O
- O O
dependent O O
interactions O O
. O O

We O O
also O O
demonstrate O O
that O O
soluble O B_PROTEIN[GENE]/B_LOCATION
TfR O I_PROTEIN[GENE]/I_LOCATION
and O O
HFE O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bind O O
tightly O O
at O O
the O O
basic O B_LOCATION/B_MEASURE
pH O I_LOCATION/I_MEASURE
of O O
the O O
cell O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
surface O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O O
but O O
not O O
at O O
the O O
acidic O B_MEASURE/B_LOCATION
pH O B_MEASURE/I_LOCATION
of O O
intracellular O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vesicles O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

TfR O B_GENE/B_MEASURE
HFE O B_GENE/I_MEASURE
stoichiometry O B_GENE/I_MEASURE
( O O
2 O B_MEASURE
1 O I_MEASURE
) O O
differs O O
from O O
TfR O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transferrin O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stoichiometry O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
2 O B_MEASURE
2 O I_MEASURE
) O O
, O O
implying O O
a O O
different O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mode O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
binding O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
HFE O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O O
transferrin O B_GENE
to O O
TfR O B_GENE
, O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
our O O
demonstration O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O O
HFE O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
transferrin O B_GENE
, O O
and O O
TfR O B_GENE
form O O
a O O
ternary O B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex O I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Identification O O
of O O
three O O
novel O O
mutations O O
and O O
a O O
high O O
frequency O O
of O O
the O O
Arg778Leu O O
mutation O O
in O O
Korean O O
patients O O
with O O
Wilson B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
. O O

Four O O
mutations O O
- O O
- O O
R778L O O
, O O
A874V O O
, O O
L1083F O O
, O O
and O O
2304delC O O
- O O
- O O
in O O
the O O
copper O O
- O O
transporting O O
enzyme O O
, O O
P O O
- O O
type O O
ATPase O O
( O O
ATP7B O O
) O O
, O O
were O O
identified O O
in O O
Korean O O
Patients O O
with O O
Wilson B B_DISEASE
disease I I_DISEASE
. O O

Arg778Leu O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
the O O
most O O
frequently O O
reported O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
of O O
this O O
enzyme O B_BIO/B_GENE
, O O
was O O
found O O
in O O
six O B_NUMBER[MEASURE]
of O O
eight O B_NUMBER[MEASURE]/B_PERSON
unrelated O I_NUMBER[MEASURE]/I_PERSON
patients O I_NUMBER[MEASURE]/I_PERSON
studied O O
, O O
an O O
allele O B_MEASURE
frequency O I_MEASURE
of O O
37 O B_NUMBER[MEASURE]
. O O

5 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
, O O
which O O
is O O
considerably O O
higher O B_MEASURE
than O O
those O O
in O O
other O B_LOCATION
Asian O I_LOCATION
populations O I_LOCATION
. O O

The O O
novel O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
single O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
nucleotide O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
deletion O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O O
2304delC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
was O O
found O O
in O O
one O B_PERSON/B_BIO
patient O B_PERSON/I_BIO
. O O

Since O O
a O O
mutation O O
at O O
cDNA O O
nucleotide O O
2302 O O
( O O
2302insC O O
) O O
had O O
been O O
previously O O
described O O
, O O
this O O
region O O
of O O
the O O
ATP7B O O
gene O O
may O O
be O O
susceptible O O
to O O
gene O O
rearrangements O O
causing O O
Wilson B B_DISEASE
disease I I_DISEASE
. O O

Disruption O O
of O O
splicing O O
regulated O O
by O O
a O O
CUG O O
- O O
binding O O
protein O O
in O O
myotonic B B_DISEASE/B_BIO
dystrophy I I_DISEASE/I_BIO
. O O

Myotonic B B_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_LOCATION
) O O
is O O
caused O O
by O O
a O O
CTG O O
expansion O O
in O O
the O O
3 O O
untranslated O O
region O O
of O O
the O O
DM B B_GENE/B_DISEASE
gene O O
. O O

One O O
model O O
of O O
DM B B_DISEASE
pathogenesis O O
suggests O O
that O O
RNAs O O
from O O
the O O
expanded O O
allele O O
create O O
a O O
gain O O
- O O
of O O
- O O
function O O
mutation O O
by O O
the O O
inappropriate O O
binding O O
of O O
proteins O O
to O O
the O O
CUG O O
repeats O O
. O O

Data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presented O O
here O O
indicate O O
that O O
the O O
conserved O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heterogeneous O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribonucleoprotein O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
CUG O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
binding O O
protein O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O O
CUG O B_PROTEIN[GENE]/B_LOCATION
- O O
BP O B_PROTEIN[GENE]/B_LOCATION
) O O
, O O
may O O
mediate O O
the O O
trans O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
dominant O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
effect O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
RNA O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

CUG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
BP O B_MEASURE
was O O
found O O
to O O
bind O O
to O O
the O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cardiac O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
troponin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
cTNT O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
messenger O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
regulate O O
its O O
alternative O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Splicing O O
of O O
cTNT O O
was O O
disrupted O O
in O O
DM B B_DISEASE/B_MEASURE
striated O O
muscle O O
and O O
in O O
normal O O
cells O O
expressing O O
transcripts O O
that O O
contain O O
CUG O O
repeats O O
. O O

Altered O O
expression O O
of O O
genes O O
regulated O O
posttranscriptionally O O
by O O
CUG O O
- O O
BP O O
therefore O O
may O O
contribute O O
to O O
DM B B_DISEASE/B_LOCATION
pathogenesis O O
. O O
. O O

Identification O O
of O O
a O O
novel O O
nonsense O O
mutation O O
and O O
a O O
missense O O
substitution O O
in O O
the O O
vasopressin O O
- O O
neurophysin O O
II O O
gene O O
in O O
two O O
Spanish O O
kindreds O O
with O O
familial B B_DISEASE
neurohypophyseal I I_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
. O O

Familial B B_DISEASE/B_PERSON
neurohypophyseal I I_DISEASE/I_PERSON
diabetes I I_DISEASE/I_PERSON
insipidus I I_DISEASE/I_PERSON
( O O
FNDI B B_DISEASE
) O O
is O O
an O O
autosomal B B_DISEASE
dominant I I_DISEASE
disease I I_DISEASE
caused O O
by O O
deficiency O O
in O O
the O O
antidiuretic O O
hormone O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
encoded O O
by O O
the O O
AVP O O
- O O
neurophysin O O
II O O
( O O
AVP O O
- O O
NPII O O
) O O
gene O O
on O O
chromosome O O
20p13 O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
two O O
families O O
with O O
FNDI B B_DISEASE
using O O
direct O O
automated O O
fluorescent O O
, O O
solid O O
phase O O
, O O
single O O
- O O
stranded O O
DNA O O
sequencing O O
of O O
PCR O O
- O O
amplified O O
AVP O O
- O O
NPII O O
DNA O O
. O O

In O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
families O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
affected O B_PERSON
individuals O I_PERSON
presented O O
a O O
novel O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
nonsense O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
exon O B_GENE/B_LOCATION
3 O B_GENE/I_LOCATION
of O O
the O O
gene O B_GENE/B_DISEASE
, O O
consisting O O
in O O
a O O
G O B_OTHER/B_LOCATION
to O O
T O B_MEASURE/B_DISEASE
transition O I_MEASURE/I_DISEASE
at O O
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
2101 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
produces O O
a O O
stop O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
codon O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
82 O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
( O O
Glu O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
of O O
NPII O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
. O O

The O O
premature O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
termination O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eliminates O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
terminal O B_LOCATION/B_MEASURE
domain O I_LOCATION/I_MEASURE
of O O
NPII O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
a O O
cysteine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
position O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
85 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
, O O
which O O
could O O
be O O
involved O O
in O O
the O O
correct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
folding O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
the O O
prohormone O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

In O O
the O O
second O B_PERSON/B_TIME[MEASURE]
family O I_PERSON/I_TIME[MEASURE]
, O O
a O O
G279A O B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitution O B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
position O B_LOCATION
- O O
1 O B_MEASURE
of O O
the O O
signal O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
observed O O
in O O
all O O
affected O O
individuals O B_PERSON/B_BIO
. O O

This O O
missense O O
mutation O O
, O O
which O O
replaces O O
Ala O O
with O O
Thr O O
, O O
is O O
frequent O O
among O O
FNDI B B_DISEASE/B_LOCATION
patients O O
and O O
is O O
thought O O
to O O
reduce O O
the O O
efficiency O O
of O O
cleavage O O
by O O
signal O O
peptidases O O
. O O
. O O

Genetic O O
heterogeneity O O
of O O
Saethre B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Chotzen I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
, O O
due O O
to O O
TWIST O O
and O O
FGFR O O
mutations O O
. O O

Thirty O O
- O O
two O O
unrelated O O
patients O O
with O O
features O O
of O O
Saethre B B_DISEASE
- I I_DISEASE
Chotzen I I_DISEASE
syndrome I I_DISEASE
, O O
a O O
common O O
autosomal B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dominant I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
condition I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
craniosynostosis B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
limb B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anomalies I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
were O O
screened O O
for O O
mutations O O
in O O
TWIST O O
, O O
FGFR2 O O
, O O
and O O
FGFR3 O O
. O O

Nine O B_NUMBER[MEASURE]/B_ENT
novel O I_NUMBER[MEASURE]/I_ENT
and O O
three O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
recurrent O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
TWIST O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O O
found O O
in O O
12 O B_PERSON/B_ENT
families O I_PERSON/I_ENT
. O O

Seven O B_NUMBER[MEASURE]/B_ENT
families O I_NUMBER[MEASURE]/I_ENT
were O O
found O O
to O O
have O O
the O O
FGFR3 O B_DISEASE_ADJECTIVE[DISEASE]
P250R O I_DISEASE_ADJECTIVE[DISEASE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
one O B_NUMBER[MEASURE]/B_PERSON
individual O I_NUMBER[MEASURE]/I_PERSON
was O O
found O O
to O O
have O O
an O O
FGFR2 O B_LOCATION/B_GENE
VV269 O I_LOCATION/I_GENE
- O O
270 O B_DISEASE_ADJECTIVE[DISEASE]
deletion O I_DISEASE_ADJECTIVE[DISEASE]
. O O

To O O
date O O
, O O
our O O
detection O O
rate O O
for O O
TWIST O O
or O O
FGFR O O
mutations O O
is O O
68 O O
% O O
in O O
our O O
Saethre B B_NUMBER[MEASURE]
- I I_NUMBER[MEASURE]
Chotzen I I_NUMBER[MEASURE]
syndrome I I_NUMBER[MEASURE]
patients O O
, O O
including O O
our O O
five O O
patients O O
elsewhere O O
reported O O
with O O
TWIST O O
mutations O O
. O O

More O B_MEASURE/B_PERSON
than O O
35 O B_NUMBER[MEASURE]
different O I_NUMBER[MEASURE]
TWIST O I_NUMBER[MEASURE]
mutations O I_NUMBER[MEASURE]
are O O
now O O
known O O
in O O
the O O
literature O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
most O O
common O O
phenotypic O O
features O O
, O O
present O O
in O O
more O O
than O O
a O O
third O O
of O O
our O O
patients O O
with O O
TWIST O O
mutations O O
, O O
are O O
coronal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
synostosis I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
brachycephaly B B_DISEASE
, O O
low B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
frontal I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hairline I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
facial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
asymmetry I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
ptosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
hypertelorism B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
broad B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
great I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
toes I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
clinodactyly B B_DISEASE
. O O

Significant O B_DISEASE/B_MEASURE
intra O I_DISEASE/I_MEASURE
- O O
and O O
interfamilial O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotypic O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
variability O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O O
either O O
TWIST O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O O
FGFR O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

The O O
overlap O O
in O O
clinical O O
features O O
and O O
the O O
presence O O
, O O
in O O
the O O
same O O
genes O O
, O O
of O O
mutations O O
for O O
more O O
than O O
one O O
craniosynostotic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
condition I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O O
such O O
as O O
Saethre B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
Chotzen I I_DISEASE/I_LOCATION
, I I_DISEASE/I_LOCATION
Crouzon I I_DISEASE/I_LOCATION
, I I_DISEASE/I_LOCATION
and I I_DISEASE/I_LOCATION
Pfeiffer I I_DISEASE/I_LOCATION
syndromes I I_DISEASE/I_LOCATION
- O O
support O O
the O O
hypothesis O O
that O O
TWIST O O
and O O
FGFRs O O
are O O
components O O
of O O
the O O
same O O
molecular O O
pathway O O
involved O O
in O O
the O O
modulation O O
of O O
craniofacial O O
and O O
limb O O
development O O
in O O
humans O O
. O O
. O O

Mutation O O
analysis O O
of O O
UBE3A O O
in O O
Angelman B B_DISEASE/B_NUMBER[MEASURE]
syndrome I I_DISEASE/I_NUMBER[MEASURE]
patients O O
. O O

Angelman B B_DISEASE/B_PERSON
syndrome I I_DISEASE/I_PERSON
( O O
AS B B_DISEASE/B_PROTEIN[GENE]
) O O
is O O
caused O O
by O O
chromosome O O
15q11 O O
- O O
q13 O O
deletions O O
of O O
maternal O O
origin O O
, O O
by O O
paternal O O
uniparental B B_DISEASE/B_GENE
disomy I I_DISEASE/I_GENE
( O O
UPD B B_LOCATION
) O O
15 O O
, O O
by O O
imprinting O O
defects O O
, O O
and O O
by O O
mutations O O
in O O
the O O
UBE3A O O
gene O O
. O O

UBE3A O B_GENE
encodes O O
a O O
ubiquitin O B_GENE
- O O
protein O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ligase O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
shows O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imprinting O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Here O O
we O O
describe O O
UBE3A O O
coding O O
- O O
region O O
mutations O O
detected O O
by O O
SSCP O O
analysis O O
in O O
13 O O
AS B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
individuals O O
or O O
families O O
. O O

Two O B_MEASURE/B_LOCATION
identical O B_MEASURE/I_LOCATION
de O B_MEASURE/I_LOCATION
novo O B_MEASURE/I_LOCATION
5 O B_MEASURE/I_LOCATION
- O O
bp O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
duplications O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
exon O B_GENE
16 O I_GENE
were O O
found O O
. O O

Among O O
the O O
other O B_DISEASE_ADJECTIVE[DISEASE]
11 O I_DISEASE_ADJECTIVE[DISEASE]
unique O I_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
, O O
8 O B_NUMBER[MEASURE]
were O O
small O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
deletions O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
or O O
insertions O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
predicted O O
to O O
cause O O
frameshifts O B_DISEASE/B_GENE
, O O
1 O B_NUMBER[MEASURE]
was O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
to O O
a O O
stop O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codon O B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
1 O B_MEASURE
was O O
a O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O O
and O O
1 O B_NUMBER[MEASURE]
was O O
predicted O O
to O O
cause O O
insertion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
isoleucine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
hect O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
domain O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O O
the O O
UBE3A O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
functions O O
in O O
E2 O B_GENE
binding O I_GENE
and O O
ubiquitin O B_GENE
transfer O I_GENE
. O O

Eight O B_NUMBER[MEASURE]
of O O
the O O
cases O B_PERSON/B_DISEASE
were O O
familial O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O O
and O O
five O B_NUMBER[MEASURE]/B_PERSON
were O O
sporadic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

In O O
two O O
familial O O
cases O O
and O O
one O O
sporadic O O
case O O
, O O
mosaicism O O
for O O
UBE3A O O
mutations O O
was O O
detected O O
in O O
the O O
mother O O
of O O
three O O
AS B B_DISEASE
sons O O
, O O
in O O
the O O
maternal O O
grandfather O O
of O O
two O O
AS B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
first O O
cousins O O
, O O
and O O
in O O
the O O
mother O O
of O O
an O O
AS B B_LOCATION/B_DISEASE
daughter O O
. O O

The O O
frequencies O B_MEASURE/B_ORGANIZATION
with O O
which O O
we O O
detected O O
mutations O B_DISEASE/B_GENE
were O O
5 O B_MEASURE
( O O
14 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
of O O
35 O B_NUMBER[MEASURE]
in O O
sporadic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cases O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O O
8 O B_MEASURE
( O O
80 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
) O O
of O O
10 O B_MEASURE
in O O
familial O B_DISEASE/B_PERSON
cases O I_DISEASE/I_PERSON
. O O
. O O

The O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
845 O O
G O O
- O O
- O O
> O O
A O O
and O O
187 O O
C O O
- O O
- O O
> O O
G O O
mutations O O
: O O
prevalence O O
in O O
non O O
- O O
Caucasian O O
populations O O
. O O

Hemochromatosis B B_DISEASE
, O O
the O O
inherited B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disorder I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
iron I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
metabolism I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
leads O O
, O O
if O O
untreated O O
, O O
to O O
progressive O O
iron B B_DISEASE
overload I I_DISEASE
and O O
premature B B_DISEASE
death I I_DISEASE
. O O

The O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
gene O O
, O O
HFE O O
, O O
recently O O
has O O
been O O
identified O O
, O O
and O O
characterization O O
of O O
this O O
gene O O
has O O
shown O O
that O O
it O O
contains O O
two O O
mutations O O
that O O
result O O
in O O
amino O O
acid O O
substitutions O O
- O O
cDNA O O
nucleotides O O
845 O O
G O O
- O O
- O O
> O O
A O O
( O O
C282Y O O
) O O
and O O
187 O O
C O O
- O O
- O O
> O O
G O O
( O O
H63D O O
) O O
. O O

Although O O
hemochromatosis B B_DISEASE/B_LOCATION
is O O
common O O
in O O
Caucasians O O
, O O
affecting O O
> O O
= O O
1 O O
/ O O
300 O O
individuals O O
of O O
northern O O
European O O
origin O O
, O O
it O O
has O O
not O O
been O O
recognized O O
in O O
other O O
populations O O
. O O

The O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
used O O
PCR O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
restriction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
enzyme O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
digestion O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
analyze O O
the O O
frequency O B_MEASURE
of O O
the O O
845 O B_PROTEIN[GENE]/B_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_PERSON/B_PROTEIN[GENE]
A O B_PERSON/I_PROTEIN[GENE]
and O O
187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_GENE
G O I_GENE
mutations O I_GENE
in O O
HLA O B_GENE/B_MEASURE
- O O
typed O O
samples O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
non O B_LOCATION/B_MEASURE
- O O
Caucasian O B_PERSON/B_LOCATION
populations O I_PERSON/I_LOCATION
, O O
comprising O O
Australian O B_PERSON/B_LOCATION
Aboriginal O I_PERSON/I_LOCATION
, O O
Chinese O B_LOCATION/B_PERSON
, O O
and O O
Pacific O B_PERSON/B_ORGANIZATION
Islanders O I_PERSON/I_ORGANIZATION
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O O
that O O
the O O
845 O B_PROTEIN[GENE]/B_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_GENE/B_DISEASE
A O I_GENE/I_DISEASE
mutation O I_GENE/I_DISEASE
was O O
present O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
these O O
populations O B_LOCATION/B_PERSON
( O O
allele O B_MEASURE
frequency O I_MEASURE
0 O I_MEASURE
. O O
32 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
) O O
, O O
and O O
, O O
furthermore O O
, O O
it O O
was O O
always O O
seen O O
in O O
conjunction O B_PERSON/B_LOCATION
with O O
HLA O B_DISEASE/B_PERSON
haplotypes O I_DISEASE/I_PERSON
common O I_DISEASE/I_PERSON
in O O
Caucasians O B_LOCATION/B_PERSON
, O O
suggesting O O
that O O
845 O B_PROTEIN[GENE]/B_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_PERSON/B_PROTEIN[GENE]
A O B_PERSON/I_PROTEIN[GENE]
may O O
have O O
been O O
introduced O O
into O O
these O O
populations O B_LOCATION/B_PERSON
by O O
Caucasian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admixture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_DISEASE/B_GENE
G O B_DISEASE/I_GENE
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
an O O
allele O B_MEASURE/B_PERSON
frequency O I_MEASURE/I_PERSON
of O O
2 O B_NUMBER[MEASURE]
. O O

68 O B_PERSON/B_MEASURE
% O B_PERSON/I_MEASURE
in O O
the O O
two O B_LOCATION/B_MEASURE
populations O I_LOCATION/I_MEASURE
analyzed O O
( O O
Australian O B_PERSON/B_LOCATION
Aboriginal O I_PERSON/I_LOCATION
and O O
Chinese O B_LOCATION/B_PERSON
) O O
. O O

In O O
the O O
Australian O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Aboriginal O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
samples O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O O
187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_PROTEIN[GENE]/B_DISEASE
G O I_PROTEIN[GENE]/I_DISEASE
was O O
found O O
to O O
be O O
associated O O
with O O
HLA O B_DISEASE/B_LOCATION
haplotypes O I_DISEASE/I_LOCATION
common O I_DISEASE/I_LOCATION
in O O
Caucasians O B_LOCATION/B_PERSON
, O O
suggesting O O
that O O
it O O
was O O
introduced O O
by O O
recent O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
admixture O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

In O O
the O O
Chinese O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analyzed O O
, O O
187 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
- O O
> O B_DISEASE/B_PROTEIN[GENE]
G O B_DISEASE/I_PROTEIN[GENE]
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
association O B_ORGANIZATION/B_PERSON
with O O
a O O
wide O B_MEASURE/B_ENT
variety O I_MEASURE/I_ENT
of O O
HLA O B_DISEASE/B_GENE
haplotypes O I_DISEASE/I_GENE
, O O
showing O O
this O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
be O O
widespread O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O O
predate O O
the O O
more O O
genetically O O
restricted O B_PROTEIN[GENE]/B_LOCATION
845 O I_PROTEIN[GENE]/I_LOCATION
G O I_PROTEIN[GENE]/I_LOCATION
- O O
- O O
> O B_GENE/B_DISEASE
A O I_GENE/I_DISEASE
mutation O I_GENE/I_DISEASE
. O O

Genotype O O
- O O
phenotype O O
correlations O O
in O O
attenuated B B_DISEASE/B_BIO
adenomatous I I_DISEASE/I_BIO
polyposis I I_DISEASE/I_BIO
coli I I_DISEASE/I_BIO
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
tumor B B_DISEASE/B_GENE
suppressor O O
APC O O
are O O
implicated O O
in O O
attenuated B B_DISEASE/B_GENE
adenomatous I I_DISEASE/I_GENE
polyposis I I_DISEASE/I_GENE
coli I I_DISEASE/I_GENE
( O O
AAPC B B_LOCATION/B_PERSON
) O O
, O O
a O O
variant O O
of O O
familial B B_DISEASE/B_GENE
adenomatous I I_DISEASE/I_GENE
polyposis I I_DISEASE/I_GENE
( O O
FAP B B_DISEASE/B_GENE
) O O
. O O

AAPC B B_DISEASE/B_PERSON
is O O
recognized O O
by O O
the O O
occurrence O O
of O O
< O O
100 O O
colonic B B_DISEASE/B_PERSON
adenomas I I_DISEASE/I_PERSON
and O O
a O O
later O O
onset O O
of O O
colorectal B B_DISEASE
cancer I I_DISEASE
( O O
age O O
> O O
40 O O
years O O
) O O
. O O

The O O
aim O O
of O O
this O O
study O O
was O O
to O O
assess O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
AAPC B B_PERSON/B_LOCATION
families O O
. O O

By O O
protein O O
- O O
truncation O O
test O O
( O O
PTT O O
) O O
assay O O
, O O
the O O
entire O O
coding O O
region O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
was O O
screened O O
in O O
affected O O
individuals O O
from O O
11 O O
AAPC B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
kindreds O O
, O O
and O O
their O O
phenotypic O O
differences O O
were O O
examined O O
. O O

Five O O
novel O O
germ O O
- O O
line O O
APC B B_GENE/B_BACTERIUM[BIO]
mutations O O
were O O
identified O O
in O O
seven O O
kindreds O O
. O O

Mutations O O
were O O
located O O
in O O
three O O
different O O
regions O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
( O O
1 O O
) O O
at O O
the O O
5 O O
end O O
spanning O O
exons O O
4 O O
and O O
5 O O
, O O
( O O
2 O O
) O O
within O O
exon O O
9 O O
, O O
and O O
( O O
3 O O
) O O
at O O
the O O
3 O O
distal O O
end O O
of O O
the O O
gene O O
. O O

Variability O O
in O O
the O O
number O O
of O O
colorectal B B_DISEASE/B_PERSON
adenomas I I_DISEASE/I_PERSON
was O O
most O O
apparent O O
in O O
individuals O O
with O O
mutations O O
in O O
region O O
1 O O
, O O
and O O
upper O O
- O O
gastrointestinal O O
manifestations O O
were O O
more O O
severe O O
in O O
them O O
. O O

In O O
individuals O O
with O O
mutations O O
in O O
either O O
region O O
2 O O
or O O
region O O
3 O O
, O O
the O O
average O O
number O O
of O O
adenomas B B_DISEASE/B_BIO
tended O O
to O O
be O O
lower O O
than O O
those O O
in O O
individuals O O
with O O
mutations O O
in O O
region O O
1 O O
, O O
although O O
age O O
at O O
diagnosis O O
was O O
similar O O
. O O

In O O
all O O
AAPC B B_NUMBER[MEASURE]/B_PERSON
kindreds O O
, O O
a O O
predominance O O
of O O
right O O
- O O
sided O O
colorectal B B_DISEASE
adenomas I I_DISEASE
and O O
rectal B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
polyp I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
sparing O O
was O O
observed O O
. O O

No O O
desmoid B B_DISEASE/B_GENE
tumors I I_DISEASE/I_GENE
were O O
found O O
in O O
these O O
kindreds O O
. O O

Our O O
data O O
suggest O O
that O O
, O O
in O O
AAPC B B_DISEASE/B_NUMBER[MEASURE]
families O O
, O O
the O O
location O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
mutation O O
may O O
partially O O
predict O O
specific O O
phenotypic O O
expression O O
. O O

This O O
should O O
help O O
in O O
the O O
design O O
of O O
tailored O O
clinical O O
- O O
management O O
protocols O O
in O O
this O O
subset O O
of O O
FAP B B_DISEASE/B_PERSON
patients O O
. O O
. O O

Wilms B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
' I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O O
and O O
Dax O O
- O O
1 O O
modulate O O
the O O
orphan O O
nuclear O O
receptor O O
SF O O
- O O
1 O O
in O O
sex O O
- O O
specific O O
gene O O
expression O O
. O O

Products O O
of O O
steroidogenic O O
factor O O
1 O O
( O O
SF O O
- O O
1 O O
) O O
and O O
Wilms B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O O
( O O
WT1 O O
) O O
genes O O
are O O
essential O O
for O O
mammalian O O
gonadogenesis O O
prior O O
to O O
sexual O O
differentiation O O
. O O

In O O
males O B_PERSON/B_BIO
, O O
SF O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
participates O O
in O O
sexual O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
by O O
regulating O O
expression O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
polypeptide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hormone O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
Mullerian O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
inhibiting O O
substance O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O O
MIS O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Here O O
, O O
we O O
show O O
that O O
WT1 O B_PROTEIN[GENE]/B_LOCATION
- O O
KTS O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O O
associate O B_PERSON/B_TIME[MEASURE]
and O O
synergize O O
with O O
SF O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_MEASURE/B_LOCATION
to O O
promote O O
MIS O B_DISEASE
expression O I_DISEASE
. O O

In O O
contrast O O
, O O
WT1 O O
missense O O
mutations O O
, O O
associated O O
with O O
male B B_DISEASE/B_GENE
pseudohermaphroditism I I_DISEASE/I_GENE
in O O
Denys B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Drash I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
fail O O
to O O
synergize O O
with O O
SF O O
- O O
1 O O
. O O

Additionally O O
, O O
the O O
X O B_OTHER/B_DISEASE
- O O
linked O O
, O O
candidate O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
sensitive O B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sex O B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
reversal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Dax O B_PERSON/B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
, O O
antagonizes O O
synergy O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
between O O
SF O B_LOCATION
- O O
1 O B_NUMBER[MEASURE]
and O O
WT1 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
most O O
likely O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
through O O
a O O
direct O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O O
SF O B_LOCATION/B_GENE
- O O
1 O B_NUMBER[MEASURE]
. O O

We O O
propose O O
that O O
WT1 O B_GENE
and O O
Dax O B_PERSON/B_LOCATION
- O O
1 O B_MEASURE
functionally O O
oppose O O
each O O
other O B_NUMBER[MEASURE]/B_DISEASE
in O O
testis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
development O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O O
modulating O O
SF O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
1 O B_NUMBER[MEASURE]
- O O
mediated O O
transactivation O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O
. O O

A O O
mouse O O
model O O
for O O
Prader B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
Willi I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
imprinting O O
- O O
centre O O
mutations O O
. O O

Imprinting O O
in O O
the O O
15q11 O B_GENE/B_MEASURE
- O O
q13 O B_MEASURE/B_GENE
region O I_MEASURE/I_GENE
involves O O
an O O
imprinting O O
centre O B_LOCATION/B_MEASURE
( O O
IC O B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
mapping O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O O
part O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O O
the O O
promoter O B_GENE
and O O
first O B_GENE
exon O I_GENE
of O O
SNRPN O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Deletion O O
of O O
this O O
IC O O
abolishes O O
local O O
paternally O O
derived O O
gene O O
expression O O
and O O
results O O
in O O
Prader B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
Willi I I_DISEASE/I_ORGANISM_FUNCTION
syndrome I I_DISEASE/I_ORGANISM_FUNCTION
( O O
PWS B B_MEASURE/B_DISEASE
) O O
. O O

We O O
have O O
created O O
two O O
deletion O O
mutations O O
in O O
mice O O
to O O
understand O O
PWS B B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
mechanism O O
of O O
this O O
IC O O
. O O

Mice O O
harbouring O O
an O O
intragenic O O
deletion O O
in O O
Snrpn O O
are O O
phenotypically O O
normal O O
, O O
suggesting O O
that O O
mutations O O
of O O
SNRPN O O
are O O
not O O
sufficient O O
to O O
induce O O
PWS B B_DISEASE
. O O

Mice O O
with O O
a O O
larger O O
deletion O O
involving O O
both O O
Snrpn O O
and O O
the O O
putative O O
PWS O O
- O O
IC O O
lack O O
expression O O
of O O
the O O
imprinted O O
genes O O
Zfp127 O O
( O O
mouse O O
homologue O O
of O O
ZNF127 O O
) O O
, O O
Ndn O O
and O O
Ipw O O
, O O
and O O
manifest O O
several O O
phenotypes O O
common O O
to O O
PWS B B_PERSON
infants O O
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O O
that O O
both O O
the O O
position O B_LOCATION/B_MEASURE
of O O
the O O
IC O B_GENE/B_DISEASE
and O O
its O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
coordinate O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
conserved O O
between O O
mouse O B_SPECIES[BIO]/B_DISEASE
and O O
human O B_SPECIES[BIO]
, O O
and O O
indicate O O
that O O
the O O
mouse O B_SPECIES[BIO]/B_DISEASE
is O O
a O O
suitable O B_LOCATION/B_PERSON
model O I_LOCATION/I_PERSON
system O I_LOCATION/I_PERSON
in O O
which O O
to O O
investigate O O
the O O
molecular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
imprinting O O
in O O
this O O
region O B_LOCATION/B_MEASURE
of O O
the O O
genome O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O
. O O

Mutations O O
of O O
the O O
ATM O O
gene O O
detected O O
in O O
Japanese O O
ataxia B B_DISEASE
- I I_DISEASE
telangiectasia I I_DISEASE
patients O O
: O O
possible O O
preponderance O O
of O O
the O O
two O O
founder O O
mutations O O
4612del165 O O
and O O
7883del5 O O
. O O

The O O
ATM O B_GENE/B_DISEASE
( O O
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
T O B_GENE/B_LOCATION
, O O
mutated O O
) O O
gene O B_LOCATION/B_GENE
on O O
human O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosome O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
11q22 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

3 O O
has O O
recently O O
been O O
identified O O
as O O
the O O
gene O O
responsible O O
for O O
the O O
human O O
recessive B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
disease I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ataxia B B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
telangiectasia I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
order O O
to O O
define O O
the O O
types O O
of O O
disease O O
- O O
causing O O
ATM O O
mutations O O
in O O
Japanese O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
as O O
well O O
as O O
to O O
look O O
for O O
possible O O
mutational O O
hotspots O O
, O O
reverse O O
- O O
transcribed O O
RNA O O
derived O O
from O O
ten O O
patients O O
belonging O O
to O O
eight O O
unrelated O O
Japanese O O
A B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
T I I_DISEASE/I_PERSON
families O O
was O O
analyzed O O
for O O
mutations O O
by O O
the O O
restriction O O
endonuclease O O
fingerprinting O O
method O O
. O O

As O O
has O O
been O O
reported O O
by O O
others O B_PERSON
, O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]
that O O
lead O O
to O O
exon O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
skipping O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
premature O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
protein O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
truncation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O O
also O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
our O O
mutants O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O O

Six O B_PERSON
different O I_PERSON
mutations O I_PERSON
were O O
identified O O
on O O
12 O B_NUMBER[MEASURE]
of O O
the O O
16 O B_GENE/B_PERSON
alleles O I_GENE/I_PERSON
examined O O
. O O

Four O B_NUMBER[MEASURE]/B_PERSON
were O O
deletions O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
involving O O
a O O
loss O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LOCATION
of O O
a O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
exon O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
exon O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
7 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
exon O B_MEASURE
16 O I_MEASURE
, O O
exon O B_MEASURE
33 O I_MEASURE
or O O
exon O B_MEASURE
35 O I_MEASURE
. O O

The O O
others O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O O
minute O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
deletions O I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
4649delA O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O O
exon O B_GENE/B_MEASURE
33 O I_GENE/I_MEASURE
and O O
7883del5 O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
exon O B_GENE/B_PERSON
55 O I_GENE/I_PERSON
. O O

The O O
mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
4612del165 O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
7883del5 O B_MEASURE/B_GENE
were O O
found O O
in O O
more O B_MEASURE/B_PERSON
than O O
two O B_NUMBER[MEASURE]
unrelated O I_NUMBER[MEASURE]
families O I_NUMBER[MEASURE]
; O O
44 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
( O O
7 O B_TIME[MEASURE]/B_LOCATION
of O O
16 O B_NUMBER[MEASURE]
) O O
of O O
the O O
mutant O B_PERSON/B_BIO
alleles O I_PERSON/I_BIO
had O O
one O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O O
the O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O O

The O O
4612del165 O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
three O B_PERSON/B_ENT
different O I_PERSON/I_ENT
families O I_PERSON/I_ENT
were O O
all O O
ascribed O O
to O O
the O O
same O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
T O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
- O O
- O O
> O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
substitution O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O O
the O O
splice O B_LOCATION/B_GENE
donor O I_LOCATION/I_GENE
site O I_LOCATION/I_GENE
in O O
intron O B_GENE/B_BIO
33 O I_GENE/I_BIO
. O O

Microsatellite O B_GENE
genotyping O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
around O O
the O O
ATM O B_GENE/B_BIO
locus O I_GENE/I_BIO
also O O
indicated O O
that O O
a O O
common O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
haplotype O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
shared O O
by O O
the O O
mutant O B_PERSON/B_BIO
alleles O B_PERSON/I_BIO
in O O
both O O
mutations O B_PERSON/B_DISEASE
. O O

This O O
suggests O O
that O O
these O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
founder O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
may O O
be O O
predominant O B_DISEASE_ADJECTIVE[DISEASE]
among O O
Japanese O B_PERSON/B_BIO
ATM O I_PERSON/I_BIO
mutant O I_PERSON/I_BIO
alleles O I_PERSON/I_BIO
. O O

W474C O O
amino O O
acid O O
substitution O O
affects O O
early O O
processing O O
of O O
the O O
alpha O O
- O O
subunit O O
of O O
beta O O
- O O
hexosaminidase O O
A O O
and O O
is O O
associated O O
with O O
subacute O O
G B B_DISEASE
( I I_DISEASE
M2 I I_DISEASE
) I I_DISEASE
gangliosidosis I I_DISEASE
. O O

Mutations O O
in O O
the O O
HEXA O O
gene O O
, O O
encoding O O
the O O
alpha O O
- O O
subunit O O
of O O
beta O O
- O O
hexosaminidase O O
A O O
( O O
Hex O O
A O O
) O O
, O O
that O O
abolish O O
Hex O O
A O O
enzyme O O
activity O O
cause O O
Tay B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Sachs I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
( O O
TSD B B_DISEASE/B_LOCATION
) O O
, O O
the O O
fatal O O
infantile B B_DISEASE_ADJECTIVE[DISEASE]
form I I_DISEASE_ADJECTIVE[DISEASE]
of I I_DISEASE_ADJECTIVE[DISEASE]
G I I_DISEASE_ADJECTIVE[DISEASE]
( I I_DISEASE_ADJECTIVE[DISEASE]
M2 I I_DISEASE_ADJECTIVE[DISEASE]
) I I_DISEASE_ADJECTIVE[DISEASE]
gangliosidosis I I_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
Type I I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DISEASE_ADJECTIVE[DISEASE]
. O O

Less O O
severe O B_DISEASE_ADJECTIVE[DISEASE]
, O O
subacute O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O O
juvenile O B_PERSON
- O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O O
and O O
chronic O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
( O O
adult O B_PERSON
- O O
onset O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O O
variants O B_DISEASE
are O O
characterized O O
by O O
a O O
broad O B_DISEASE/B_MEASURE
spectrum O B_DISEASE/I_MEASURE
of O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
manifestations O I_DISEASE_ADJECTIVE[DISEASE]
and O O
are O O
associated O O
with O O
residual O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
Hex O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
identified O O
a O O
1422 O O
G O O
- O O
- O O
> O O
C O O
( O O
amino O O
acid O O
W474C O O
) O O
substitution O O
in O O
the O O
first O O
position O O
of O O
exon O O
13 O O
of O O
HEXA O O
of O O
a O O
non O O
- O O
Jewish O O
proband O O
who O O
manifested O O
a O O
subacute O O
variant O O
of O O
G B B_DISEASE/B_GENE
( I I_DISEASE/I_GENE
M2 I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
gangliosidosis I I_DISEASE/I_GENE
. O O

On O O
the O O
second O B_SEQUENCE[MEASURE]
maternally O O
inherited O O
allele O B_GENE/B_PERSON
, O O
we O O
identified O O
the O O
common O B_DISEASE/B_GENE
infantile O I_DISEASE/I_GENE
disease O I_DISEASE/I_GENE
- O O
causing O O
4 O B_MEASURE/B_LOCATION
- O O
bp O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
insertion O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
+ O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TATC O B_MEASURE/B_PERSON
1278 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O O
in O O
exon O B_GENE/B_PERSON
11 O I_GENE/I_PERSON
. O O

Pulse O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
chase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
proband O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fibroblasts O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O O
that O O
the O O
W474C O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
containing O O
alpha O B_PROTEIN[GENE]/B_MEASURE
- O O
subunit O B_GENE
precursor O I_GENE
was O O
normally O O
synthesized O O
, O O
but O O
not O O
phosphorylated O O
or O O
secreted O O
, O O
and O O
the O O
mature O B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lysosomal O I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha O I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
subunit O B_GENE
was O O
not O O
detected O O
. O O

When O O
the O O
W474C O O
- O O
containing O O
alpha O O
- O O
subunit O O
was O O
transiently O O
co O O
- O O
expressed O O
with O O
the O O
beta O O
- O O
subunit O O
to O O
produce O O
Hex O O
A O O
( O O
alphabeta O O
) O O
in O O
COS O O
- O O
7 O O
cells O O
, O O
the O O
mature O O
alpha O O
- O O
subunit O O
was O O
present O O
, O O
but O O
its O O
level O O
was O O
much O O
lower O O
than O O
that O O
from O O
normal O O
alpha O O
- O O
subunit O O
transfections O O
, O O
although O O
higher O O
than O O
in O O
those O O
cells O O
transfected O O
with O O
an O O
alpha O O
- O O
subunit O O
associated O O
with O O
infantile O O
TSD B B_DISEASE
. O O

Furthermore O O
, O O
the O O
precursor O B_GENE/B_DISEASE
level O I_GENE/I_DISEASE
of O O
the O O
W474C O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
subunit O B_GENE
was O O
found O O
to O O
accumulate O O
in O O
comparison O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
the O O
normal O B_PROTEIN[GENE]/B_MEASURE
alpha O I_PROTEIN[GENE]/I_MEASURE
- O O
subunit O B_GENE
precursor O I_GENE
levels O I_GENE
. O O

We O O
conclude O O
that O O
the O O
1422 O O
G O O
- O O
- O O
> O O
C O O
mutation O O
is O O
the O O
cause O O
of O O
Hex B B_DISEASE/B_GENE
A I I_DISEASE/I_GENE
enzyme I I_DISEASE/I_GENE
deficiency I I_DISEASE/I_GENE
in O O
the O O
proband O O
. O O

The O O
resulting O O
W474C O O
substitution O O
clearly O O
interferes O O
with O O
alpha O O
- O O
subunit O O
processing O O
, O O
but O O
because O O
the O O
base O O
substitution O O
falls O O
at O O
the O O
first O O
position O O
of O O
exon O O
13 O O
, O O
aberrant O O
splicing O O
may O O
also O O
contribute O O
to O O
Hex B B_DISEASE
A I I_DISEASE
deficiency I I_DISEASE
in O O
this O O
proband O O
. O O
. O O

Two O O
frequent O O
missense O O
mutations O O
in O O
Pendred B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Pendred B B_DISEASE/B_LOCATION
syndrome I I_DISEASE/I_LOCATION
is O O
an O O
autosomal B B_DISEASE_ADJECTIVE[DISEASE]
recessive I I_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
characterized O O
by O O
early O O
childhood O O
deafness B B_DISEASE
and O O
goiter B B_DISEASE
. O O

A O O
century O B_TIME[MEASURE]
after O O
its O O
recognition O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
as O O
a O O
syndrome O B_DISEASE/B_PERSON
by O O
Vaughan O B_PERSON
Pendred O I_PERSON
, O O
the O O
disease O B_DISEASE/B_GENE
gene O I_DISEASE/I_GENE
( O O
PDS O B_LOCATION/B_DISEASE
) O O
was O O
mapped O O
to O O
chromosome O B_GENE/B_MEASURE
7q22 O B_GENE/I_MEASURE
- O O
q31 O B_MEASURE
. O O

1 O B_TIME[MEASURE]
and O O
, O O
recently O O
, O O
found O O
to O O
encode O O
a O O
putative O B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transporter O I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
performed O O
mutation O O
analysis O O
of O O
the O O
PDS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
in O O
patients O O
from O O
14 O O
Pendred B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
families O O
originating O O
from O O
seven O O
countries O O
and O O
identified O O
all O O
mutations O O
. O O

The O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
include O O
three O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
single O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
base O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
deletions O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
one O B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
splice O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
site O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
mutation O I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
10 O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
missense O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O O

One O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
missense O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
L236P O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
was O O
found O O
in O O
a O O
homozygous O B_PERSON/B_LOCATION
state O I_PERSON/I_LOCATION
in O O
two O B_NUMBER[MEASURE]/B_PERSON
consanguineous O I_NUMBER[MEASURE]/I_PERSON
families O I_NUMBER[MEASURE]/I_PERSON
and O O
in O O
a O O
heterozygous O B_MEASURE/B_PERSON
state O I_MEASURE/I_PERSON
in O O
five O B_NUMBER[MEASURE]/B_LOCATION
additional O I_NUMBER[MEASURE]/I_LOCATION
non O I_NUMBER[MEASURE]/I_LOCATION
- O O
consanguineous O B_PERSON/B_BIO
families O I_PERSON/I_BIO
. O O

Another O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O O
T416P O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
was O O
found O O
in O O
a O O
homozygous O B_PERSON/B_LOCATION
state O I_PERSON/I_LOCATION
in O O
one O B_NUMBER[MEASURE]
family O I_NUMBER[MEASURE]
and O O
in O O
a O O
heterozygous O B_MEASURE/B_PERSON
state O I_MEASURE/I_PERSON
in O O
four O B_NUMBER[MEASURE]/B_ENT
families O I_NUMBER[MEASURE]/I_ENT
. O O

Pendred B B_NUMBER[MEASURE]/B_LOCATION
patients O O
in O O
three O O
non O O
- O O
consanguineous O O
families O O
were O O
shown O O
to O O
be O O
compound O O
heterozygotes O O
for O O
L236P O O
and O O
T416P O O
. O O

In O O
total O B_MEASURE
, O O
one O B_NUMBER[MEASURE]/B_PERSON
or O O
both O O
of O O
these O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O O
found O O
in O O
nine O B_NUMBER[MEASURE]
of O O
the O O
14 O B_PERSON/B_BIO
families O I_PERSON/I_BIO
analyzed O O
. O O

The O O
identification O O
of O O
two O O
frequent O O
PDS B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O O
will O O
facilitate O O
the O O
molecular O O
diagnosis O O
of O O
Pendred B B_DISEASE
syndrome I I_DISEASE
. O O

Insertional O O
mutation O O
by O O
transposable O O
element O O
, O O
L1 O O
, O O
in O O
the O O
DMD B B_DISEASE/B_GENE
gene O O
results O O
in O O
X B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
linked I I_DISEASE/I_GENE
dilated I I_DISEASE/I_GENE
cardiomyopathy I I_DISEASE/I_GENE
. O O

X B B_DISEASE
- I I_DISEASE
linked I I_DISEASE
dilated I I_DISEASE
cardiomyopathy I I_DISEASE
( O O
XLDCM B B_DISEASE/B_LOCATION
) O O
is O O
a O O
clinical O O
phenotype O O
of O O
dystrophinopathy B B_DISEASE
which O O
is O O
characterized O O
by O O
preferential O O
myocardial B B_DISEASE/B_ORGANISM_FUNCTION
involvement I I_DISEASE/I_ORGANISM_FUNCTION
without O O
any O O
overt O O
clinical O O
signs O O
of O O
skeletal B B_DISEASE
myopathy I I_DISEASE
. O O

To O O
date O O
, O O
several O O
mutations O O
in O O
the O O
Duchenne B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
muscular I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
dystrophy I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
gene O O
, O O
DMD O O
, O O
have O O
been O O
identified O O
in O O
patients O O
with O O
XLDCM B B_DISEASE
, O O
but O O
a O O
pathogenic O O
correlation O O
of O O
these O O
cardiospecific O O
mutations O O
in O O
DMD O O
with O O
the O O
XLDCM B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
phenotype O O
has O O
remained O O
to O O
be O O
elucidated O O
. O O

We O O
report O O
here O O
the O O
identification O O
of O O
a O O
unique O O
de O O
novo O O
L1 O O
insertion O O
in O O
the O O
muscle O O
exon O O
1 O O
in O O
DMD O O
in O O
three O O
XLDCM B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O O
from O O
two O O
unrelated O O
Japanese O O
families O O
. O O

The O O
insertion O B_SEQUENCE[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O O
a O O
5 O B_NUMBER[MEASURE]
- O O
truncated O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
human O B_GENE/B_DISEASE
L1 O I_GENE/I_DISEASE
inversely O O
integrated O O
in O O
the O O
5 O B_TIME[MEASURE]/B_LOCATION
- O O
untranslated O O
region O B_LOCATION/B_MEASURE
in O O
the O O
muscle O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exon O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
affected O O
the O O
transcription O B_GENE/B_MEASURE
or O O
the O O
stability O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
muscle O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
dystrophin O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
but O O
not O O
that O O
of O O
the O O
brain O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
or O O
Purkinje O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
form O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O O
probably O O
due O O
to O O
its O O
unique O B_LOCATION/B_MEASURE
site O B_LOCATION/I_MEASURE
of O O
integration O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
. O O

We O O
speculate O O
that O O
this O O
insertion O O
of O O
an O O
L1 O O
sequence O O
in O O
DMD O O
is O O
responsible O O
for O O
some O O
of O O
the O O
population O O
of O O
Japanese O O
patients O O
with O O
XLDCM B B_DISEASE
. O O
. O O

Severe O O
early O O
- O O
onset O O
obesity B B_DISEASE
, O O
adrenal B B_DISEASE/B_COLOR
insufficiency I I_DISEASE/I_COLOR
and O O
red O O
hair O O
pigmentation O O
caused O O
by O O
POMC O O
mutations O O
in O O
humans O O
. O O

Sequential O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cleavage O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
precursor O B_GENE
protein O I_GENE
pre O I_GENE
- O O
pro O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
opiomelanocortin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O O
POMC O B_LOCATION/B_GENE
) O O
generates O O
the O O
melanocortin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptides O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenocorticotrophin O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ACTH O B_LOCATION/B_PERSON
) O O
, O O
melanocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
stimulating O O
hormones O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
MSH O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
alpha O B_PROTEIN[GENE]
, O O
beta O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
gamma O B_PROTEIN[GENE]
as O O
well O O
as O O
the O O
opioid O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
receptor O B_PROTEIN[GENE]/B_DISEASE
ligand O I_PROTEIN[GENE]/I_DISEASE
beta O I_PROTEIN[GENE]/I_DISEASE
- O O
endorphin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

While O O
a O O
few O O
cases O O
of O O
isolated O O
ACTH B B_DISEASE
deficiency I I_DISEASE
have O O
been O O
reported O O
( O O
OMIM O O
201400 O O
) O O
, O O
an O O
inherited O O
POMC O O
defect O O
has O O
not O O
been O O
described O O
so O O
far O O
. O O

Recent O O
studies O O
in O O
animal O O
models O O
elucidated O O
a O O
central O O
role O O
of O O
alpha O O
- O O
MSH O O
in O O
the O O
regulation O O
of O O
food O O
intake O O
by O O
activation O O
of O O
the O O
brain O O
melanocortin O O
- O O
4 O O
- O O
receptor O O
( O O
MC4 O O
- O O
R O O
; O O
refs O O
3 O O
- O O
5 O O
) O O
and O O
the O O
linkage O O
of O O
human O O
obesity B B_DISEASE/B_GENE
to O O
chromosome O O
2 O O
in O O
close O O
proximity O O
to O O
the O O
POMC O O
locus O O
, O O
led O O
to O O
the O O
proposal O O
of O O
an O O
association O O
of O O
POMC O O
with O O
human O O
obesity B B_DISEASE/B_ORGANISM_FUNCTION
. O O

The O O
dual O O
role O O
of O O
alpha O O
- O O
MSH O O
in O O
regulating O O
food O O
intake O O
and O O
influencing O O
hair O O
pigmentation O O
predicts O O
that O O
the O O
phenotype O O
associated O O
with O O
a O O
defect O O
in O O
POMC O O
function O O
would O O
include O O
obesity B B_DISEASE
, O O
alteration O O
in O O
pigmentation O O
and O O
ACTH B B_DISEASE/B_ORGANISM_FUNCTION
deficiency I I_DISEASE/I_ORGANISM_FUNCTION
. O O

The O O
observation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
these O O
symptoms O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
two O B_PERSON/B_BIO
probands O I_PERSON/I_BIO
prompted O O
us O O
to O O
search O O
for O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
within O O
their O O
POMC O B_GENE/B_BIO
genes O I_GENE/I_BIO
. O O

Patient O B_PERSON/B_LOCATION
1 O I_PERSON/I_LOCATION
was O O
found O O
to O O
be O O
a O O
compound O B_PERSON/B_GENE
heterozygote O I_PERSON/I_GENE
for O O
two O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
exon O B_GENE
3 O I_GENE
( O O
G7013T O B_GENE/B_DISEASE
, O O
C7133delta O B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
which O O
interfere O O
with O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis O B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O O
ACTH O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
alpha O B_PROTEIN[GENE]/B_LOCATION
- O O
MSH O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Patient O B_PERSON/B_LOCATION
2 O I_PERSON/I_LOCATION
was O O
homozygous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
C3804A O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
which O O
abolishes O O
POMC O B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
translation O I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
findings O O
represent O O
the O O
first O O
examples O O
of O O
a O O
genetic B B_DISEASE/B_GENE
defect I I_DISEASE/I_GENE
within O O
the O O
POMC O O
gene O O
and O O
define O O
a O O
new O O
monogenic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
endocrine I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
disorder I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
resulting O O
in O O
early O O
- O O
onset O O
obesity B B_DISEASE
, O O
adrenal B B_DISEASE
insufficiency I I_DISEASE
and O O
red O O
hair O O
pigmentation O O
. O O
. O O

A O O
European O O
multicenter O O
study O O
of O O
phenylalanine B B_DISEASE/B_LOCATION
hydroxylase I I_DISEASE/I_LOCATION
deficiency I I_DISEASE/I_LOCATION
: O O
classification O O
of O O
105 O O
mutations O O
and O O
a O O
general O O
system O O
for O O
genotype O O
- O O
based O O
prediction O O
of O O
metabolic O O
phenotype O O
. O O

Phenylketonuria B B_DISEASE/B_GENE
( O O
PKU B B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
mild B B_DISEASE
hyperphenylalaninemia I I_DISEASE
( O O
MHP B B_LOCATION
) O O
are O O
allelic B B_DISEASE_ADJECTIVE[DISEASE]
disorders I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
mutations O O
in O O
the O O
gene O O
encoding O O
phenylalanine O O
hydroxylase O O
( O O
PAH O O
) O O
. O O

Previous O O
studies O O
have O O
suggested O O
that O O
the O O
highly O O
variable O O
metabolic O O
phenotypes O O
of O O
PAH B B_DISEASE/B_BIO
deficiency I I_DISEASE/I_BIO
correlate O O
with O O
PAH O O
genotypes O O
. O O

We O O
identified O O
both O O
causative O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
686 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
from O O
seven O B_LOCATION/B_ORGANIZATION
European O I_LOCATION/I_ORGANIZATION
centers O I_LOCATION/I_ORGANIZATION
. O O

On O O
the O O
basis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
the O O
phenotypic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
characteristics O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
297 O B_NUMBER[MEASURE]/B_PERSON
functionally O O
hemizygous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
105 O B_NUMBER[MEASURE]
of O O
the O O
mutations O B_PERSON/B_DISEASE
were O O
assigned O O
to O O
one O B_NUMBER[MEASURE]/B_LOCATION
of O O
four O B_NUMBER[MEASURE]/B_PERSON
arbitrary O I_NUMBER[MEASURE]/I_PERSON
phenotype O I_NUMBER[MEASURE]/I_PERSON
categories O I_NUMBER[MEASURE]/I_PERSON
. O O

We O O
proposed O O
and O O
tested O O
a O O
simple O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
genotype O B_GENE
and O O
phenotypic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
outcome O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
observed O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matched O O
the O O
predicted O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
79 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
cases O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
in O O
only O O
5 O B_NUMBER[MEASURE]
of O O
184 O B_NUMBER[MEASURE]/B_PERSON
patients O B_NUMBER[MEASURE]/I_PERSON
was O O
the O O
observed O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
more O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O O
one O B_TIME[MEASURE]/B_LOCATION
category O I_TIME[MEASURE]/I_LOCATION
away O O
from O O
that O O
expected O O
. O O

Among O O
the O O
seven O B_NUMBER[MEASURE]
contributing O O
centers O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
proportion O B_MEASURE/B_DISEASE
of O O
patients O B_PERSON
for O O
whom O O
the O O
observed O O
phenotype O B_GENE/B_DISEASE
did O O
not O O
match O O
the O O
predicted O O
phenotype O B_GENE/B_DISEASE
was O O
4 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
- O O
23 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
( O O
P O B_MEASURE/B_LOCATION
< O I_MEASURE/I_LOCATION
. O O
0001 O B_MEASURE
) O O
, O O
suggesting O O
that O O
differences O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
methods O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O O
for O O
mutation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
detection O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classification O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O O
account O O
for O O
a O O
considerable O B_MEASURE/B_LOCATION
proportion O I_MEASURE/I_LOCATION
of O O
genotype O B_GENE/B_MEASURE
- O O
phenotype O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inconsistencies O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Our O O
data O O
indicate O O
that O O
the O O
PAH O O
- O O
mutation O O
genotype O O
is O O
the O O
main O O
determinant O O
of O O
metabolic O O
phenotype O O
in O O
most O O
patients O O
with O O
PAH B B_DISEASE/B_LOCATION
deficiency I I_DISEASE/I_LOCATION
. O O

In O O
the O O
present O O
study O O
, O O
the O O
classification O O
of O O
105 O O
PAH O O
mutations O O
may O O
allow O O
the O O
prediction O O
of O O
the O O
biochemical O O
phenotype O O
in O O
> O O
10 O O
, O O
000 O O
genotypes O O
, O O
which O O
may O O
be O O
useful O O
for O O
the O O
management O O
of O O
hyperphenylalaninemia B B_DISEASE
in O O
newborns O O
. O O

Somatic O O
instability O O
of O O
the O O
CTG O O
repeat O O
in O O
mice O O
transgenic O O
for O O
the O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region O O
is O O
age O O
dependent O O
but O O
not O O
correlated O O
to O O
the O O
relative O O
intertissue O O
transcription O O
levels O O
and O O
proliferative O O
capacities O O
. O O

A O O
( O O
CTG O O
) O O
nexpansion O O
in O O
the O O
3 O O
- O O
untranslated O O
region O O
( O O
UTR O O
) O O
of O O
the O O
DM O O
protein O O
kinase O O
gene O O
( O O
DMPK O O
) O O
is O O
responsible O O
for O O
causing O O
myotonic B B_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

Major O B_DISEASE_ADJECTIVE[DISEASE]
instability O I_DISEASE_ADJECTIVE[DISEASE]
, O O
with O O
very O O
large O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expansions O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
generations O B_MEASURE/B_DISEASE
and O O
high O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
somatic O B_DISEASE/B_GENE
mosaicism O I_DISEASE/I_GENE
, O O
is O O
observed O O
in O O
patients O B_PERSON/B_BIO
. O O

There O O
is O O
a O O
good O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O O
repeat O B_MEASURE/B_DISEASE
size O I_MEASURE/I_DISEASE
( O O
at O O
least O O
in O O
leucocytes O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
) O O
, O O
clinical O B_MEASURE/B_LOCATION
severity O I_MEASURE/I_LOCATION
and O O
age O B_TIME[MEASURE]/B_LOCATION
of O O
onset O B_DISEASE/B_PERSON
. O O

The O O
trinucleotide O O
repeat O O
instability O O
mechanisms O O
involved O O
in O O
DM B B_DISEASE/B_LOCATION
and O O
other O O
human O O
genetic B B_DISEASE/B_GENE
diseases I I_DISEASE/I_GENE
are O O
unknown O O
. O O

We O O
studied O O
somatic O O
instability O O
by O O
measuring O O
the O O
CTG O O
repeat O O
length O O
at O O
several O O
ages O O
in O O
various O O
tissues O O
of O O
transgenic O O
mice O O
carrying O O
a O O
( O O
CTG O O
) O O
55expansion O O
surrounded O O
by O O
45 O O
kb O O
of O O
the O O
human O O
DM B B_DISEASE/B_GENE
region O O
, O O
using O O
small O O
- O O
pool O O
PCR O O
. O O

These O O
mice O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
have O O
been O O
shown O O
to O O
reproduce O O
the O O
intergenerational O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O O
somatic O B_DISEASE_ADJECTIVE[DISEASE]
instability O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
55 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CTG O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O O
that O O
surrounding O O
sequences O B_DISEASE/B_GENE
and O O
the O O
chromatin O B_GENE
environment O I_GENE
are O O
involved O O
in O O
instability O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

As O O
observed O O
in O O
some O O
of O O
the O O
tissues O O
of O O
DM B B_DISEASE/B_PERSON
patients O O
, O O
there O O
is O O
a O O
tendency O O
for O O
repeat O O
length O O
and O O
somatic O O
mosaicism O O
to O O
increase O O
with O O
the O O
age O O
of O O
the O O
mouse O O
. O O

Furthermore O O
, O O
we O O
observed O O
no O O
correlation O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O O
the O O
somatic O B_MEASURE/B_DISEASE
mutation O I_MEASURE/I_DISEASE
rate O I_MEASURE/I_DISEASE
and O O
tissue O B_DISEASE/B_GENE
proliferation O I_DISEASE/I_GENE
capacity O I_DISEASE/I_GENE
. O O

The O O
somatic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mutation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
rates O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
different O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tissues O B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O O
also O O
not O O
correlated O O
to O O
the O O
relative O B_MEASURE/B_BIO
inter O B_MEASURE/I_BIO
- O O
tissue O B_MEASURE
difference O I_MEASURE
in O O
transcriptional O B_MEASURE
levels O I_MEASURE
of O O
the O O
three O B_GENE
genes O I_GENE
( O O
DMAHP O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
DMPK O B_MEASURE/B_ORGANIZATION
and O O
59 O B_MEASURE/B_LOCATION
) O O
surrounding O O
the O O
repeat O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O
. O O

A O O
novel O O
missense O O
mutation O O
in O O
patients O O
from O O
a O O
retinoblastoma B B_DISEASE/B_LOCATION
pedigree O O
showing O O
only O O
mild O O
expression O O
of O O
the O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
phenotype O O
. O O

We O O
have O O
used O O
single O O
strand O O
conformation O O
polymorphism O O
analysis O O
to O O
study O O
the O O
27 O O
exons O O
of O O
the O O
RB1 O O
gene O O
in O O
individuals O O
from O O
a O O
family O O
showing O O
mild O O
expression O O
of O O
the O O
retinoblastoma B B_DISEASE
phenotype O O
. O O

In O O
this O O
family O O
affected O O
individuals O O
developed O O
unilateral B B_DISEASE
tumors I I_DISEASE
and O O
, O O
as O O
a O O
result O O
of O O
linkage O O
analysis O O
, O O
unaffected O O
mutation O O
carriers O O
were O O
also O O
identified O O
within O O
the O O
pedigree O O
. O O

A O O
single O B_LOCATION/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
band O B_LOCATION/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
shift O B_LOCATION/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
using O O
SSCP O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O O
identified O O
in O O
exon O B_MEASURE
21 O I_MEASURE
which O O
resulted O O
in O O
a O O
missense O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
converting O O
a O O
cys O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
- O O
> O B_GENE
arg O I_GENE
at O O
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
position O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
28 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
exon O B_GENE/B_PERSON
. O O

The O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
destroyed O O
an O O
NdeI O B_GENE
restriction O I_GENE
enzyme O I_GENE
site O I_GENE
. O O

Analysis O O
of O O
all O O
family O O
members O O
demonstrated O O
that O O
the O O
missense O O
mutation O O
co O O
- O O
segregated O O
with O O
patients O O
with O O
tumors B B_DISEASE/B_GENE
or O O
who O O
, O O
as O O
a O O
result O O
of O O
linkage O O
analysis O O
had O O
been O O
predicted O O
to O O
carry O O
the O O
predisposing O O
mutation O O
. O O

These O O
observations O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point O O
to O O
another O O
region O B_LOCATION/B_MEASURE
of O O
the O O
RB1 O B_GENE
gene O I_GENE
where O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
only O O
modify O O
the O O
function O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O O
the O O
gene O B_GENE/B_LOCATION
and O O
raise O O
important O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
questions O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O O
genetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
counseling O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O O
families O B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O O
these O O
distinctive O B_DISEASE/B_PERSON
phenotypes O I_DISEASE/I_PERSON
. O O
. O O

Maternal B B_PERSON
disomy I I_PERSON
and O O
Prader B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
Willi I I_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]
consistent O O
with O O
gamete O O
complementation O O
in O O
a O O
case O O
of O O
familial O O
translocation O O
( O O
3 O O
; O O
15 O O
) O O
( O O
p25 O O
; O O
q11 O O
. O O
2 O O
) O O
. O O

Maternal B B_DISEASE
uniparental I I_DISEASE
disomy I I_DISEASE
( I I_DISEASE
UPD I I_DISEASE
) I I_DISEASE
for I I_DISEASE
chromosome I I_DISEASE
15 I I_DISEASE
is O O
responsible O O
for O O
an O O
estimated O O
30 O O
% O O
of O O
cases O O
of O O
Prader B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
Willi I I_DISEASE/I_ORGANISM_FUNCTION
syndrome I I_DISEASE/I_ORGANISM_FUNCTION
( O O
PWS B B_DISEASE
) O O
. O O

We O O
report O O
on O O
an O O
unusual O O
case O O
of O O
maternal B B_DISEASE
disomy I I_DISEASE
15 I I_DISEASE
in O O
PWS B B_DISEASE/B_PERSON
that O O
is O O
most O O
consistent O O
with O O
adjacent O O
- O O
1 O O
segregation O O
of O O
a O O
paternal O O
t O O
( O O
3 O O
; O O
15 O O
) O O
( O O
p25 O O
; O O
q11 O O
. O O
2 O O
) O O
with O O
simultaneous O O
maternal O O
meiotic O O
nondisjunction O O
for O O
chromosome O O
15 O O
. O O

The O O
patient O O
( O O
J O O
. O O
B O O
. O O
) O O
, O O
a O O
17 O O
- O O
year O O
- O O
old O O
white O O
male O O
with O O
PWS B B_DISEASE/B_GENE
, O O
was O O
found O O
to O O
have O O
47 O O
chromosomes O O
with O O
a O O
supernumerary O O
, O O
paternal O O
der O O
( O O
15 O O
) O O
consisting O O
of O O
the O O
short O O
arm O O
and O O
the O O
proximal O O
long O O
arm O O
of O O
chromosome O O
15 O O
, O O
and O O
distal O O
chromosome O O
arm O O
3p O O
. O O

The O O
t O B_OTHER/B_DISEASE
( O O
3 O B_MEASURE
; O O
15 O B_MEASURE
) O O
was O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
balanced O B_LOCATION/B_PERSON
state O I_LOCATION/I_PERSON
in O O
the O O
patients O B_PERSON/B_SEQUENCE[MEASURE]
father O B_PERSON/I_SEQUENCE[MEASURE]
and O O
a O O
sister O B_PERSON
. O O

Fluorescent O O
in O O
situ O O
hybridization O O
analysis O O
demonstrated O O
that O O
the O O
PWS B B_DISEASE/B_PROTEIN[GENE]
critical O O
region O O
resided O O
on O O
the O O
derivative O O
chromosome O O
3 O O
and O O
that O O
there O O
was O O
no O O
deletion O O
of O O
the O O
PWS B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
region O O
on O O
the O O
normal O O
pair O O
of O O
15s O O
present O O
in O O
J O O
. O O

B O B_OTHER/B_DISEASE
. O O

Methylation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
exon O B_GENE/B_MEASURE
alpha O B_GENE/I_MEASURE
of O O
the O O
small O B_DISEASE
nuclear O I_DISEASE
ribonucleoprotein O I_DISEASE
- O O
associated O O
polypeptide O B_PROTEIN[GENE]
N O I_PROTEIN[GENE]
( O O
SNRPN O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
gene O B_GENE/B_LOCATION
showed O O
a O O
pattern O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
characteristic O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
only O O
the O O
maternal O B_GENE/B_DISEASE
chromosome O B_GENE/I_DISEASE
15 O B_GENE/I_DISEASE
in O O
J O B_OTHER/B_PERSON
. O O

B O B_OTHER/B_DISEASE
. O O

Maternal B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disomy I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
polymerase O O
chain O O
reaction O O
analysis O O
of O O
microsatellite O O
repeats O O
at O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
receptor O O
beta3 O O
subunit O O
( O O
GABRB3 O O
) O O
locus O O
. O O

A O O
niece O B_PERSON/B_BIO
( O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O
B O B_OTHER/B_LOCATION
. O O
) O O
with O O
45 O B_DISEASE/B_GENE
chromosomes O I_DISEASE/I_GENE
and O O
the O O
derivative O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
3 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
but O O
without O O
the O O
der O B_PERSON/B_DISEASE
( O O
15 O B_MEASURE/B_LOCATION
) O O
demonstrated O O
a O O
phenotype O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O O
that O O
reported O O
for O O
haploinsufficiency O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O O
distal O B_GENE
3 O I_GENE
p O I_GENE
. O O

Uniparental B B_DISEASE/B_GENE
disomy I I_DISEASE/I_GENE
associated O O
with O O
unbalanced O O
segregation O O
of O O
non O O
- O O
Robertsonian O O
translocations O O
has O O
been O O
reported O O
previously O O
but O O
has O O
not O O
, O O
to O O
our O O
knowledge O O
, O O
been O O
observed O O
in O O
a O O
case O O
of O O
PWS B B_DISEASE/B_GENE
. O O

Furthermore O O
, O O
our O O
findings O O
are O O
best O O
interpreted O O
as O O
true O O
gamete O O
complementation O O
resulting O O
in O O
maternal B B_PROTEIN[GENE]/B_DISEASE
UPD I B_PROTEIN[GENE]/I_DISEASE
15 I B_PROTEIN[GENE]/I_DISEASE
and O O
PWS B B_MEASURE/B_LOCATION

Schwartz B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Jampel I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
type I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
2 I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
Stuve B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
Wiedemann I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
: O O
a O O
case O O
for O O
" O O
lumping O O
" O O
. O O

Recent O O
studies O O
demonstrated O O
the O O
existence O O
of O O
a O O
genetically O O
distinct O O
, O O
usually O O
lethal O O
form O O
of O O
the O O
Schwartz B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Jampel I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
( O O
SJS B B_DISEASE/B_LOCATION
) O O
of O O
myotonia B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
skeletal B B_DISEASE
dysplasia I I_DISEASE
, O O
which O O
we O O
called O O
SJS B B_DISEASE/B_PERSON
type I I_DISEASE/I_PERSON
2 I I_DISEASE/I_PERSON
. O O

This O O
disorder O O
is O O
reminiscent O O
of O O
another O O
rare O O
condition O O
, O O
the O O
Stuve B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Wiedemann I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SWS B B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
which O O
comprises O O
campomelia B B_DISEASE/B_BIO
at O O
birth O O
with O O
skeletal B B_DISEASE
dysplasia I I_DISEASE
, O O
contractures B B_DISEASE
, O O
and O O
early B B_DISEASE
death I I_DISEASE
. O O

To O O
test O O
for O O
possible O O
nosologic O O
identity O O
between O O
these O O
disorders O O
, O O
we O O
reviewed O O
the O O
literature O O
and O O
obtained O O
a O O
follow O O
- O O
up O O
of O O
the O O
only O O
two O O
surviving O O
patients O O
, O O
one O O
with O O
SJS B B_DISEASE
type I I_DISEASE
2 I I_DISEASE
at O O
age O O
10 O O
years O O
and O O
another O O
with O O
SWS B B_DISEASE
at O O
age O O
7 O O
years O O
. O O

Patients O O
reported O O
as O O
having O O
either O O
neonatal O O
SJS B B_DISEASE
or O O
SWS B B_DISEASE
presented O O
a O O
combination O O
of O O
a O O
severe O O
, O O
prenatal O O
- O O
onset O O
neuromuscular B B_DISEASE
disorder I I_DISEASE
( O O
with O O
congenital B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joint I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
contractures I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
respiratory O O
and O O
feeding O O
difficulties O O
, O O
tendency O O
to O O
hyperthermia B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
and O O
frequent O O
death O O
in O O
infancy O O
) O O
with O O
a O O
distinct O O
campomelic B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
metaphyseal I I_DISEASE_ADJECTIVE[DISEASE]
skeletal I I_DISEASE_ADJECTIVE[DISEASE]
dysplasia I I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
similarity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
clinical O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
radiographic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O O
so O O
extensive O B_DISEASE_ADJECTIVE[DISEASE]
that O O
these O O
disorders O B_DISEASE
appear O O
to O O
be O O
a O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
entity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O O

The O O
follow O O
- O O
up O O
observation O O
of O O
an O O
identical O O
and O O
unique O O
pattern O O
of O O
progressive O O
bone B B_DISEASE
dysplasia I I_DISEASE
in O O
the O O
two O O
patients O O
( O O
one O O
with O O
SJS B B_DISEASE/B_GENE
type I I_DISEASE/I_GENE
2 I I_DISEASE/I_GENE
, O O
one O O
with O O
SWS B B_DISEASE/B_GENE
) O O
surviving O O
beyond O O
infancy O O
adds O O
to O O
the O O
evidence O O
in O O
favor O O
of O O
identity O O
. O O

The O O
hypothesis O O
that O O
SWS B B_DISEASE/B_GENE
and O O
SJS B B_LOCATION
type I I_LOCATION
2 I I_LOCATION
are O O
the O O
same O O
disorder O O
should O O
be O O
testable O O
by O O
molecular O O
methods O O
. O O
. O O

A O O
mouse O O
model O O
of O O
severe O O
von B B_DISEASE
Willebrand I I_DISEASE
disease I I_DISEASE
: O O
defects O O
in O O
hemostasis O O
and O O
thrombosis B B_DISEASE
. O O

von B B_DISEASE/B_LOCATION
Willebrand I I_DISEASE/I_LOCATION
factor I I_DISEASE/I_LOCATION
( I I_DISEASE/I_LOCATION
vWf I I_DISEASE/I_LOCATION
) I I_DISEASE/I_LOCATION
deficiency I I_DISEASE/I_LOCATION
causes O O
severe O O
von B B_DISEASE
Willebrand I I_DISEASE
disease I I_DISEASE
in O O
humans O O
. O O

We O O
generated O O
a O O
mouse O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
this O O
disease O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
using O O
gene O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targeting O B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

vWf B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
deficient I I_PERSON/I_LOCATION
mice O O
appeared O O
normal O O
at O O
birth O O
; O O
they O O
were O O
viable O O
and O O
fertile O O
. O O

Neither O O
vWf O O
nor O O
vWf O O
propolypeptide O O
( O O
von B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Willebrand I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
antigen O O
II O O
) O O
were O O
detectable O O
in O O
plasma O O
, O O
platelets O O
, O O
or O O
endothelial O O
cells O O
of O O
the O O
homozygous O O
mutant O O
mice O O
. O O

The O O
mutant O B_PERSON/B_DISEASE
mice O I_PERSON/I_DISEASE
exhibited O O
defects O B_DISEASE_ADJECTIVE[DISEASE]
in O O
hemostasis O B_DISEASE
with O O
a O O
highly O O
prolonged O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bleeding O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
time O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O O
spontaneous O B_DISEASE
bleeding O I_DISEASE
events O I_DISEASE
in O O
approximately O O
10 O B_MEASURE
% O I_MEASURE
of O O
neonates O B_BIO/B_PERSON
. O O

As O O
in O O
the O O
human O B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
disease O B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O O
the O O
factor O B_DISEASE
VIII O I_DISEASE
level O I_DISEASE
in O O
these O O
mice O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
reduced O O
strongly O O
as O O
a O O
result O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O O
protection O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
provided O O
by O O
vWf O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Defective O O
thrombosis B B_DISEASE
in O O
mutant O O
mice O O
was O O
also O O
evident O O
in O O
an O O
in O O
vivo O O
model O O
of O O
vascular B B_DISEASE/B_LOCATION
injury I I_DISEASE/I_LOCATION
. O O

In O O
this O O
model O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O O
the O O
exteriorized O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mesentery O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O O
superfused O O
with O O
ferric O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
the O O
accumulation O B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O O
fluorescently O O
labeled O O
platelets O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O O
observed O O
by O O
intravital O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

We O O
conclude O O
that O O
these O O
mice O O
very O O
closely O O
mimic O O
severe O O
human O O
von B B_DISEASE
Willebrand I I_DISEASE
disease I I_DISEASE
and O O
will O O
be O O
very O O
useful O O
for O O
investigating O O
the O O
role O O
of O O
vWf O O
in O O
normal O O
physiology O O
and O O
in O O
disease O O
models O O
. O O
. O O

Oral O O
contraceptives O O
and O O
the O O
risk O O
of O O
hereditary B B_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O

Hereditary B B_LOCATION/B_PERSON
Ovarian I I_LOCATION/I_PERSON
Cancer I I_LOCATION/I_PERSON
Clinical O O
Study O O
Group O O
. O O

BACKGROUND O O
Women O O
with O O
mutations O O
in O O
either O O
the O O
BRCA1 O O
or O O
the O O
BRCA2 O O
gene O O
have O O
a O O
high O O
lifetime O O
risk O O
of O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

Oral O O
contraceptives O O
protect O O
against O O
ovarian B B_DISEASE/B_ORGANISM_FUNCTION
cancer I I_DISEASE/I_ORGANISM_FUNCTION
in O O
general O O
, O O
but O O
it O O
is O O
not O O
known O O
whether O O
they O O
also O O
protect O O
against O O
hereditary B B_DISEASE
forms I I_DISEASE
of I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O

METHODS O O
We O O
enrolled O O
207 O O
women O O
with O O
hereditary B B_DISEASE/B_LOCATION
ovarian I I_DISEASE/I_LOCATION
cancer I I_DISEASE/I_LOCATION
and O O
161 O O
of O O
their O O
sisters O O
as O O
controls O O
in O O
a O O
case O O
- O O
control O O
study O O
. O O

All O O
the O O
patients O B_PERSON/B_BIO
carried O O
a O O
pathogenic O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
in O O
either O O
BRCA1 O B_GENE/B_DISEASE
( O O
179 O B_MEASURE/B_PERSON
women O I_MEASURE/I_PERSON
) O O
or O O
BRCA2 O B_GENE/B_LOCATION
( O O
28 O B_TIME[MEASURE]/B_PERSON
women O I_TIME[MEASURE]/I_PERSON
) O O
. O O

The O O
control O B_PERSON/B_ORGANIZATION
women O I_PERSON/I_ORGANIZATION
were O O
enrolled O O
regardless O O
of O O
whether O O
or O O
not O O
they O O
had O O
either O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Lifetime O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
histories O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
oral O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O O
contraceptive O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O O
obtained O O
by O O
interview O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
or O O
by O O
written O O
questionnaire O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
were O O
compared O O
between O O
patients O B_PERSON
and O O
control O B_PERSON/B_ORGANIZATION
women O I_PERSON/I_ORGANIZATION
, O O
after O O
adjustment O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O O
year O B_TIME[MEASURE]
of O O
birth O B_TIME[MEASURE]/B_PERSON
and O O
parity O B_PERSON/B_TIME[MEASURE]
. O O

RESULTS O O
The O O
adjusted O O
odds O O
ratio O O
for O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
associated O O
with O O
any O O
past O O
use O O
of O O
oral O O
contraceptives O O
was O O
0 O O
. O O

5 O O
( O O
95 O B_MEASURE/B_LOCATION
percent O I_MEASURE/I_LOCATION
confidence O I_MEASURE/I_LOCATION
interval O I_MEASURE/I_LOCATION
, O O
0 O B_MEASURE
. O O
3 O B_MEASURE
to O O
0 O B_MEASURE
. O O
8 O B_MEASURE
) O O
. O O

The O O
risk O B_DISEASE/B_MEASURE
decreased O O
with O O
increasing O O
duration O B_TIME[MEASURE]
of O O
use O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O O
P O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
trend O B_TIME[MEASURE]
, O O
< O O
0 O B_MEASURE
. O O
001 O B_MEASURE
) O O
; O O
use O O
for O O
six O B_NUMBER[MEASURE]
or O O
more O B_NUMBER[MEASURE]/B_ENT
years O I_NUMBER[MEASURE]/I_ENT
was O O
associated O O
with O O
a O O
60 O B_MEASURE
percent O I_MEASURE
reduction O I_MEASURE
in O O
risk O B_DISEASE
. O O

Oral O O
- O O
contraceptive O O
use O O
protected O O
against O O
ovarian B B_DISEASE
cancer I I_DISEASE
both O O
for O O
carriers O O
of O O
the O O
BRCA1 O O
mutation O O
( O O
odds O O
ratio O O
, O O
0 O O
. O O
5 O O
; O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
3 O O
to O O
0 O O
. O O
9 O O
) O O
and O O
for O O
carriers O O
of O O
the O O
BRCA2 O O
mutation O O
( O O
odds O O
ratio O O
, O O
0 O O
. O O
4 O O
; O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
2 O O
to O O
1 O O
. O O
1 O O
) O O
. O O

CONCLUSIONS O O
Oral O O
- O O
contraceptive O O
use O O
may O O
reduce O O
the O O
risk O O
of O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
in O O
women O O
with O O
pathogenic O O
mutations O O
in O O
the O O
BRCA1 O O
or O O
BRCA2 O O
gene O O

A O O
Japanese O O
family O O
with O O
adrenoleukodystrophy B B_DISEASE/B_GENE
with O O
a O O
codon O O
291 O O
deletion O O
: O O
a O O
clinical O O
, O O
biochemical O O
, O O
pathological O O
, O O
and O O
genetic O O
report O O
. O O

We O O
report O O
a O O
Japanese O O
family O O
with O O
adrenoleukodystrophy B B_DISEASE
( O O
ALD B B_DISEASE/B_PROTEIN[GENE]
) O O
with O O
a O O
three O O
base O O
pair O O
deletion O O
( O O
delGAG O O
291 O O
) O O
in O O
the O O
ALD B B_DISEASE/B_GENE
gene O O
. O O

A O O
variety O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
phenotypes O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O O
observed O O
within O O
this O O
family O B_PERSON/B_BIO
. O O

While O O
the O O
proband O O
( O O
patient O O
1 O O
) O O
was O O
classified O O
as O O
having O O
a O O
rare O O
intermediate O O
type O O
of O O
adult O O
cerebral O O
and O O
cerebello O O
- O O
brain O O
stem O O
forms O O
, O O
his O O
younger O O
brother O O
( O O
patient O O
2 O O
) O O
and O O
nephew O O
( O O
patient O O
3 O O
) O O
had O O
a O O
childhood O O
ALD B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
type O O
. O O

Another O O
nephew O B_PERSON
( O O
patient O B_PERSON
4 O I_PERSON
) O O
of O O
patient O B_PERSON
1 O I_PERSON
was O O
classified O O
as O O
having O O
an O O
adolescent O B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form O I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

The O O
tau O O
level O O
in O O
the O O
cerebrospinal O O
fluid O O
( O O
CSF O O
) O O
in O O
patient O O
1 O O
was O O
as O O
high O O
as O O
that O O
of O O
patients O O
with O O
Alzheimers B B_DISEASE
disease I I_DISEASE
( O O
AD B B_DISEASE
) O O
. O O

His O O
brain O O
magnetic O O
resonance O O
image O O
( O O
MRI O O
) O O
showed O O
abnormalities B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
bilateral I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cerebellar I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hemispheres I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
brain O O
stem O O
, O O
but O O
not O O
in O O
the O O
cerebral O O
white O O
matter O O
, O O
where O O
marked O O
reductions O O
of O O
the O O
cerebral O O
blood O O
flow O O
and O O
oxygen O O
metabolism O O
were O O
clearly O O
demonstrated O O
by O O
positron O O
emission O O
tomography O O
( O O
PET O O
) O O
. O O

In O O
patients O O
2 O O
and O O
3 O O
, O O
the O O
autopsy O O
findings O O
showed O O
massive O O
demyelination B B_DISEASE
of I I_DISEASE
the I I_DISEASE
cerebral I I_DISEASE
white I I_DISEASE
matter I I_DISEASE
with O O
sparing O O
of O O
the O O
U O O
- O O
fibers O O
, O O
compatible O O
with O O
the O O
findings O O
of O O
childhood O O
ALD B B_DISEASE/B_LOCATION
. O O

Oleic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
erucic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
Lorenzos O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
Oil O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O O
were O O
administered O O
to O O
patients O B_PERSON
1 O I_PERSON
and O O
4 O B_SEQUENCE[MEASURE]
, O O
but O O
sufficient O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effectiveness O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O O
not O O
obtained O O
. O O

The O O
findings O O
in O O
this O O
family O O
suggest O O
that O O
delGAG291 O O
is O O
part O O
of O O
the O O
cause O O
of O O
Japanese O O
ALD B B_DISEASE/B_PERSON
with O O
phenotypic O O
variations O O
. O O

Moreover O O
, O O
although O O
the O O
scale O O
of O O
the O O
study O O
is O O
limited O O
, O O
there O O
is O O
a O O
possibility O O
that O O
PET O O
can O O
detect O O
an O O
insidious B B_DISEASE/B_GENE
lesion I I_DISEASE/I_GENE
which O O
is O O
undetectable O O
by O O
computed O O
tomogram O O
( O O
CT O O
) O O
or O O
MRI O O
analysis O O
, O O
and O O
that O O
the O O
higher O O
level O O
of O O
tau O O
reflects O O
the O O
process O O
of O O
neuronal B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degeneration I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
ALD B B_DISEASE/B_LOCATION
. O O

Lorenzos O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
Oil O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
should O O
be O O
given O O
in O O
the O O
early O B_TIME[MEASURE]/B_LOCATION
stage O I_TIME[MEASURE]/I_LOCATION
. O O
. O O

Nonsense O O
mutation O O
in O O
exon O O
4 O O
of O O
human O O
complement O O
C9 O O
gene O O
is O O
the O O
major O O
cause O O
of O O
Japanese O O
complement B B_DISEASE/B_PERSON
C9 I I_DISEASE/I_PERSON
deficiency I I_DISEASE/I_PERSON
. O O

Deficiency B B_DISEASE/B_PROTEIN[GENE]
of I B_DISEASE/I_PROTEIN[GENE]
the I B_DISEASE/I_PROTEIN[GENE]
ninth I B_DISEASE/I_PROTEIN[GENE]
component I B_DISEASE/I_PROTEIN[GENE]
of I B_DISEASE/I_PROTEIN[GENE]
human I B_DISEASE/I_PROTEIN[GENE]
complement I B_DISEASE/I_PROTEIN[GENE]
( O O
C9 O O
) O O
is O O
the O O
most O O
common O O
complement B B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_DISEASE_ADJECTIVE[DISEASE]
in O O
Japan O O
but O O
is O O
rare O O
in O O
other O O
countries O O
. O O

We O O
studied O O
the O O
molecular O O
basis O O
of O O
C9 B B_DISEASE
deficiency I I_DISEASE
in O O
four O O
Japanese O O
C9 B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
deficient I I_PERSON/I_LOCATION
patients O O
who O O
had O O
suffered O O
from O O
meningococcal B B_DISEASE
meningitis I I_DISEASE
. O O

Direct O O
sequencing O O
of O O
amplified O O
C9 O O
cDNA O O
and O O
DNA O O
revealed O O
a O O
nonsense O O
substitution O O
( O O
CGA O O
- O O
- O O
> O O
TGA O O
) O O
at O O
codon O O
95 O O
in O O
exon O O
4 O O
in O O
the O O
four O O
C9 B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
deficient I I_DISEASE_ADJECTIVE[DISEASE]
individuals O O
. O O

An O O
allele O B_GENE/B_BIO
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polymerase O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
designed O O
to O O
detect O O
exclusively O O
only O O
one O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
normal O B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
mutant O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles O B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
indicated O O
that O O
all O O
the O O
four O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
were O O
homozygous O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
exon O B_MEASURE/B_GENE
4 O I_MEASURE/I_GENE
and O O
that O O
the O O
parents O B_PERSON/B_DISEASE
of O O
patient O B_PERSON/B_NUMBER[MEASURE]
2 O B_PERSON/I_NUMBER[MEASURE]
were O O
heterozygous O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
common O O
mutation O O
at O O
codon O O
95 O O
in O O
exon O O
4 O O
might O O
be O O
responsible O O
for O O
most O O
Japanese O O
C9 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O
. O O

BRCA1 O B_GENE/B_DISEASE
required O O
for O O
transcription O B_GENE
- O O
coupled O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxidative O B_DISEASE/B_GENE
DNA O I_DISEASE/I_GENE
damage O I_DISEASE/I_GENE
. O O

The O O
breast B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ovarian I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
susceptibility O O
gene O O
BRCA1 O O
encodes O O
a O O
zinc O O
finger O O
protein O O
of O O
unknown O O
function O O
. O O

Association O B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
BRCA1 O B_GENE/B_BIO
protein O I_GENE/I_BIO
with O O
the O O
DNA O B_GENE
repair O I_GENE
protein O I_GENE
Rad51 O I_GENE
and O O
changes O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
phosphorylation O B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cellular O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
protein O B_ENZYME[GENE]/B_BACTERIUM[BIO]
after O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O O
DNA O B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
damaging O O
agents O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O O
consistent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O O
a O O
role O B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
BRCA1 O B_GENE/B_DISEASE
in O O
DNA O B_DISEASE/B_BIO
repair O I_DISEASE/I_BIO
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
mouse O O
embryonic O O
stem O O
cells O O
deficient B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
BRCA1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
defective O O
in O O
the O O
ability O O
to O O
carry O O
out O O
transcription O O
- O O
coupled O O
repair O O
of O O
oxidative O O
DNA O O
damage O O
, O O
and O O
are O O
hypersensitive O O
to O O
ionizing O O
radiation O O
and O O
hydrogen O O
peroxide O O
. O O

These O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
BRCA1 O B_GENE/B_DISEASE
participates O O
, O O
directly O O
or O O
indirectly O O
, O O
in O O
transcription O B_GENE/B_LOCATION
- O O
coupled O O
repair O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
oxidative O B_DISEASE/B_GENE
DNA O B_DISEASE/I_GENE
damage O B_DISEASE/I_GENE
. O O
. O O

Truncation O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
transactivation O B_LOCATION/B_BIO
region O I_LOCATION/I_BIO
of O O
PAX6 O B_GENE
result O O
in O O
dominant O B_DISEASE/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]
mutants O I_DISEASE_ADJECTIVE[DISEASE]
. O O

PAX6 O B_GENE
is O O
a O O
transcription O B_GENE/B_BIO
factor O I_GENE/I_BIO
with O O
two O B_GENE
DNA O I_GENE
- O O
binding O O
domains O B_LOCATION/B_PERSON
( O O
paired O O
box O B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O O
homeobox O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
a O O
proline O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
serine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O O
threonine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
PST O B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O O
- O O
rich O B_MEASURE/B_LOCATION
transactivation O B_MEASURE/I_LOCATION
domain O B_MEASURE/I_LOCATION
. O O

PAX6 O B_GENE
regulates O O
eye O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development O B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O O
animals O B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ranging O O
from O O
jellyfish O B_SPECIES[BIO]
to O O
Drosophila O B_SPECIES[BIO]
to O O
humans O B_SPECIES[BIO]
. O O

Heterozygous O O
mutations O O
in O O
the O O
human O O
PAX6 O O
gene O O
result O O
in O O
various O O
phenotypes O O
, O O
including O O
aniridia B B_DISEASE/B_SPECIES[BIO]
, O O
Peters B B_DISEASE
anomaly I I_DISEASE
, O O
autosomal B B_DISEASE
dominant I I_DISEASE
keratitis I I_DISEASE
, O O
and O O
familial B B_DISEASE
foveal I I_DISEASE
dysplasia I I_DISEASE
. O O

It O O
is O O
believed O O
that O O
the O O
mutated O O
allele O O
of O O
PAX6 O O
produces O O
an O O
inactive O O
protein O O
and O O
aniridia B B_DISEASE/B_SPECIES[BIO]
is O O
caused O O
due O O
to O O
genetic O O
haploinsufficiency O O
. O O

However O O
, O O
several O O
truncation O O
mutations O O
have O O
been O O
found O O
to O O
occur O O
in O O
the O O
C O O
- O O
terminal O O
half O O
of O O
PAX6 O O
in O O
patients O O
with O O
Aniridia B B_DISEASE/B_SPECIES[BIO]
resulting O O
in O O
mutant O O
proteins O O
that O O
retain O O
the O O
DNA O O
- O O
binding O O
domains O O
but O O
have O O
lost O O
most O O
of O O
the O O
transactivation O O
domain O O
. O O

It O O
is O O
not O O
clear O B_DISEASE_ADJECTIVE[DISEASE]
whether O O
such O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
really O O
behave O O
as O O
loss O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
of O O
- O O
function O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O O
predicted O O
by O O
haploinsufficiency O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Contrary O B_PERSON/B_MEASURE
to O O
this O O
theory O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
, O O
our O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O O
that O O
these O O
mutants O B_DISEASE/B_GENE
are O O
dominant O B_DISEASE/B_GENE
- O O
negative O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
transient O B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
transfection O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
assays O B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
when O O
they O O
are O O
coexpressed O O
with O O
wild O B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
type O B_GENE/B_MEASURE
PAX6 O I_GENE/I_MEASURE
. O O

We O O
found O O
that O O
the O O
dominant O B_DISEASE
- O O
negative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result O O
from O O
the O O
enhanced O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ability O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
these O O
mutants O B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Kinetic O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
binding O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
dissociation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O O
that O O
various O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
truncation O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mutants O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O O
3 O B_NUMBER[MEASURE]/B_LOCATION
- O O
5 O B_NUMBER[MEASURE]
- O O
fold O O
higher O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity O B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
various O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
binding O O
sites O B_LOCATION/B_ENT
when O O
compared O O
with O O
the O O
wild O B_PERSON/B_BIO
- O O
type O B_PROTEIN[GENE]/B_MEASURE
PAX6 O I_PROTEIN[GENE]/I_MEASURE
. O O

These O O
results O O
provide O O
a O O
new O O
insight O O
into O O
the O O
role O O
of O O
mutant O O
PAX6 O O
in O O
causing O O
aniridia B B_DISEASE/B_SPECIES[BIO]
. O O
. O O

Reversal O O
of O O
severe O O
hypertrophic B B_DISEASE
cardiomyopathy I I_DISEASE
and O O
excellent O O
neuropsychologic O O
outcome O O
in O O
very B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
long I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
acyl I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
coenzyme I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
A I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Very B B_DISEASE
- I I_DISEASE
long I I_DISEASE
- I I_DISEASE
chain I I_DISEASE
acyl I I_DISEASE
- I I_DISEASE
coenzyme I I_DISEASE
A I I_DISEASE
dehydrogenase I I_DISEASE
( I I_DISEASE
VLCAD I I_DISEASE
) I I_DISEASE
deficiency I I_DISEASE
is O O
a O O
disorder O O
of O O
fatty O O
acid O O
beta O O
oxidation O O
that O O
reportedly O O
has O O
high O O
rates O O
of O O
morbidity O O
and O O
mortality O O
. O O

We O O
describe O O
the O O
outcome O O
of O O
a O O
5 O O
- O O
year O O
- O O
old O O
girl O O
with O O
VLCAD B B_DISEASE
deficiency I I_DISEASE
who O O
was O O
first O O
seen O O
at O O
5 O O
months O O
of O O
age O O
with O O
severe O O
hypertrophic B B_DISEASE
cardiomyopathy I I_DISEASE
, O O
hepatomegaly B B_DISEASE
, O O
encephalopathy B B_DISEASE
, O O
and O O
hypotonia B B_DISEASE
. O O

Biochemical O O
studies O O
indicated O O
VLCAD B B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
a O O
stable O O
yet O O
inactive O O
enzyme O O
. O O

Molecular O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
her O O
VLCAD O B_GENE/B_BIO
gene O I_GENE/I_BIO
revealed O O
a O O
T1372C O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
F458L O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
missense O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O O
a O O
1668 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ACAG O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1669 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splice O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
site O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

After O O
initial O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O O
intravenous O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glucose O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
carnitine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
patient O B_PERSON/B_BIO
has O O
thrived O O
on O O
a O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
fat O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diet O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
supplemented O O
with O O
medium O B_MEASURE/B_COLOR
- O O
chain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
triglyceride O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
oil O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O O
carnitine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O O
avoidance O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
fasting O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

Her O O
ventricular O B_DISEASE
hypertrophy O I_DISEASE
resolved O O
significantly O O
over O O
1 O B_TIME[MEASURE]/B_PERSON
year O I_TIME[MEASURE]/I_PERSON
, O O
and O O
cognitively O O
, O O
she O O
is O O
in O O
the O O
superior O B_LOCATION/B_PERSON
range O I_LOCATION/I_PERSON
for O O
age O B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Clinical O O
recognition O O
of O O
VLCAD B B_DISEASE
deficiency I I_DISEASE
is O O
important O O
because O O
it O O
is O O
one O O
of O O
the O O
few O O
directly O O
treatable O O
causes O O
of O O
cardiomyopathy B B_DISEASE
in O O
children O O
. O O
. O O

Cloning O O
of O O
a O O
novel O B_PERSON/B_GENE
member O I_PERSON/I_GENE
of O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
density O B_MEASURE/B_PERSON
lipoprotein O I_MEASURE/I_PERSON
receptor O I_MEASURE/I_PERSON
family O I_MEASURE/I_PERSON
. O O

A O O
gene O O
encoding O O
a O O
novel O O
transmembrane O O
protein O O
was O O
identified O O
by O O
DNA O O
sequence O O
analysis O O
within O O
the O O
insulin B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
dependent I I_DISEASE/I_GENE
diabetes I I_DISEASE/I_GENE
mellitus I I_DISEASE/I_GENE
( O O
IDDM B B_DISEASE/B_GENE
) O O
locus O O
IDDM4 O O
on O O
chromosome O O
11q13 O O
. O O

Based O O
on O O
its O O
chromosomal O O
position O O
, O O
this O O
gene O O
is O O
a O O
candidate O O
for O O
conferring O O
susceptibility O O
to O O
diabetes B B_DISEASE/B_LOCATION
. O O

The O O
gene O B_GENE
, O O
termed O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
density O B_GENE/B_MEASURE
lipoprotein O B_GENE/I_MEASURE
receptor O B_GENE/I_MEASURE
related O O
protein O B_GENE/B_NUMBER[MEASURE]
5 O B_GENE/I_NUMBER[MEASURE]
( O O
LRP5 O B_GENE
) O O
, O O
encodes O O
a O O
protein O B_BIO/B_PROTEIN[GENE]
of O O
1615 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
amino O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acids O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O O
contains O O
conserved O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
modules O B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O O
are O O
characteristic O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
low O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O O
density O B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipoprotein O I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
LDL O B_PROTEIN[GENE]/B_LOCATION
) O O
receptor O B_GENE/B_BIO
family O I_GENE/I_BIO
. O O

These O O
modules O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
include O O
a O O
putative O B_GENE/B_LOCATION
signal O B_GENE/I_LOCATION
peptide O B_GENE/I_LOCATION
for O O
protein O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
export O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
four O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
epidermal O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
EGF O B_GENE/B_LOCATION
) O O
repeats O O
with O O
associated O O
spacer O B_LOCATION/B_BIO
domains O I_LOCATION/I_BIO
, O O
three O B_GENE
LDL O I_GENE
- O O
receptor O B_GENE
( O O
LDLR O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
repeats O O
, O O
a O O
single O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transmembrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
spanning O O
domain O B_LOCATION/B_MEASURE
, O O
and O O
a O O
cytoplasmic O B_GENE
domain O I_GENE
. O O

The O O
encoded O B_GENE/B_LOCATION
protein O I_GENE/I_LOCATION
has O O
a O O
unique O B_LOCATION/B_PERSON
organization O I_LOCATION/I_PERSON
of O O
EGF O B_GENE
and O O
LDLR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repeats O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O O
therefore O O
, O O
LRP5 O B_GENE/B_MEASURE
likely O O
represents O O
a O O
new O B_MEASURE/B_PERSON
category O B_MEASURE/I_PERSON
of O O
the O O
LDLR O B_GENE/B_BIO
family O I_GENE/I_BIO
. O O

Both O O
human O B_SPECIES[BIO]
and O O
mouse O B_SPECIES[BIO]/B_GENE
LRP5 O I_SPECIES[BIO]/I_GENE
cDNAs O I_SPECIES[BIO]/I_GENE
have O O
been O O
isolated O O
and O O
the O O
encoded O O
mature O B_PROTEIN[GENE]
proteins O I_PROTEIN[GENE]
are O O
95 O B_MEASURE
% O I_MEASURE
identical O I_MEASURE
, O O
indicating O O
a O O
high O B_MEASURE/B_LOCATION
degree O I_MEASURE/I_LOCATION
of O O
evolutionary O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conservation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O
. O O

The O O
APC B B_GENE/B_BACTERIUM[BIO]
variants O O
I1307K O O
and O O
E1317Q O O
are O O
associated O O
with O O
colorectal B B_DISEASE/B_LOCATION
tumors I I_DISEASE/I_LOCATION
, O O
but O O
not O O
always O O
with O O
a O O
family O O
history O O
. O O

Classical O O
familial B B_DISEASE
adenomatous I I_DISEASE
polyposis I I_DISEASE
( O O
FAP B B_DISEASE/B_LOCATION
) O O
is O O
a O O
high O O
- O O
penetrance O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
that O O
predisposes O O
to O O
hundreds O O
or O O
thousands O O
of O O
colorectal B B_DISEASE/B_PERSON
adenomas I I_DISEASE/I_PERSON
and I I_DISEASE/I_PERSON
carcinoma I I_DISEASE/I_PERSON
and O O
that O O
results O O
from O O
truncating O O
mutations O O
in O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
. O O

A O O
variant O O
of O O
FAP B B_DISEASE/B_GENE
is O O
attenuated B B_DISEASE_ADJECTIVE[DISEASE]
adenomatous I I_DISEASE_ADJECTIVE[DISEASE]
polyposis I I_DISEASE_ADJECTIVE[DISEASE]
coli I I_DISEASE_ADJECTIVE[DISEASE]
, O O
which O O
results O O
from O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
5 O O
and O O
3 O O
regions O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
. O O

Attenuated B B_NUMBER[MEASURE]/B_PERSON
adenomatous I I_NUMBER[MEASURE]/I_PERSON
polyposis I I_NUMBER[MEASURE]/I_PERSON
coli I I_NUMBER[MEASURE]/I_PERSON
patients O O
have O O
" O O
multiple O O
" O O
colorectal B B_DISEASE/B_GENE
adenomas I I_DISEASE/I_GENE
( O O
typically O O
fewer O O
than O O
100 O O
) O O
without O O
the O O
florid O O
phenotype O O
of O O
classical O O
FAP B B_DISEASE
. O O

Another O O
group O O
of O O
patients O O
with O O
multiple O O
adenomas B B_DISEASE
has O O
no O O
mutations O O
in O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
, O O
and O O
their O O
phenotype O O
probably O O
results O O
from O O
variation O O
at O O
a O O
locus O O
, O O
or O O
loci O O
, O O
elsewhere O O
in O O
the O O
genome O O
. O O

Recently O O
, O O
however O O
, O O
a O O
missense O O
variant O O
of O O
APC B B_GENE/B_BACTERIUM[BIO]
( O O
I1307K O O
) O O
was O O
described O O
that O O
confers O O
an O O
increased O O
risk O O
of O O
colorectal B B_DISEASE
tumors I I_DISEASE
, O O
including O O
multiple O O
adenomas B B_DISEASE
, O O
in O O
Ashkenazim O O
. O O

We O O
have O O
studied O O
a O O
set O O
of O O
164 O O
patients O O
with O O
multiple O O
colorectal B B_DISEASE
adenomas I I_DISEASE
and I I_DISEASE
/ I I_DISEASE
or I I_DISEASE
carcinoma I I_DISEASE
and O O
analyzed O O
codons O O
1263 O O
- O O
1377 O O
( O O
exon O O
15G O O
) O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
for O O
germ O O
- O O
line O O
variants O O
. O O

Three O B_PERSON
patients O I_PERSON
with O O
the O O
I1307K O B_DISEASE/B_GENE
allele O I_DISEASE/I_GENE
were O O
detected O O
, O O
each O O
of O O
Ashkenazi O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
descent O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

Four O O
patients O O
had O O
a O O
germ O O
- O O
line O O
E1317Q O O
missense O O
variant O O
of O O
APC O O
that O O
was O O
not O O
present O O
in O O
controls O O
; O O
one O O
of O O
these O O
individuals O O
had O O
an O O
unusually O O
large O O
number O O
of O O
metaplastic B B_DISEASE/B_GENE
polyps I I_DISEASE/I_GENE
of I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
colorectum I I_DISEASE/I_GENE
. O O

There O O
is O O
increasing O O
evidence O O
that O O
there O O
exist O O
germ O O
- O O
line O O
variants O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
that O O
predispose O O
to O O
the O O
development O O
of O O
multiple O O
colorectal B B_DISEASE
adenomas I I_DISEASE
and I I_DISEASE
carcinoma I I_DISEASE
, O O
but O O
without O O
the O O
florid O O
phenotype O O
of O O
classical O O
FAP B B_DISEASE
, O O
and O O
possibly O O
with O O
importance O O
for O O
colorectal B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
risk O O
in O O
the O O
general O O
population O O
. O O
. O O

Genomic O O
structure O O
of O O
the O O
human O O
congenital B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
chloride I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
diarrhea I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
CLD B B_DISEASE/B_LOCATION
) O O
gene O O
. O O

Congenital B B_DISEASE
chloride I I_DISEASE
diarrhea I I_DISEASE
( O O
CLD B B_LOCATION
) O O
is O O
caused O O
by O O
mutations O O
in O O
a O O
gene O O
which O O
encodes O O
an O O
intestinal O O
anion O O
transporter O O
. O O

We O O
report O O
here O O
the O O
complete O O
genomic O O
organization O O
of O O
the O O
human O O
CLD B B_GENE/B_DISEASE
gene O O
which O O
spans O O
approximately O O
39kb O O
, O O
and O O
comprises O O
21 O O
exons O O
. O O

All O O
exon O B_GENE
/ O O
intron O B_GENE/B_LOCATION
boundaries O I_GENE/I_LOCATION
conform O O
to O O
the O O
GT O B_LOCATION/B_ORGANIZATION
/ O O
AG O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rule O I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

An O O
analysis O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
the O O
putative O B_GENE
promoter O I_GENE
region O I_GENE
sequence O I_GENE
shows O O
a O O
putative O B_MEASURE/B_GENE
TATA O I_MEASURE/I_GENE
box O I_MEASURE/I_GENE
and O O
predicts O O
multiple O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcription O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

The O O
genomic O O
structure O O
was O O
determined O O
using O O
DNA O O
from O O
several O O
sources O O
including O O
multiple O O
large O O
- O O
insert O O
libaries O O
and O O
genomic O O
DNA O O
from O O
Finnish O O
CLD B B_DISEASE/B_LOCATION
patients O O
and O O
controls O O
. O O

Exon O B_GENE/B_PERSON
- O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
primers O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
developed O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O O
facilitate O O
mutation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
patients O B_PERSON/B_BIO
with O O
the O O
disease O B_DISEASE/B_GENE
. O O

Genomic O O
sequencing O O
of O O
a O O
BAC O O
clone O O
H O O
_ O O
RG364P16 O O
revealed O O
the O O
presence O O
of O O
another O O
, O O
highly O O
homologous O O
gene O O
3 O O
of O O
the O O
CLD B B_DISEASE/B_GENE
gene O O
, O O
with O O
a O O
similar O O
genomic O O
structure O O
, O O
recently O O
identified O O
as O O
the O O
Pendred B B_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]
gene O O
( O O
PDS B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O
. O O

The O O
APCI1307K O O
allele O O
and O O
cancer B B_DISEASE/B_LOCATION
risk O O
in O O
a O O
community O O
- O O
based O O
study O O
of O O
Ashkenazi O O
Jews O O
. O O

Mutations O O
in O O
APC O O
are O O
classically O O
associated O O
with O O
familial B B_DISEASE
adenomatous I I_DISEASE
polyposis I I_DISEASE
( O O
FAP B B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
a O O
highly O O
penetrant O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
characterized O O
by O O
multiple O O
intestinal O O
polyps B B_DISEASE
and O O
, O O
without O O
surgical O O
intervention O O
, O O
the O O
development O O
of O O
colorectal B B_DISEASE
cancer I I_DISEASE
( O O
CRC B B_DISEASE/B_LOCATION
) O O
. O O

APC B B_GENE/B_BACTERIUM[BIO]
is O O
a O O
tumour O O
- O O
suppressor O O
gene O O
, O O
and O O
somatic O O
loss O O
occurs O O
in O O
tumours B B_DISEASE/B_PERSON
. O O

The O O
germline O B_PROTEIN[GENE]/B_LOCATION
T O B_PROTEIN[GENE]/I_LOCATION
- O O
to O O
- O O
A O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transversion O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
responsible O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O O
the O O
APC O B_DISEASE_ADJECTIVE[DISEASE]
I1307K O I_DISEASE_ADJECTIVE[DISEASE]
allele O I_DISEASE_ADJECTIVE[DISEASE]
converts O O
the O O
wild O B_BIO/B_GENE
- O O
type O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
homopolymer O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tract O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
A8 O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
that O O
is O O
genetically O O
unstable O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O O
prone O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
somatic O B_DISEASE
mutation O I_DISEASE
. O O

The O O
I1307K O B_DISEASE_ADJECTIVE[DISEASE]
allele O I_DISEASE_ADJECTIVE[DISEASE]
was O O
found O O
in O O
6 O B_NUMBER[MEASURE]/B_LOCATION
. O O

1 O O
% O O
of O O
unselected O O
Ashkenazi O O
Jews O O
and O O
higher O O
proportions O O
of O O
Ashkenazim O O
with O O
family O O
or O O
personal O O
histories O O
of O O
CRC B B_DISEASE/B_LOCATION
( O O
ref O O
. O O
2 O O
) O O
. O O

To O O
evaluate O O
the O O
role O O
of O O
I1307K O O
in O O
cancer B B_DISEASE/B_LOCATION
, O O
we O O
genotyped O O
5 O O
, O O
081 O O
Ashkenazi O O
volunteers O O
in O O
a O O
community O O
survey O O
. O O

Risk O O
of O O
developing O O
colorectal B B_DISEASE
, I I_DISEASE
breast I I_DISEASE
and I I_DISEASE
other I I_DISEASE
cancers I I_DISEASE
were O O
compared O O
between O O
genotyped O O
I1307K O O
carriers O O
and O O
non O O
- O O
carriers O O
and O O
their O O
first O O
- O O
degree O O
relatives O O
. O O

Sperm O O
DNA O O
analysis O O
in O O
a O O
Friedreich B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ataxia I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
premutation O O
carrier O O
suggests O O
both O O
meiotic O O
and O O
mitotic O O
expansion O O
in O O
the O O
FRDA B B_DISEASE/B_GENE
gene O O
. O O

Friedreich B B_DISEASE
ataxia I I_DISEASE
is O O
usually O O
caused O O
by O O
an O O
expansion O O
of O O
a O O
GAA O O
trinucleotide O O
repeat O O
in O O
intron O O
1 O O
of O O
the O O
FRDA B B_DISEASE/B_GENE
gene O O
. O O

Occasionally O O
, O O
a O O
fully O O
expanded O O
allele O B_GENE/B_LOCATION
has O O
been O O
found O O
to O O
arise O O
from O O
a O O
premutation O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O O
100 O B_NUMBER[MEASURE]
or O O
less O B_MEASURE
triplet O I_MEASURE
repeats O I_MEASURE
. O O

We O O
have O O
examined O O
the O O
sperm O B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
a O O
premutation O B_PERSON/B_BIO
carrier O I_PERSON/I_BIO
. O O

This O O
mans O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leucocyte O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O O
one O B_NUMBER[MEASURE]/B_GENE
normal O I_NUMBER[MEASURE]/I_GENE
allele O I_NUMBER[MEASURE]/I_GENE
and O O
one O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
allele O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
approximately O O
100 O B_NUMBER[MEASURE]
repeats O I_NUMBER[MEASURE]
. O O

His O O
sperm O B_BIO/B_PERSON
showed O O
an O O
expanded O O
allele O B_GENE
in O O
a O O
tight O B_PERSON/B_LOCATION
range O B_PERSON/I_LOCATION
centering O O
on O O
a O O
size O B_MEASURE/B_LOCATION
of O O
approximately O O
320 O B_NUMBER[MEASURE]
trinucleotide O I_NUMBER[MEASURE]
repeats O I_NUMBER[MEASURE]
. O O

His O O
affected O B_GENE
son O I_GENE
has O O
repeat O B_TIME[MEASURE]/B_PERSON
sizes O I_TIME[MEASURE]/I_PERSON
of O O
1040 O B_MEASURE
and O O
540 O B_MEASURE
. O O

These O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O O
that O O
expansion O B_DISEASE/B_ORGANISM_FUNCTION
occurs O O
in O O
two O B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages O I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
during O O
meiosis O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
followed O O
by O O
a O O
second O B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitotic O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
expansion O I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
also O O
show O O
that O O
in O O
all O O
informative O B_PERSON/B_LOCATION
carrier O I_PERSON/I_LOCATION
father O I_PERSON/I_LOCATION
to O O
affected O B_PERSON
child O I_PERSON
transmissions O I_PERSON
, O O
with O O
the O O
notable O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
exception O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O O
the O O
premutation O B_PERSON
carrier O I_PERSON
, O O
the O O
expansion O B_MEASURE
size O I_MEASURE
decreases O O
. O O
. O O

The O O
R496H O O
mutation O O
of O O
arylsulfatase O O
A O O
does O O
not O O
cause O O
metachromatic B B_DISEASE
leukodystrophy I I_DISEASE
. O O

Deficiency B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
arylsulfatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
A I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ARSA O O
) O O
enzyme O O
activity O O
causes O O
metachromatic B B_DISEASE
leukodystrophy I I_DISEASE
( O O
MLD B B_DISEASE
) O O
. O O

A O O
number O O
of O O
ARSA O O
gene O O
mutations O O
responsible O O
for O O
MLD B B_DISEASE
have O O
been O O
identified O O
. O O

Recently O O
, O O
the O O
R496H O O
mutation O O
of O O
ARSA O O
was O O
proposed O O
to O O
be O O
a O O
cause O O
of O O
MLD B B_DISEASE
( O O
Draghia O O
et O O
al O O
. O O
, O O
1997 O O
) O O
. O O

We O O
have O O
investigated O O
the O O
R496H O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
found O O
this O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
at O O
a O O
relatively O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequency O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
an O O
African O B_MEASURE/B_PERSON
American O I_MEASURE/I_PERSON
population O I_MEASURE/I_PERSON
( O O
f O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
09 O B_MEASURE
, O O
n O O
= O O
61 O B_MEASURE
subjects O I_MEASURE
) O O
. O O

The O O
ARSA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
subjects O B_PERSON/B_BIO
with O O
and O O
without O O
the O O
R496H O B_DISEASE/B_GENE
mutation O I_DISEASE/I_GENE
was O O
determined O O
and O O
found O O
to O O
be O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

It O O
is O O
therefore O O
concluded O O
that O O
the O O
R496H O O
mutation O O
of O O
ARSA O O
does O O
not O O
negatively O O
influence O O
the O O
activity O O
of O O
ARSA O O
and O O
is O O
not O O
a O O
cause O O
of O O
MLD B B_DISEASE

Down O O
- O O
regulation O O
of O O
transmembrane O O
carbonic O O
anhydrases O O
in O O
renal B B_DISEASE
cell I I_DISEASE
carcinoma I I_DISEASE
cell O O
lines O O
by O O
wild O O
- O O
type O O
von B B_DISEASE/B_GENE
Hippel I B_DISEASE/I_GENE
- I B_DISEASE/I_GENE
Lindau I B_DISEASE/I_GENE
transgenes O O
. O O

To O O
discover O O
genes O O
involved O O
in O O
von B B_DISEASE/B_VIRUS[BIO]
Hippel I B_DISEASE/I_VIRUS[BIO]
- I B_DISEASE/I_VIRUS[BIO]
Lindau I B_DISEASE/I_VIRUS[BIO]
( O O
VHL B B_DISEASE/B_GENE
) O O
- O O
mediated O O
carcinogenesis O O
, O O
we O O
used O O
renal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinoma I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O O
lines O O
stably O O
transfected O O
with O O
wild O O
- O O
type O O
VHL O O
- O O
expressing O O
transgenes O O
. O O

Large O B_MEASURE/B_GENE
- O O
scale O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNA O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
differential O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
display O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
technology O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
applied O O
to O O
these O O
cell O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines O B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O O
several O B_NUMBER[MEASURE]
differentially O O
expressed O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
including O O
an O O
alpha O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
carbonic O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
anhydrase O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
termed O O
CA12 O B_GENE/B_DISEASE
. O O

The O O
deduced O B_PROTEIN[GENE]/B_LOCATION
protein O I_PROTEIN[GENE]/I_LOCATION
sequence O I_PROTEIN[GENE]/I_LOCATION
was O O
classified O O
as O O
a O O
one O B_NUMBER[MEASURE]
- O O
pass O B_GENE/B_MEASURE
transmembrane O B_GENE/I_MEASURE
CA O B_GENE/I_MEASURE
possessing O O
an O O
apparently O O
intact O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
catalytic O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
domain O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O O
the O O
extracellular O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
CA O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
module O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Reintroduced O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
strongly O O
inhibited O O
the O O
overexpression O O
of O O
the O O
CA12 O O
gene O O
in O O
the O O
parental O O
renal B B_DISEASE
cell I I_DISEASE
carcinoma I I_DISEASE
cell O O
lines O O
. O O

Similar O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O O
obtained O O
with O O
CA9 O B_GENE/B_LOCATION
, O O
encoding O O
another O O
transmembrane O B_ENZYME[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
CA O I_ENZYME[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O O
an O O
intact O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
catalytic O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

Although O O
both O O
domains O O
of O O
the O O
VHL B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
protein O O
contribute O O
to O O
regulation O O
of O O
CA12 O O
expression O O
, O O
the O O
elongin O O
binding O O
domain O O
alone O O
could O O
effectively O O
regulate O O
CA9 O O
expression O O
. O O

We O O
mapped O O
CA12 O B_GENE/B_LOCATION
and O O
CA9 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
loci O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O O
chromosome O B_MEASURE/B_GENE
bands O I_MEASURE/I_GENE
15q22 O I_MEASURE/I_GENE
and O O
17q21 O B_MEASURE
. O O

2 O O
respectively O O
, O O
regions O O
prone O O
to O O
amplification O O
in O O
some O O
human O O
cancers B B_DISEASE/B_BIO
. O O

Additional O O
experiments O O
are O O
needed O O
to O O
define O O
the O O
role O O
of O O
CA O O
IX O O
and O O
CA O O
XII O O
enzymes O O
in O O
the O O
regulation O O
of O O
pH O O
in O O
the O O
extracellular O O
microenvironment O O
and O O
its O O
potential O O
impact O O
on O O
cancer B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell O O
growth O O
. O O

A O O
gene O O
encoding O O
a O O
transmembrane O O
protein O O
is O O
mutated O O
in O O
patients O O
with O O
diabetes B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mellitus I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
optic B B_DISEASE
atrophy I I_DISEASE
( O O
Wolfram B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O O
. O O

Wolfram B B_DISEASE/B_GENE
syndrome I I_DISEASE/I_GENE
( O O
WFS B B_DISEASE/B_PROTEIN[GENE]
; O O
OMIM O O
222300 O O
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
neurodegenerative I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
defined O O
by O O
young O O
- O O
onset O O
non O O
- O O
immune O O
insulin B B_DISEASE
- I I_DISEASE
dependent I I_DISEASE
diabetes I I_DISEASE
mellitus I I_DISEASE
and O O
progressive O O
optic B B_DISEASE
atrophy I I_DISEASE
. O O

Linkage O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
markers O B_DISEASE/B_GENE
on O O
chromosome O B_GENE/B_MEASURE
4p O I_GENE/I_MEASURE
was O O
confirmed O O
in O O
five O B_PERSON/B_TIME[MEASURE]
families O I_PERSON/I_TIME[MEASURE]
. O O

On O O
the O O
basis O O
of O O
meiotic O O
recombinants O O
and O O
disease O O
- O O
associated O O
haplotypes O O
, O O
the O O
WFS B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
gene O O
was O O
localized O O
to O O
a O O
BAC O O
/ O O
P1 O O
contig O O
of O O
less O O
than O O
250 O O
kb O O
. O O

Mutations O O
in O O
a O O
novel O O
gene O O
( O O
WFS1 O O
) O O
encoding O O
a O O
putative O O
transmembrane O O
protein O O
were O O
found O O
in O O
all O O
affected O O
individuals O O
in O O
six O O
WFS B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
families O O
, O O
and O O
these O O
mutations O O
were O O
associated O O
with O O
the O O
disease O O
phenotype O O
. O O

WFS1 O B_GENE
appears O O
to O O
function O O
in O O
survival O B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O O
islet O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
beta O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O O
cells O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
neurons O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O O
. O O

Stable O O
interaction O O
between O O
the O O
products O O
of O O
the O O
BRCA1 O O
and O O
BRCA2 O O
tumor B B_DISEASE
suppressor O O
genes O O
in O O
mitotic O O
and O O
meiotic O O
cells O O
. O O

BRCA1 O O
and O O
BRCA2 O O
account O O
for O O
most O O
cases O O
of O O
familial O O
, O O
early O O
onset O O
breast B B_DISEASE
and I I_DISEASE
/ I I_DISEASE
or I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
and O O
encode O O
products O O
that O O
each O O
interact O O
with O O
hRAD51 O O
. O O

Results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presented O O
here O O
show O O
that O O
BRCA1 O B_GENE/B_DISEASE
and O O
BRCA2 O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coexist O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
a O O
biochemical O B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
complex O I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
colocalize O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O O
subnuclear O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
foci O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
somatic O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O O
on O O
the O O
axial O B_LOCATION/B_MEASURE
elements O I_LOCATION/I_MEASURE
of O O
developing O O
synaptonemal O B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
complexes O I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
. O O

Like O O
BRCA1 O B_GENE/B_DISEASE
and O O
RAD51 O B_GENE
, O O
BRCA2 O B_GENE/B_DISEASE
relocates O O
to O O
PCNA O B_PROTEIN[GENE]/B_MEASURE
+ O O
replication O B_LOCATION/B_ORGANIZATION
sites O I_LOCATION/I_ORGANIZATION
following O O
exposure O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O O
S O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
phase O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
to O O
hydroxyurea O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O O
UV O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
irradiation O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Thus O O
, O O
BRCA1 O B_GENE/B_DISEASE
and O O
BRCA2 O B_GENE
participate O O
, O O
together O O
, O O
in O O
a O O
pathway O B_LOCATION
( O O
s O O
) O O
associated O O
with O O
the O O
activation O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O O
double O B_NUMBER[MEASURE]/B_BIO
- O O
strand O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
break O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
repair O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
/ O O
or O O
homologous O B_DISEASE/B_GENE
recombination O I_DISEASE/I_GENE
. O O

Dysfunction O O
of O O
this O O
pathway O O
may O O
be O O
a O O
general O O
phenomenon O O
in O O
the O O
majority O O
of O O
cases O O
of O O
hereditary B B_DISEASE
breast I I_DISEASE
and I I_DISEASE
/ I I_DISEASE
or I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O
. O O

A O O
novel O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Arg362Ser O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
the O O
sterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
hydroxylase O B_ENZYME[GENE]/B_PERSON
gene O I_ENZYME[GENE]/I_PERSON
( O O
CYP27 O B_GENE
) O O
: O O
its O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE
splicing O I_GENE
and O O
enzyme O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O O

A O O
novel O O
C O O
to O O
A O O
mutation O O
in O O
the O O
sterol O O
27 O O
- O O
hydroxylase O O
gene O O
( O O
CYP27 O O
) O O
was O O
identified O O
by O O
sequencing O O
amplified O O
CYP27 O O
gene O O
products O O
from O O
a O O
patient O O
with O O
cerebrotendinous B B_DISEASE
xanthomatosis I I_DISEASE
( O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

The O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
changed O O
the O O
adrenodoxin O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cofactor O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residue O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
362Arg O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
362Ser O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O O
CGT O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
362Arg O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O O
AGT O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
362Ser O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O O
, O O
and O O
was O O
responsible O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
deficiency O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
sterol O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O O
hydroxylase O B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity O I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
confirmed O O
by O O
expression O B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
mutant O B_GENE
cDNA O I_GENE
into O O
COS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
1 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Quantitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
that O O
the O O
expression O B_MEASURE/B_GENE
of O O
CYP27 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
patient O B_BODY_PART_OR_ORGAN_COMPONENT
represented O O
52 O B_MEASURE/B_DISEASE
. O O

5 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
normal O B_MEASURE/B_PERSON
level O B_MEASURE/I_PERSON
. O O

As O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O O
at O O
the O O
penultimate O B_LOCATION/B_MEASURE
nucleotide O I_LOCATION/I_MEASURE
of O O
exon O B_GENE
6 O I_GENE
( O O
- O O
2 O B_LOCATION/B_MEASURE
position O I_LOCATION/I_MEASURE
of O O
exon O B_GENE/B_DISEASE
6 O I_GENE/I_DISEASE
- O O
intron O B_MEASURE
6 O I_MEASURE
splice O I_MEASURE
site O I_MEASURE
) O O
of O O
the O O
gene O B_PERSON/B_GENE
, O O
we O O
hypothesized O O
that O O
the O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]
may O O
partially O O
affect O O
the O O
normal O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
efficiency O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
exon O B_GENE/B_BIO
6 O I_GENE/I_BIO
and O O
cause O O
alternative O B_DISEASE/B_GENE
splicing O I_DISEASE/I_GENE
elsewhere O O
, O O
which O O
resulted O O
in O O
decreased O B_DISEASE/B_GENE
transcript O I_DISEASE/I_GENE
in O O
the O O
patient O B_PERSON/B_BIO
. O O

Transfection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
constructed O O
minigenes O B_GENE/B_BIO
, O O
with O O
or O O
without O O
the O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O O
into O O
COS O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O O
1 O B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells O I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
confirmed O O
that O O
the O O
mutant O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
minigene O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
responsible O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O O
a O O
mRNA O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
species O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alternatively O O
spliced O O
at O O
an O O
activated O O
cryptic O B_LOCATION/B_PERSON
5 O I_LOCATION/I_PERSON
splice O I_LOCATION/I_PERSON
site O I_LOCATION/I_PERSON
88 O I_LOCATION/I_PERSON
bp O I_LOCATION/I_PERSON
upstream O O
from O O
the O O
3 O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
exon O B_GENE
6 O I_GENE
. O O

Our O O
data O O
suggest O O
that O O
the O O
C O O
to O O
A O O
mutation O O
at O O
the O O
penultimate O O
nucleotide O O
of O O
exon O O
6 O O
of O O
the O O
CYP27 O O
gene O O
not O O
only O O
causes O O
the O O
deficiency B B_DISEASE/B_GENE
in I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
sterol I I_DISEASE/I_GENE
27 I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
hydroxylase I I_DISEASE/I_GENE
activity I I_DISEASE/I_GENE
, O O
but O O
also O O
partially O O
leads O O
to O O
alternative O O
pre O O
- O O
mRNA O O
splicing O O
of O O
the O O
gene O O
. O O

To O O
our O O
knowledge O B_PERSON
, O O
this O O
is O O
the O O
first O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
report O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
regarding O O
effects O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
pre O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O O
mRNA O B_GENE
splicing O I_GENE
of O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
the O O
- O O
2 O B_LOCATION/B_MEASURE
position O I_LOCATION/I_MEASURE
of O O
a O O
5 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splice O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

ATM O O
germline O O
mutations O O
in O O
classical O O
ataxia B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
telangiectasia I I_DISEASE/I_GENE
patients O O
in O O
the O O
Dutch O O
population O O
. O O

Germline O O
mutations O O
in O O
the O O
ATM O O
gene O O
are O O
responsible O O
for O O
the O O
autosomal B B_DISEASE_ADJECTIVE[DISEASE]
recessive I I_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
ataxia B I_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
telangiectasia I I_DISEASE_ADJECTIVE[DISEASE]
( O O
A B B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

In O O
our O O
study O O
, O O
we O O
have O O
determined O O
the O O
ATM O O
mutation O O
spectrum O O
in O O
19 O O
classical O O
A B B_DISEASE/B_LOCATION
- I B_DISEASE/I_LOCATION
T I B_DISEASE/I_LOCATION
patients O O
, O O
including O O
some O O
immigrant O O
populations O O
, O O
as O O
well O O
as O O
12 O O
of O O
Dutch O O
ethnic O O
origin O O
. O O

Both O O
the O O
protein O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
truncation O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
test O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O O
PTT O B_LOCATION/B_ORGANIZATION
) O O
and O O
the O O
restriction O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
endonuclease O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fingerprinting O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
REF O B_LOCATION/B_ORGANIZATION
) O O
method O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O O
used O O
and O O
compared O O
for O O
their O O
detection O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiency O B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
identifying O O
76 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
and O O
60 O B_MEASURE/B_LOCATION
% O I_MEASURE/I_LOCATION
of O O
the O O
mutations O B_GENE/B_DISEASE
, O O
respectively O O
. O O

Most O B_PERSON/B_NUMBER[MEASURE]
patients O I_PERSON/I_NUMBER[MEASURE]
were O O
found O O
to O O
be O O
compound O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
heterozygote O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Seventeen O B_NUMBER[MEASURE]
mutations O I_NUMBER[MEASURE]
were O O
distinct O B_DISEASE_ADJECTIVE[DISEASE]
, O O
of O O
which O O
10 O B_NUMBER[MEASURE]
were O O
not O O
reported O O
previously O O
. O O

Mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_NUMBER[MEASURE]
are O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletions O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O O
point O B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]
frequently O O
affecting O O
splice O B_GENE/B_BIO
sites O I_GENE/I_BIO
. O O

Moreover O O
, O O
a O O
16 O B_NUMBER[MEASURE]/B_LOCATION
. O O

7 O O
- O O
kb O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
genomic O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
deletion O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
3 O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
gene O B_GENE/B_LOCATION
, O O
most O O
likely O O
a O O
result O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O O
recombination O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
between O O
two O B_GENE/B_PERSON
LINE O I_GENE/I_PERSON
elements O I_GENE/I_PERSON
, O O
was O O
identified O O
. O O

The O O
most O O
frequently O O
found O O
mutation O O
, O O
identified O O
in O O
three O O
unrelated O O
Turkish O O
A B B_PERSON/B_LOCATION
- I I_PERSON/I_LOCATION
T I I_PERSON/I_LOCATION
individuals O O
, O O
was O O
previously O O
described O O
to O O
be O O
a O O
Turkish O O
A B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
T I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
founder O O
mutation O O
. O O

The O O
presence O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
a O O
founder O B_GENE/B_DISEASE
mutation O I_GENE/I_DISEASE
among O O
relatively O O
small O B_PERSON/B_MEASURE
ethnic O I_PERSON/I_MEASURE
population O I_PERSON/I_MEASURE
groups O I_PERSON/I_MEASURE
in O O
Western O B_LOCATION
Europe O I_LOCATION
could O O
indicate O O
a O O
high O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
carrier O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
frequency O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O O
such O B_LOCATION/B_PERSON
communities O I_LOCATION/I_PERSON
. O O

In O O
patients O B_PERSON/B_LOCATION
of O O
Dutch O B_DISEASE/B_PERSON
ethnic O I_DISEASE/I_PERSON
origin O I_DISEASE/I_PERSON
, O O
however O O
, O O
no O O
significant O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
founder O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
effect O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
could O O
be O O
identified O O
. O O

The O O
observed O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genetic O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
heterogeneity O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O O
the O O
relative O B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percentage O B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
splice O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O O
site O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
had O O
no O O
reflection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O O
the O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O O

All O O
patients O O
manifested O O
classical O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
increased O O
cellular O O
radioresistant O O
DNA O O
synthesis O O
. O O

Determination O O
of O O
the O O
genomic O O
structure O O
of O O
the O O
COL4A4 O O
gene O O
and O O
of O O
novel O O
mutations O O
causing O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
Alport I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
. O O

Autosomal B B_DISEASE
recessive I I_DISEASE
Alport I I_DISEASE
syndrome I I_DISEASE
is O O
a O O
progressive O O
hematuric B B_DISEASE
glomerulonephritis I I_DISEASE
characterized O O
by O O
glomerular B B_DISEASE
basement I I_DISEASE
membrane I I_DISEASE
abnormalities I I_DISEASE
and O O
associated O O
with O O
mutations O O
in O O
either O O
the O O
COL4A3 O O
or O O
the O O
COL4A4 O O
gene O O
, O O
which O O
encode O O
the O O
alpha3 O O
and O O
alpha4 O O
type O O
IV O O
collagen O O
chains O O
, O O
respectively O O
. O O

To O O
date O B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
mutation O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
two O B_LOCATION/B_GENE
genes O I_LOCATION/I_GENE
has O O
been O O
hampered O O
by O O
the O O
lack O B_DISEASE_ADJECTIVE[DISEASE]
of O O
genomic O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
information O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

We O O
report O O
here O O
the O O
complete O O
characterization O O
of O O
the O O
48 O O
exons O O
of O O
the O O
COL4A4 O O
gene O O
, O O
a O O
comprehensive O O
gene O O
screen O O
, O O
and O O
the O O
subsequent O O
detection O O
of O O
10 O O
novel O O
mutations O O
in O O
eight O O
patients O O
diagnosed O O
with O O
autosomal B B_DISEASE
recessive I I_DISEASE
Alport I I_DISEASE
syndrome I I_DISEASE
. O O

Furthermore O O
, O O
we O O
identified O O
a O O
glycine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
alanine O O
substitution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O O
the O O
collagenous O B_GENE/B_DISEASE
domain O I_GENE/I_DISEASE
that O O
is O O
apparently O O
silent O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
the O O
heterozygous O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
carriers O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
in O O
11 O B_MEASURE/B_BIO
. O O

5 O B_TIME[MEASURE]/B_PERSON
% O I_TIME[MEASURE]/I_PERSON
of O O
all O O
control O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individuals O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
in O O
one O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individual O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homozygous O I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
this O O
glycine O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitution O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

There O O
has O O
been O O
no O O
previous O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
finding O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O O
a O O
glycine O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitution O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O O
is O O
not O O
associated O O
with O O
any O O
obvious O B_DISEASE/B_GENE
phenotype O I_DISEASE/I_GENE
in O O
homozygous O B_PERSON/B_BIO
individuals O B_PERSON/I_BIO
. O O

Founder O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
in O O
French O O
Canadian O O
breast B B_DISEASE/B_PERSON
and I I_DISEASE/I_PERSON
ovarian I I_DISEASE/I_PERSON
cancer I I_DISEASE/I_PERSON
families O O
. O O

We O O
have O O
identified O O
four O O
mutations O O
in O O
each O O
of O O
the O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
- O O
susceptibility O O
genes O O
, O O
BRCA1 O O
and O O
BRCA2 O O
, O O
in O O
French O O
Canadian O O
breast B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
and O O
breast B B_DISEASE/B_PERSON
/ I I_DISEASE/I_PERSON
ovarian I I_DISEASE/I_PERSON
cancer I I_DISEASE/I_PERSON
families O O
from O O
Quebec O O
. O O

To O O
identify O O
founder O O
effects O O
, O O
we O O
examined O O
independently O O
ascertained O O
French O O
Canadian O O
cancer B B_DISEASE/B_LOCATION
families O O
for O O
the O O
distribution O O
of O O
these O O
eight O O
mutations O O
. O O

Mutations O B_DISEASE/B_PERSON
were O O
found O O
in O O
41 O B_NUMBER[MEASURE]
of O O
97 O B_PERSON/B_ENT
families O I_PERSON/I_ENT
. O O

Six O B_NUMBER[MEASURE]
of O O
eight O B_NUMBER[MEASURE]/B_PERSON
mutations O B_NUMBER[MEASURE]/I_PERSON
were O O
observed O O
at O O
least O O
twice O O
. O O

The O O
BRCA1 O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
C4446T O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O O
the O O
most O O
common O B_DISEASE_ADJECTIVE[DISEASE]
mutation O I_DISEASE_ADJECTIVE[DISEASE]
found O O
, O O
followed O O
by O O
the O O
BRCA2 O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
8765delAG O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutation O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

Together O O
, O O
these O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O O
found O O
in O O
28 O B_NUMBER[MEASURE]
of O O
41 O B_MEASURE/B_PERSON
families O I_MEASURE/I_PERSON
identified O O
to O O
have O O
a O O
mutation O B_DISEASE/B_GENE
. O O

The O O
odds O B_TIME[MEASURE]/B_PERSON
of O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
of O O
the O O
four O B_DISEASE/B_GENE
BRCA1 O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
was O O
18 O B_TIME[MEASURE]
. O O

7x O O
greater O O
if O O
one O O
or O O
more O O
cases O O
of O O
ovarian B B_DISEASE
cancer I I_DISEASE
were O O
also O O
present O O
in O O
the O O
family O O
. O O

The O O
odds O B_PERSON/B_MEASURE
of O O
detection O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O O
any O O
of O O
the O O
four O B_DISEASE/B_GENE
BRCA2 O I_DISEASE/I_GENE
mutations O I_DISEASE/I_GENE
was O O
5 O B_TIME[MEASURE]
. O O

3x O O
greater O O
if O O
there O O
were O O
at O O
least O O
five O O
cases O O
of O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
in O O
the O O
family O O
. O O

Interestingly O O
, O O
the O O
presence O O
of O O
a O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
case O O
< O O
36 O O
years O O
of O O
age O O
was O O
strongly O O
predictive O O
of O O
the O O
presence O O
of O O
any O O
of O O
the O O
eight O O
mutations O O
screened O O
. O O

Carriers O B_PERSON
of O O
the O O
same O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PERSON
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_PERSON
, O O
from O O
different O B_LOCATION/B_PERSON
families O I_LOCATION/I_PERSON
, O O
shared O O
similar O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
haplotypes O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
, O O
indicating O O
that O O
the O O
mutant O B_PERSON/B_GENE
alleles O I_PERSON/I_GENE
were O O
likely O B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O O
be O O
identical O B_DISEASE_ADJECTIVE[DISEASE]
by O O
descent O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
mutation O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
the O O
founder O B_PERSON/B_BIO
population O I_PERSON/I_BIO
. O O

The O O
identification O O
of O O
common O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
will O O
facilitate O O
carrier O O
detection O O
in O O
French O O
Canadian O O
breast B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
breast B B_DISEASE/B_GENE
/ I I_DISEASE/I_GENE
ovarian I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
families O O
. O O

Are O O
Dp71 O O
and O O
Dp140 O O
brain O O
dystrophin O O
isoforms O O
related O O
to O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]
in O O
Duchenne B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
muscular I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
dystrophy I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON

Molecular O O
study O O
and O O
neuropsychological O O
analysis O O
were O O
performed O O
concurrently O O
on O O
49 O O
patients O O
with O O
Duchenne B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscular I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
dystrophy I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
DMD B B_DISEASE
) O O
in O O
order O O
to O O
find O O
a O O
molecular O O
explanation O O
for O O
the O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]
observed O O
in O O
most O O
DMD B B_DISEASE/B_MEASURE
patients O O
. O O

Complete O O
analysis O O
of O O
the O O
dystrophin O O
gene O O
was O O
performed O O
to O O
define O O
the O O
localization O O
of O O
deletions O O
and O O
duplications O O
in O O
relation O O
to O O
the O O
different O O
DMD B B_DISEASE/B_GENE
promoters O O
. O O

Qualitative O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O O
the O O
Dp71 O B_GENE/B_BIO
transcript O I_GENE/I_BIO
and O O
testing O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O O
the O O
specific O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
first O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
exon O I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O O
Dp140 O B_GENE
were O O
also O O
carried O O
out O O
. O O

Neuropsychological O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assessed O O
verbal O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O O
visuospatial O B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
intelligence O I_EDU[ORGANIZATION]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
verbal O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
memory O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O O
and O O
reading O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
skills O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Comparison O O
of O O
molecular O O
and O O
psychometric O O
findings O O
demonstrated O O
that O O
deletions O O
and O O
duplications O O
that O O
were O O
localized O O
in O O
the O O
distal O O
part O O
of O O
the O O
gene O O
seemed O O
to O O
be O O
preferentially O O
associated O O
with O O
cognitive B B_DISEASE
impairment I I_DISEASE
. O O

Two O O
altered O O
Dp71 O O
transcripts O O
and O O
two O O
deleted O O
Dp140 O O
DNA O O
sequences O O
were O O
found O O
in O O
four O O
patients O O
with O O
severe O O
cerebral B B_DISEASE
dysfunction I I_DISEASE
. O O

These O O
findings O O
suggest O O
that O O
some O O
sequences O O
located O O
in O O
the O O
distal O O
part O O
of O O
the O O
gene O O
and O O
, O O
in O O
particular O O
, O O
some O O
DMD B B_DISEASE/B_GENE
isoforms O O
expressed O O
in O O
the O O
brain O O
may O O
be O O
related O O
to O O
the O O
cognitive B B_DISEASE/B_GENE
impairment I I_DISEASE/I_GENE
associated O O
with O O
DMD B B_DISEASE
. O O
. O O

I1307K O O
APC O O
and O O
hMLH1 O O
mutations O O
in O O
a O O
non O O
- O O
Jewish O O
family O O
with O O
hereditary B B_DISEASE
non I I_DISEASE
- I I_DISEASE
polyposis I I_DISEASE
colorectal I I_DISEASE
cancer I I_DISEASE
. O O

We O O
describe O O
a O O
French O O
Canadian O O
hereditary B B_DISEASE
non I I_DISEASE
- I I_DISEASE
polyposis I I_DISEASE
colorectal I I_DISEASE
cancer I I_DISEASE
( O O
HNPCC B B_DISEASE/B_GENE
) O O
kindred O O
which O O
carries O O
a O O
novel O O
truncating O O
mutation O O
in O O
hMLH1 O O
. O O

Interestingly O O
, O O
the O O
I1307K O O
APC O O
polymorphism O O
, O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
colorectal B B_DISEASE
cancer I I_DISEASE
, O O
is O O
also O O
present O O
in O O
this O O
family O O
. O O

The O O
I1307K O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O O
previously O O
only O O
been O O
identified O O
in O O
individuals O B_PERSON/B_BIO
of O O
self O B_PERSON/B_MEASURE
- O O
reported O O
Ashkenazi O B_DISEASE/B_LOCATION
Jewish O I_DISEASE/I_LOCATION
origins O I_DISEASE/I_LOCATION
. O O

In O O
addition O O
, O O
in O O
this O O
family O O
, O O
there O O
appears O O
to O O
be O O
no O O
relationship O O
between O O
the O O
I1307K O O
polymorphism O O
and O O
the O O
presence O O
or O O
absence O O
of O O
cancer B B_DISEASE
. O O
. O O

Identification O O
of O O
a O O
novel O O
mutation O O
of O O
the O O
CPO O O
gene O O
in O O
a O O
Japanese O O
hereditary B B_DISEASE/B_BIO
coproporphyria I I_DISEASE/I_BIO
family O O
. O O

Hereditary B B_DISEASE
coproporphyria I I_DISEASE
( O O
HCP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
characterized O O
by O O
a O O
deficiency B B_DISEASE
of I I_DISEASE
coproporphyrinogen I I_DISEASE
oxidase I I_DISEASE
( O O
CPO O O
) O O
caused O O
by O O
a O O
mutation O O
in O O
the O O
CPO O O
gene O O
. O O

Only O O
11 O O
mutations O O
of O O
the O O
gene O O
have O O
been O O
reported O O
in O O
HCP B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients O O
. O O

We O O
report O O
another O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O O
a O O
Japanese O B_PERSON/B_ORGANIZATION
family O I_PERSON/I_ORGANIZATION
. O O

Polymerase O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O O
single O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strand O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conformational O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism O B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
direct O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analyses O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
demonstrated O O
a O O
C O B_PROTEIN[GENE]/B_LOCATION
to O O
T O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
substitution O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O O
exon O B_GENE/B_MEASURE
1 O I_GENE/I_MEASURE
of O O
the O O
CPO O B_GENE/B_BIO
gene O I_GENE/I_BIO
at O O
nucleotide O B_TIME[MEASURE]/B_PROTEIN[GENE]
position O I_TIME[MEASURE]/I_PROTEIN[GENE]
85 O I_TIME[MEASURE]/I_PROTEIN[GENE]
, O O
which O O
lies O O
in O O
the O O
putative O B_LOCATION/B_MEASURE
presequence O I_LOCATION/I_MEASURE
for O O
targeting O O
to O O
mitochondria O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O O

This O O
mutation O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes O O
the O O
codon O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
glutamine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O O
a O O
termination O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
codon O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O O
amino O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
position O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
29 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

MaeI O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
restriction O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O O
two O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
other O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
carriers O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O O
the O O
family O B_PERSON/B_BIO
. O O

The O O
C O B_PROTEIN[GENE]
- O O
T O B_LOCATION/B_GENE
mutation O I_LOCATION/I_GENE
is O O
located O O
within O O
a O O
recently O O
proposed O O
putative O B_GENE/B_LOCATION
alternative O I_GENE/I_LOCATION
translation O I_GENE/I_LOCATION
initiation O I_GENE/I_LOCATION
codon O I_GENE/I_LOCATION
( O O
TIC O B_LOCATION/B_ORGANIZATION
- O O
1 O B_NUMBER[MEASURE]/B_LOCATION
) O O
, O O
supporting O O
that O O
TIC O B_LOCATION/B_ORGANIZATION
- O O
1 O B_NUMBER[MEASURE]
is O O
the O O
real O B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
TIC O I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rather O O
than O O
TIC O B_LOCATION
- O O
2 O B_NUMBER[MEASURE]/B_LOCATION
. O O
. O O

Human B B_DISEASE/B_PERSON
complement I I_DISEASE/I_PERSON
factor I I_DISEASE/I_PERSON
H I I_DISEASE/I_PERSON
deficiency I I_DISEASE/I_PERSON
associated O O
with O O
hemolytic B B_DISEASE/B_GENE
uremic I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
. O O

This O O
study O O
reports O O
on O O
six O O
cases O O
of O O
deficiency B B_DISEASE
in I I_DISEASE
the I I_DISEASE
human I I_DISEASE
complement I I_DISEASE
regulatory I I_DISEASE
protein I I_DISEASE
Factor I I_DISEASE
H I I_DISEASE
( O O
FH O O
) O O
in O O
the O O
context O O
of O O
an O O
acute B B_DISEASE
renal I I_DISEASE
disease I I_DISEASE
. O O

Five O O
of O O
the O O
cases O O
were O O
observed O O
in O O
children O O
presenting O O
with O O
idiopathic O O
hemolytic B B_DISEASE
uremic I I_DISEASE
syndrome I I_DISEASE
( O O
HUS B B_DISEASE/B_LOCATION
) O O
. O O

Two O B_NUMBER[MEASURE]/B_PERSON
of O O
the O O
children O B_PERSON/B_BIO
exhibited O O
a O O
homozygous O B_DISEASE_ADJECTIVE[DISEASE]
deficiency O I_DISEASE_ADJECTIVE[DISEASE]
characterized O O
by O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
the O O
150 O B_MEASURE
- O O
kD O B_MEASURE/B_LOCATION
form O I_MEASURE/I_LOCATION
of O O
Factor O B_PROTEIN[GENE]/B_DISEASE
H O I_PROTEIN[GENE]/I_DISEASE
and O O
the O O
presence O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
upon O O
immunoblotting O O
, O O
of O O
the O O
42 O B_MEASURE
- O O
kD O B_PROTEIN[GENE]/B_MEASURE
Factor O I_PROTEIN[GENE]/I_MEASURE
H O I_PROTEIN[GENE]/I_MEASURE
- O O
like O B_DISEASE_ADJECTIVE[DISEASE]
protein O I_DISEASE_ADJECTIVE[DISEASE]
1 O I_DISEASE_ADJECTIVE[DISEASE]
( O O
FHL O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
1 O B_NUMBER[MEASURE]
) O O
and O O
other O B_DISEASE/B_GENE
FH O B_DISEASE/I_GENE
- O O
related O O
protein O B_GENE/B_BACTERIUM[BIO]
( O O
FHR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
bands O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

Southern O B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blot O B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
PCR O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
DNA O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O O
one O B_PERSON/B_BIO
patient O I_PERSON/I_BIO
with O O
homozygous O B_DISEASE
deficiency O I_DISEASE
ruled O O
out O O
the O O
presence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O O
a O O
large O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
deletion O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O O
the O O
FH O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
underlying O O
defect O B_DISEASE_ADJECTIVE[DISEASE]
for O O
the O O
deficiency O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O O

The O O
other O B_PERSON/B_ENT
four O I_PERSON/I_ENT
children O I_PERSON/I_ENT
presented O O
with O O
heterozygous O B_DISEASE
deficiency O I_DISEASE
and O O
exhibited O O
a O O
normal O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
immunoblotting O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
proteins O B_BIO/B_PERSON
of O O
the O O
FH O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
family O B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Factor B B_DISEASE/B_PROTEIN[GENE]
H I B_DISEASE/I_PROTEIN[GENE]
deficiency I B_DISEASE/I_PROTEIN[GENE]
is O O
the O O
only O O
complement B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficiency I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
associated O O
with O O
HUS B B_DISEASE
. O O

These O O
observations O O
suggest O O
a O O
role O O
for O O
FH O O
and O O
/ O O
or O O
FH O O
receptors O O
in O O
the O O
pathogenesis O O
of O O
idiopathic O O
HUS B B_DISEASE
. O O
. O O

Further O O
evidence O O
for O O
a O O
major O O
ancient O O
mutation O O
underlying O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
linkage O O
disequilibrium O O
studies O O
in O O
the O O
Japanese O O
population O O
. O O

The O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
DM B B_LOCATION
) O O
mutation O O
is O O
an O O
unstable O O
( O O
CTG O O
) O O
n O O
repeat O O
, O O
present O O
at O O
a O O
copy O O
number O O
of O O
5 O O
- O O
37 O O
repeats O O
on O O
normal O O
chromosomes O O
but O O
amplified O O
to O O
50 O O
- O O
3000 O O
copies O O
on O O
DM B B_DISEASE/B_MEASURE
chromosomes O O
. O O

Previous O O
findings O O
in O O
Caucasian O O
populations O O
of O O
a O O
DM B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
founder O O
chromosome O O
raise O O
a O O
question O O
about O O
the O O
molecular O O
events O O
involved O O
in O O
the O O
expansion O O
mutation O O
. O O

To O O
investigate O O
whether O O
a O O
founder O O
chromosome O O
for O O
the O O
DM B B_DISEASE/B_GENE
mutation O O
exists O O
in O O
the O O
Japanese O O
population O O
, O O
we O O
genotyped O O
families O O
using O O
polymorphic O O
markers O O
near O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
region O O
and O O
constructed O O
haplotypes O O
. O O

Six O O
different O O
haplotypes O O
were O O
found O O
and O O
DM B B_PERSON
alleles O O
were O O
always O O
haplotype O O
A O O
. O O

To O O
find O O
an O O
origin O O
of O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
mutation O O
and O O
to O O
investigate O O
the O O
mechanism O O
of O O
the O O
expansion O O
mutation O O
in O O
the O O
Japanese O O
population O O
we O O
have O O
studied O O
90 O O
Japanese O O
DM B B_DISEASE/B_PERSON
families O O
comprising O O
190 O O
affected O O
and O O
130 O O
unaffected O O
members O O
. O O

The O O
results O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suggest O O
that O O
a O O
few O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
common O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ancestral O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O O
both O O
Caucasian O B_PERSON/B_LOCATION
and O O
Japanese O B_PERSON/B_LOCATION
populations O I_PERSON/I_LOCATION
have O O
originated O O
by O O
expansion O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
an O O
ancestral O B_PROTEIN[GENE]/B_LOCATION
n O I_PROTEIN[GENE]/I_LOCATION
= O O
5 O B_MEASURE
repeat O I_MEASURE
to O O
n O B_OTHER/B_PROTEIN[GENE]
= O O
19 O B_MEASURE
- O O
37 O B_MEASURE
copies O I_MEASURE
. O O

These O O
data O O
support O O
multistep O O
models O O
of O O
triplet O O
repeat O O
expansion O O
that O O
have O O
been O O
proposed O O
for O O
both O O
DM B B_DISEASE/B_GENE
and O O
Friedreichs B B_DISEASE/B_LOCATION
ataxia I B_DISEASE/I_LOCATION
. O O
. O O

The O O
molecular O O
basis O O
of O O
C6 B B_DISEASE
deficiency I I_DISEASE
in O O
the O O
western O O
Cape O O
, O O
South O O
Africa O O
. O O

Deficiency B B_DISEASE
of I I_DISEASE
the I I_DISEASE
sixth I I_DISEASE
component I I_DISEASE
of I I_DISEASE
human I I_DISEASE
complement I I_DISEASE
( O O
C6 O O
) O O
has O O
been O O
reported O O
in O O
a O O
number O O
of O O
families O O
from O O
the O O
western O O
Cape O O
, O O
South O O
Africa O O
. O O

Meningococcal B B_DISEASE/B_PROTEIN[GENE]
disease I B_DISEASE/I_PROTEIN[GENE]
is O O
endemic O O
in O O
the O O
Cape O O
and O O
almost O O
all O O
pedigrees O O
of O O
total O O
C6 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
C6Q0 O O
) O O
have O O
been O O
ascertained O O
because O O
of O O
recurrent O O
disease O O
. O O

We O O
have O O
sequenced O O
the O O
expressed O O
exons O B_GENE/B_LOCATION
of O O
the O O
C6 O B_GENE/B_BIO
gene O I_GENE/I_BIO
from O O
selected O O
cases O B_PERSON/B_BIO
and O O
have O O
found O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
defects O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leading O O
to O O
total O B_DISEASE/B_GENE
deficiency O I_DISEASE/I_GENE
879delG O I_DISEASE/I_GENE
, O O
which O O
is O O
the O O
common O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
defect O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
Cape O B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
hitherto O B_LOCATION/B_ENT
unreported O I_LOCATION/I_ENT
, O O
and O O
1195delC O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O O
1936delG O B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
which O O
have O O
been O O
previously O O
reported O O
in O O
African O B_PERSON/B_LOCATION
- O O
Americans O B_PERSON/B_SPORT[ENT]
. O O

We O O
also O O
show O O
that O O
the O O
879delG O B_MEASURE/B_GENE
and O O
1195delC O B_DISEASE/B_PROTEIN[GENE]
defects O B_DISEASE/I_PROTEIN[GENE]
are O O
associated O O
with O O
characteristic O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C6 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O O
C7 O B_PROTEIN[GENE]/B_DISEASE
region O I_PROTEIN[GENE]/I_DISEASE
DNA O I_PROTEIN[GENE]/I_DISEASE
marker O I_PROTEIN[GENE]/I_DISEASE
haplotypes O I_PROTEIN[GENE]/I_DISEASE
, O O
although O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O O
observed O O
. O O

The O O
1936delG O B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
defect O I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O O
observed O O
only O O
once O O
in O O
the O O
Cape O B_LOCATION/B_PERSON
, O O
but O O
its O O
associated O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
haplotype O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
could O O
be O O
deduced O O
. O O

The O O
data O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O O
the O O
haplotypes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indicate O O
that O O
these O O
three O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
defects O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
account O O
for O O
the O O
defects O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O O
all O O
the O O
38 O B_PERSON/B_BIO
unrelated O I_PERSON/I_BIO
C6Q0 O I_PERSON/I_BIO
individuals O I_PERSON/I_BIO
we O O
have O O
studied O O
from O O
the O O
Cape O B_LOCATION/B_TIME[MEASURE]
. O O

We O O
have O O
also O O
observed O O
the O O
879delG O O
defect O O
in O O
two O O
Dutch O O
C6 B B_LOCATION/B_PERSON
- I B_LOCATION/I_PERSON
deficient I B_LOCATION/I_PERSON
kindreds O O
, O O
but O O
the O O
879delG O O
defect O O
in O O
the O O
Cape O O
probably O O
did O O
not O O
come O O
from O O
The O O
Netherlands O O
. O O
. O O

Complement B B_MEASURE
C7 I I_MEASURE
deficiency I I_MEASURE
: O O
seven O O
further O O
molecular O O
defects O O
and O O
their O O
associated O O
marker O O
haplotypes O O
. O O

Seven O O
further O O
molecular O O
bases O O
of O O
C7 B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
described O O
. O O

All O O
these O O
new O B_DISEASE_ADJECTIVE[DISEASE]
molecular O I_DISEASE_ADJECTIVE[DISEASE]
defects O I_DISEASE_ADJECTIVE[DISEASE]
involve O O
single O B_NUMBER[MEASURE]/B_LOCATION
- O O
nucleotide O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
events O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O O
deletions O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
substitutions O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O O
some O O
of O O
which O O
alter O O
splice O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
and O O
others O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
codons O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

They O O
are O O
distributed O O
along O O
the O O
C7 O B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
gene O B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O O
but O O
predominantly O O
towards O O
the O O
3 O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end O I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

All O O
were O O
found O O
in O O
compound O B_LOCATION
heterozygous O I_LOCATION
individuals O I_LOCATION
. O O

The O O
C6 O O
/ O O
C7 O O
marker O O
haplotypes O O
associated O O
with O O
most O O
C7 B B_DISEASE/B_GENE
defects I I_DISEASE/I_GENE
are O O
tabulated O O
. O O
. O O

A O O
genome O O
- O O
wide O O
search O O
for O O
chromosomal O O
loci O O
linked O O
to O O
mental O O
health O O
wellness O O
in O O
relatives O O
at O O
high O O
risk O O
for O O
bipolar B B_DISEASE
affective I I_DISEASE
disorder I I_DISEASE
among O O
the O O
Old O O
Order O O
Amish O O
. O O

Bipolar B B_DISEASE
affective I I_DISEASE
disorder I I_DISEASE
( O O
BPAD B B_LOCATION/B_ORGANIZATION
; O O
manic B B_DISEASE/B_PROTEIN[GENE]
- I B_DISEASE/I_PROTEIN[GENE]
depressive I B_DISEASE/I_PROTEIN[GENE]
illness I B_DISEASE/I_PROTEIN[GENE]
) O O
is O O
characterized O O
by O O
episodes O O
of O O
mania B B_DISEASE
and O O
/ O O
or O O
hypomania B B_DISEASE
interspersed O O
with O O
periods O O
of O O
depression B B_DISEASE
. O O

Compelling O O
evidence O O
supports O O
a O O
significant O O
genetic O O
component O O
in O O
the O O
susceptibility O O
to O O
develop O O
BPAD B B_DISEASE/B_GENE
. O O

To O O
date O O
, O O
however O O
, O O
linkage O O
studies O O
have O O
attempted O O
only O O
to O O
identify O O
chromosomal O O
loci O O
that O O
cause O O
or O O
increase O O
the O O
risk O O
of O O
developing O O
BPAD B B_DISEASE
. O O

To O O
determine O O
whether O O
there O O
could O O
be O O
protective O O
alleles O O
that O O
prevent O O
or O O
reduce O O
the O O
risk O O
of O O
developing O O
BPAD B B_DISEASE
, O O
similar O O
to O O
what O O
is O O
observed O O
in O O
other O O
genetic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disorders I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
we O O
used O O
mental O O
health O O
wellness O O
( O O
absence O O
of O O
any O O
psychiatric B B_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
) O O
as O O
the O O
phenotype O O
in O O
our O O
genome O O
- O O
wide O O
linkage O O
scan O O
of O O
several O O
large O O
multigeneration O O
Old O O
Order O O
Amish O O
pedigrees O O
exhibiting O O
an O O
extremely O O
high O O
incidence O O
of O O
BPAD B B_DISEASE
. O O

We O O
have O O
found O O
strong O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O O
a O O
locus O B_LOCATION/B_PERSON
on O O
chromosome O B_GENE
4p O I_GENE
at O O
D4S2949 O B_PROTEIN[GENE]
( O O
maximum O B_MEASURE/B_LOCATION
GENEHUNTER O B_MEASURE/I_LOCATION
- O O
PLUS O B_MEASURE/B_LOCATION
nonparametric O I_MEASURE/I_LOCATION
linkage O I_MEASURE/I_LOCATION
score O I_MEASURE/I_LOCATION
= O O
4 O B_MEASURE
. O O
05 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
5 O B_MEASURE
. O O
22 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
- O O
4 O B_NUMBER[MEASURE]
) O O
; O O
SIBPAL O B_LOCATION/B_MEASURE
Pempirical O I_LOCATION/I_MEASURE
value O I_LOCATION/I_MEASURE
< O O
3 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
- O O
5 O B_NUMBER[MEASURE]
) O O
) O O
and O O
suggestive O B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence O I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
a O O
locus O B_GENE/B_LOCATION
on O O
chromosome O B_GENE
4q O I_GENE
at O O
D4S397 O B_GENE
( O O
maximum O B_GENE/B_DISEASE
GENEHUNTER O I_GENE/I_DISEASE
- O O
PLUS O B_MEASURE/B_LOCATION
nonparametric O I_MEASURE/I_LOCATION
linkage O I_MEASURE/I_LOCATION
score O I_MEASURE/I_LOCATION
= O O
3 O B_MEASURE
. O O
29 O B_MEASURE
, O O
P O B_PROTEIN[GENE]/B_LOCATION
= O O
2 O B_MEASURE
. O O
57 O B_MEASURE
x O O
10 O B_NUMBER[MEASURE]
( O O
- O O
3 O B_NUMBER[MEASURE]
) O O
; O O
SIBPAL O B_LOCATION/B_MEASURE
Pempirical O I_LOCATION/I_MEASURE
value O I_LOCATION/I_MEASURE
< O O
1 O B_NUMBER[MEASURE]
x O O
10 O B_NUMBER[MEASURE]
( O O
- O O
3 O B_NUMBER[MEASURE]
) O O
) O O
that O O
are O O
linked O O
to O O
mental O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
health O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
wellness O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O O

These O O
findings O O
are O O
consistent O O
with O O
the O O
hypothesis O O
that O O
certain O O
alleles O O
could O O
prevent O O
or O O
modify O O
the O O
clinical O O
manifestations O O
of O O
BPAD B B_DISEASE
and O O
perhaps O O
other O O
related O O
affective B B_DISEASE/B_GENE
disorders I I_DISEASE/I_GENE
. O O

Segregation O O
distortion O O
in O O
myotonic B B_DISEASE/B_PERSON
dystrophy I I_DISEASE/I_PERSON
. O O

Myotonic B B_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_LOCATION/B_ORGANIZATION
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
which O O
, O O
in O O
the O O
typical O O
pedigree O O
, O O
shows O O
a O O
three O O
generation O O
anticipation O O
cascade O O
. O O

This O O
results O O
in O O
infertility B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
congenital B B_DISEASE/B_ORGANISM_FUNCTION
myotonic I I_DISEASE/I_ORGANISM_FUNCTION
dystrophy I I_DISEASE/I_ORGANISM_FUNCTION
( O O
CDM B B_DISEASE/B_LOCATION
) O O
with O O
the O O
disappearance O O
of O O
DM B B_DISEASE/B_PERSON
in O O
that O O
pedigree O O
. O O

The O O
concept O O
of O O
segregation O O
distortion O O
, O O
where O O
there O O
is O O
preferential O O
transmission O O
of O O
the O O
larger O O
allele O O
at O O
the O O
DM B B_DISEASE/B_GENE
locus O O
, O O
has O O
been O O
put O O
forward O O
to O O
explain O O
partially O O
the O O
maintenance O O
of O O
DM B B_DISEASE/B_PROTEIN[GENE]
in O O
the O O
population O O
. O O

In O O
a O O
survey O O
of O O
DM B B_PERSON/B_BIO
in O O
Northern O O
Ireland O O
, O O
59 O O
pedigrees O O
were O O
ascertained O O
. O O

Sibships O O
where O O
the O O
status O O
of O O
all O O
the O O
members O O
had O O
been O O
identified O O
were O O
examined O O
to O O
determine O O
the O O
transmission O O
of O O
the O O
DM B B_DISEASE/B_PERSON
expansion O O
from O O
affected O O
parents O O
to O O
their O O
offspring O O
. O O

Where O O
the O O
transmitting O O
parent O B_PERSON/B_LOCATION
was O O
male O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O O
58 O B_TIME[MEASURE]/B_LOCATION
. O O

3 O B_NUMBER[MEASURE]/B_PERSON
% O I_NUMBER[MEASURE]/I_PERSON
of O O
the O O
offspring O B_PERSON/B_LOCATION
were O O
affected O O
, O O
and O O
in O O
the O O
case O B_PERSON/B_LOCATION
of O O
a O O
female O B_PERSON/B_DISEASE
transmitting O O
parent O B_PERSON/B_DISEASE
, O O
68 O B_NUMBER[MEASURE]/B_LOCATION
. O O

7 O B_PERSON/B_NUMBER[MEASURE]
% O B_PERSON/I_NUMBER[MEASURE]
were O O
affected O O
. O O

Studies O O
on O O
meiotic O O
drive O O
in O O
DM B B_SPECIES[BIO]/B_DISEASE
have O O
shown O O
increased O O
transmission O O
of O O
the O O
larger O O
allele O O
at O O
the O O
DM B B_GENE/B_DISEASE
locus O O
in O O
non O O
- O O
DM O O
heterozygotes O O
for O O
CTGn O O
. O O

This O O
study O O
provides O O
further O O
evidence O O
that O O
the O O
DM B B_MEASURE/B_LOCATION
expansion O O
tends O O
to O O
be O O
transmitted O O
preferentially O O
. O O

Diagnosis O O
of O O
hemochromatosis B B_DISEASE
. O O

If O O
untreated O O
, O O
hemochromatosis B B_DISEASE/B_GENE
can O O
cause O O
serious O O
illness O O
and O O
early B B_DISEASE
death I I_DISEASE
, O O
but O O
the O O
disease O O
is O O
still O O
substantially O O
under O O
- O O
diagnosed O O
. O O

The O O
cornerstone O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
screening O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
case O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
the O O
measurement O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O O
serum O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transferrin O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
saturation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
the O O
serum O B_MEASURE/B_GENE
ferritin O B_MEASURE/I_GENE
level O B_MEASURE/I_GENE
. O O

Once O O
the O O
diagnosis O O
is O O
suspected O O
, O O
physicians O O
must O O
use O O
serum O O
ferritin O O
levels O O
and O O
hepatic O O
iron O O
stores O O
on O O
liver O O
biopsy O O
specimens O O
to O O
assess O O
patients O O
for O O
the O O
presence O O
of O O
iron B B_DISEASE
overload I I_DISEASE
. O O

Liver O O
biopsy O O
is O O
also O O
used O O
to O O
establish O O
the O O
presence O O
or O O
absence O O
of O O
cirrhosis B B_DISEASE
, O O
which O O
can O O
affect O O
prognosis O O
and O O
management O O
. O O

A O O
DNA O O
- O O
based O O
test O O
for O O
the O O
HFE O O
gene O O
is O O
commercially O O
available O O
, O O
but O O
its O O
place O O
in O O
the O O
diagnosis O O
of O O
hemochromatosis B B_DISEASE/B_LOCATION
is O O
still O O
being O O
evaluated O O
. O O

Currently O O
, O O
the O O
most O O
useful O O
role O O
for O O
this O O
test O O
is O O
in O O
the O O
detection O O
of O O
hemochromatosis B B_DISEASE
in O O
the O O
family O O
members O O
of O O
patients O O
with O O
a O O
proven O O
case O O
of O O
the O O
disease O O
. O O

It O O
is O O
crucial O O
to O O
diagnose O O
hemochromatosis B B_DISEASE
before O O
hepatic B B_DISEASE
cirrhosis I I_DISEASE
develops O O
because O O
phlebotomy O O
therapy O O
can O O
avert O O
serious O O
chronic O O
disease O O
and O O
can O O
even O O
lead O O
to O O
normal O O
life O O
expectancy O O
. O O
. O O

Prevalence O O
of O O
the O O
I1307K O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
variant O O
in O O
Israeli O O
Jews O O
of O O
differing O O
ethnic O O
origin O O
and O O
risk O O
for O O
colorectal B B_DISEASE
cancer I I_DISEASE
. O O

BACKGROUND O O
& O O
AIMS O O
Israeli O O
Jews O O
of O O
European O O
birth O O
, O O
i O O
. O O
e O O
. O O
, O O
Ashkenazim O O
, O O
have O O
the O O
highest O O
colorectal B B_DISEASE
cancer I I_DISEASE
incidence O O
of O O
any O O
Israeli O O
ethnic O O
group O O
. O O

The O O
I1307K O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
variant O O
was O O
found O O
in O O
6 O O
. O O

1 O O
% O O
of O O
American O O
Jews O O
, O O
28 O O
% O O
of O O
their O O
familial O O
colorectal B B_DISEASE
cancer I I_DISEASE
cases O O
, O O
but O O
not O O
in O O
non O O
- O O
Jews O O
. O O

We O O
assessed O O
the O O
I1307K O O
prevalence O O
in O O
Israeli O O
Jews O O
of O O
differing O O
ethnic O O
origin O O
and O O
risk O O
for O O
colorectal B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

METHODS O O
DNA O O
samples O O
from O O
500 O O
unrelated O O
Jews O O
of O O
European O O
or O O
non O O
- O O
European O O
origin O O
, O O
with O O
or O O
without O O
a O O
personal O O
and O O
/ O O
or O O
family O O
history O O
of O O
neoplasia B B_PERSON/B_LOCATION
, O O
were O O
examined O O
for O O
the O O
I1307K O O
variant O O
by O O
the O O
allele O O
- O O
specific O O
oligonucleotide O O
( O O
ASO O O
) O O
method O O
. O O

RESULTS O O
In O O
persons O O
at O O
average O O
risk O O
for O O
colorectal B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
, O O
I1307K O O
was O O
found O O
in O O
5 O O
. O O

0 O B_MEASURE/B_PERSON
% O B_MEASURE/I_PERSON
of O O
120 O B_PERSON/B_LOCATION
European O I_PERSON/I_LOCATION
and O O
1 O B_NUMBER[MEASURE]/B_PERSON
. O O

6 O B_MEASURE/B_PERSON
% O I_MEASURE/I_PERSON
of O O
188 O B_LOCATION/B_DISEASE
non O I_LOCATION/I_DISEASE
- O O
European O B_PERSON/B_ORGANIZATION
Jews O I_PERSON/I_ORGANIZATION
( O O
P O B_OTHER/B_PROTEIN[GENE]
= O O
0 O B_MEASURE
. O O
08 O B_MEASURE
) O O
. O O

It O O
occurred O O
in O O
15 O B_NUMBER[MEASURE]/B_LOCATION
. O O

4 O O
% O O
of O O
52 O O
Ashkenazi O O
Israelis O O
with O O
familial O O
cancer B B_DISEASE/B_GENE
( O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
was O O
not O O
detected O O
in O O
51 O O
non O O
- O O
European O O
Jews O O
at O O
increased O O
cancer B B_DISEASE/B_GENE
risk O O
. O O

Colorectal B B_DISEASE/B_PERSON
neoplasia I I_DISEASE/I_PERSON
occurred O O
personally O O
or O O
in O O
the O O
families O O
of O O
13 O O
of O O
20 O O
Ashkenazi O O
I1307K O O
carriers O O
, O O
8 O O
of O O
whom O O
also O O
had O O
a O O
personal O O
or O O
family O O
history O O
of O O
noncolonic O O
neoplasia B B_DISEASE
. O O

CONCLUSIONS O O
The O O
I1307K O O
APC O O
variant O O
may O O
represent O O
a O O
susceptibility O O
gene O O
for O O
colorectal B B_DISEASE
, I I_DISEASE
or I I_DISEASE
other I I_DISEASE
, I I_DISEASE
cancers I I_DISEASE
in O O
Ashkenazi O O
Jews O O
, O O
and O O
partially O O
explains O O
the O O
higher O O
incidence O O
of O O
colorectal B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
in O O
European O O
Israelis O O
. O O

Systematic O O
analysis O O
of O O
coproporphyrinogen O O
oxidase O O
gene O O
defects O O
in O O
hereditary B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
coproporphyria I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O O
mutation O O
update O O
. O O

Hereditary B B_DISEASE
coproporphyria I I_DISEASE
( O O
HC B B_LOCATION/B_DISEASE
) O O
is O O
an O O
acute O O
hepatic B B_DISEASE
porphyria I I_DISEASE
with O O
autosomal O O
dominant O O
inheritance O O
caused O O
by O O
deficient B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
coproporphyrinogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
III I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CPO O O
) O O
. O O

Clinical O O
manifestations O O
of O O
the O O
disease O O
are O O
characterized O O
by O O
acute O O
attacks O O
of O O
neurological B B_DISEASE
dysfunction I I_DISEASE
often O O
precipitated O O
by O O
drugs O O
, O O
fasting O O
, O O
cyclical O O
hormonal O O
changes O O
, O O
or O O
infectious B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
diseases I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Skin O B_DISEASE_ADJECTIVE[DISEASE]
photosensitivity O I_DISEASE_ADJECTIVE[DISEASE]
may O O
also O O
be O O
present O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
seven O O
exons O O
, O O
the O O
exon O O
/ O O
intron O O
boundaries O O
and O O
part O O
of O O
3 O O
noncoding O O
sequence O O
of O O
the O O
CPO O O
gene O O
were O O
systematically O O
analyzed O O
by O O
an O O
exon O O
- O O
by O O
- O O
exon O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
strategy O O
followed O O
by O O
direct O O
sequencing O O
in O O
seven O O
unrelated O O
heterozygous O O
HC B B_DISEASE/B_GENE
patients O O
from O O
France O O
, O O
Holland O O
, O O
and O O
Czech O O
Republic O O
. O O

Seven O B_NUMBER[MEASURE]/B_PERSON
novel O I_NUMBER[MEASURE]/I_PERSON
mutations O I_NUMBER[MEASURE]/I_PERSON
and O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
new O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
detected O O
. O O

Among O O
these O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
two O I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
missense O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
G197W O B_GENE
, O O
W427R O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
two O B_NUMBER[MEASURE]/B_PERSON
are O O
nonsense O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O O
Q306X O B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
Q385X O B_PROTEIN[GENE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O O
, O O
two O B_NUMBER[MEASURE]
are O O
small O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletions O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
662de14bp O B_GENE/B_DISEASE
; O O
1168del3bp O B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
removing O O
a O O
glycine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O O
position O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
390 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
one O B_NUMBER[MEASURE]/B_PERSON
is O O
a O O
splicing O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation O I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O O
IVS1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O O
15c O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O O
- O O
> O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
g O I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
) O O
which O O
creates O O
a O O
new O B_DISEASE/B_GENE
acceptor O I_DISEASE/I_GENE
splice O I_DISEASE/I_GENE
site O I_DISEASE/I_GENE
. O O

The O O
pathological O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O O
the O O
point O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
G197W O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
W427R O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
and O O
the O O
in O O
- O O
frame O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletion O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
390delGly O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
assessed O O
by O O
their O O
respective O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
a O O
prokaryotic O B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system O I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O O
site O B_LOCATION/B_BIO
- O O
directed O O
mutagenesis O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O O

These O O
mutations O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resulted O O
in O O
the O O
absence O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O O
a O O
dramatic O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease O I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
CPO O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O O

The O O
two O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O O
localized O O
in O O
noncoding O B_LOCATION/B_BIO
part O I_LOCATION/I_BIO
of O O
the O O
gene O B_GENE
1 O I_GENE
) O O
a O O
C O B_OTHER/B_LOCATION
/ O O
G O B_PROTEIN[GENE]/B_LOCATION
polymorphism O B_PROTEIN[GENE]/I_LOCATION
in O O
the O O
promotor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
142 O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
bp O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O O
from O O
the O O
transcriptional O B_GENE
initiation O I_GENE
site O I_GENE
( O O
- O O
142C O B_LOCATION/B_PERSON
/ O O
G O B_OTHER/B_PROTEIN[GENE]
) O O
, O O
and O O
2 O B_SEQUENCE[MEASURE]
) O O
a O O
6 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bp O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
deletion O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymorphism O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
3 O B_SEQUENCE[MEASURE]/B_LOCATION
noncoding O O
part O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
the O O
CPO O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene O I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
574 O B_LOCATION
bp O I_LOCATION
downstream O I_LOCATION
of O O
the O O
last O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
base O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O O
the O O
normal O B_GENE
termination O I_GENE
codon O I_GENE
( O O
+ O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
574 O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delATTCTT O I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
. O O

Five O O
intragenic O O
dimorphisms O O
are O O
now O O
well O O
characterized O O
and O O
the O O
high O O
degree O O
of O O
allelic O O
heterogeneity O O
in O O
HC B B_DISEASE/B_LOCATION
is O O
demonstrated O O
with O O
seven O O
new O O
different O O
mutations O O
making O O
a O O
total O O
of O O
nineteen O O
CPO O O
gene B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
so O O
far O O
. O O
. O O

Coincidence O O
of O O
two O O
novel O O
arylsulfatase O O
A O O
alleles O O
and O O
mutation O O
459 O O
+ O O
1G O O
> O O
A O O
within O O
a O O
family O O
with O O
metachromatic B B_DISEASE/B_GENE
leukodystrophy I I_DISEASE/I_GENE
: O O
molecular O O
basis O O
of O O
phenotypic O O
heterogeneity O O
. O O

In O O
a O O
family O O
with O O
three O O
siblings O O
, O O
one O O
developed O O
classical O O
late O O
infantile O O
metachromatic B B_DISEASE
leukodystrophy I I_DISEASE
( O O
MLD B B_DISEASE/B_LOCATION
) O O
, O O
fatal O O
at O O
age O O
5 O O
years O O
, O O
with O O
deficient O O
arylsulfatase O O
A O O
( O O
ARSA O O
) O O
activity O O
and O O
increased O O
galactosylsulfatide O O
( O O
GS O O
) O O
excretion O O
. O O

The O O
two O O
other O O
siblings O O
, O O
apparently O O
healthy O O
at O O
12 O O
( O O
1 O O
/ O O
2 O O
) O O
and O O
15 O O
years O O
, O O
respectively O O
, O O
and O O
their O O
father O O
, O O
apparently O O
healthy O O
as O O
well O O
, O O
presented O O
ARSA O O
and O O
GS O O
values O O
within O O
the O O
range O O
of O O
MLD B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
patients O O
. O O

Mutation O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
sequence O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
disclosed O O
the O O
involvement O B_DISEASE/B_PERSON
of O O
three O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
different O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ARSA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
being O O
the O O
molecular O B_LOCATION/B_PERSON
basis O I_LOCATION/I_PERSON
of O O
intrafamilial O B_DISEASE
phenotypic O I_DISEASE
heterogeneity O I_DISEASE
. O O

The O O
late O B_PERSON
infantile O I_PERSON
patient O I_PERSON
inherited O O
from O O
his O O
mother O B_PERSON
the O O
frequent O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
0 O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O O
type O B_GENE/B_DISEASE
mutation O I_GENE/I_DISEASE
459 O I_GENE/I_DISEASE
+ O I_GENE/I_DISEASE
1G O I_GENE/I_DISEASE
> O I_GENE/I_DISEASE
A O I_GENE/I_DISEASE
, O O
and O O
from O O
his O O
father O B_PERSON
a O O
novel O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
single O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basepair O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microdeletion O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O O
guanine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O O
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O O
7delG O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
two O B_NUMBER[MEASURE]
clinically O O
unaffected O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
siblings O I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
carried O O
the O O
maternal O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
459 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
+ O O
1G O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O O
A O B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
, O O
on O O
their O O
paternal O B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
allele O I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
a O O
novel O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytosine O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O O
thymidine O O
transition O B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O O
nucleotide O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2435 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O O
exon O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
8 O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
resulting O O
in O O
substitution O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O O
alanine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
464 O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O O
valine O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
A464V O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

The O O
fathers O B_PERSON/B_ENT
genotype O O
thus O O
was O O
7delG O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O O
A464V O B_MEASURE/B_DISEASE
. O O

Mutation O O
A464V O O
was O O
not O O
found O O
in O O
18 O O
unrelated O O
MLD B B_DISEASE/B_LOCATION
patients O O
and O O
50 O O
controls O O
. O O

A464V O O
, O O
although O O
clearly O O
modifying O O
ARSA O O
and O O
GS O O
levels O O
, O O
apparently O O
bears O O
little O O
significance O O
for O O
clinical O O
manifestation O O
of O O
MLD B B_DISEASE/B_LOCATION
, O O
mimicking O O
the O O
frequent O O
ARSA O O
pseudodeficiency O O
allele O O
. O O

Our O O
results O O
demonstrate O O
that O O
in O O
certain O O
genetic O O
conditions O O
MLD B B_DISEASE/B_MEASURE
- O O
like O O
ARSA O O
and O O
GS O O
values O O
need O O
not O O
be O O
paralleled O O
by O O
clinical O O
disease O O
, O O
a O O
finding O O
with O O
serious O O
diagnostic O O
and O O
prognostic O O
implications O O
. O O

Moreover O O
, O O
further O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ARSA O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alleles O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
functionally O O
similar O B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O O
A464V O B_PERSON/B_DISEASE
might O O
exist O O
which O O
, O O
together O O
with O O
0 O B_MEASURE/B_LOCATION
- O O
type O B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations O I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
may O O
cause O O
pathological O B_DISEASE/B_PROTEIN[GENE]
ARSA O B_DISEASE/I_PROTEIN[GENE]
and O O
GS O B_DISEASE_ADJECTIVE[DISEASE]
levels O I_DISEASE_ADJECTIVE[DISEASE]
, O O
but O O
not O O
clinical O B_DISEASE_ADJECTIVE[DISEASE]
outbreak O I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
disease O B_DISEASE/B_BIO
. O O
. O O

Human O O
MLH1 O O
deficiency O O
predisposes O O
to O O
hematological B B_DISEASE
malignancy I I_DISEASE
and O O
neurofibromatosis B B_DISEASE
type I I_DISEASE
1 I I_DISEASE
. O O

Heterozygous O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
DNA O O
mismatch O O
repair O O
genes O O
lead O O
to O O
hereditary B B_DISEASE
nonpolyposis I I_DISEASE
colorectal I I_DISEASE
cancer I I_DISEASE
. O O

The O O
disease O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
susceptibility O B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
individuals O B_PERSON/B_BIO
who O O
constitutionally O O
lack O O
both O O
wild O B_PERSON/B_BIO
- O O
type O B_BIO/B_GENE
alleles O I_BIO/I_GENE
is O O
unknown O B_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
have O O
identified O O
three O O
offspring O O
in O O
a O O
hereditary B B_DISEASE/B_LOCATION
nonpolyposis I B_DISEASE/I_LOCATION
colorectal I B_DISEASE/I_LOCATION
cancer I B_DISEASE/I_LOCATION
family O O
who O O
developed O O
hematological B B_DISEASE
malignancy I I_DISEASE
at O O
a O O
very O O
early O O
age O O
, O O
and O O
at O O
least O O
two O O
of O O
them O O
displayed O O
signs O O
of O O
neurofibromatosis B B_DISEASE/B_GENE
type I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
( O O
NF1 B B_DISEASE/B_GENE
) O O
. O O

DNA O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O O
allele O B_GENE
- O O
specific O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O O
two O B_PERSON/B_GENE
siblings O B_PERSON/I_GENE
revealed O O
a O O
homozygous O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
MLH1 O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
C676T O B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O O
- O O
> O B_MEASURE/B_PROTEIN[GENE]
Arg226Stop O I_MEASURE/I_PROTEIN[GENE]
) O O
. O O

Thus O O
, O O
a O O
homozygous O O
germ O O
- O O
line O O
MLH1 O O
mutation O O
and O O
consequent O O
mismatch O O
repair O O
deficiency O O
results O O
in O O
a O O
mutator O O
phenotype O O
characterized O O
by O O
leukemia B B_DISEASE
and O O
/ O O
or O O
lymphoma B B_DISEASE
associated O O
with O O
neurofibromatosis B B_DISEASE/B_PROTEIN[GENE]
type I B_DISEASE/I_PROTEIN[GENE]
1 I B_DISEASE/I_PROTEIN[GENE]
. O O
. O O

Missense O O
mutations O O
in O O
the O O
most O O
ancient O O
residues O O
of O O
the O O
PAX6 O O
paired O O
domain O O
underlie O O
a O O
spectrum O O
of O O
human O O
congenital B B_DISEASE/B_GENE
eye I I_DISEASE/I_GENE
malformations I I_DISEASE/I_GENE
. O O

Mutations O O
of O O
the O O
human O O
PAX6 O O
gene O O
underlie O O
aniridia B B_DISEASE/B_LOCATION
( O O
congenital B B_LOCATION
absence I I_LOCATION
of I I_LOCATION
the I I_LOCATION
iris I I_LOCATION
) O O
, O O
a O O
rare O O
dominant O O
malformation B B_DISEASE/B_GENE
of I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
eye I I_DISEASE/I_GENE
. O O

The O O
spectrum O O
of O O
PAX6 O O
mutations O O
in O O
aniridia B B_DISEASE/B_PERSON
patients O O
is O O
highly O O
biased O O
, O O
with O O
92 O O
% O O
of O O
all O O
reported O O
mutations O O
leading O O
to O O
premature O O
truncation O O
of O O
the O O
protein O O
( O O
nonsense O O
, O O
splicing O O
, O O
insertions O O
and O O
deletions O O
) O O
and O O
just O O
2 O O
% O O
leading O O
to O O
substitution O O
of O O
one O O
amino O O
acid O O
by O O
another O O
( O O
missense O O
) O O
. O O

The O O
extraordinary O O
conservation O O
of O O
the O O
PAX6 O O
protein O O
at O O
the O O
amino O O
acid O O
level O O
amongst O O
vertebrates O O
predicts O O
that O O
pathological O O
missense O O
mutations O O
should O O
in O O
fact O O
be O O
common O O
even O O
though O O
they O O
are O O
hardly O O
ever O O
seen O O
in O O
aniridia B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O O
. O O

This O O
indicates O O
that O O
there O O
is O O
a O O
heavy O O
ascertainment O O
bias O O
in O O
the O O
selection O O
of O O
patients O O
for O O
PAX6 O O
mutation O O
analysis O O
and O O
that O O
the O O
missing O O
PAX6 O O
missense O O
mutations O O
frequently O O
may O O
underlie O O
phenotypes O O
distinct O O
from O O
textbook O O
aniridia B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Here O O
we O O
present O O
four O O
novel O O
PAX6 O O
missense O O
mutations O O
, O O
two O O
in O O
association O O
with O O
atypical O O
phenotypes O O
ectopia B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pupillae I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
displaced B B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pupils I I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
and O O
congenital B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nystagmus I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
searching B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gaze I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O O
, O O
and O O
two O O
in O O
association O O
with O O
more O O
recognizable O O
aniridia B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
phenotypes O O
. O O

Strikingly O O
, O O
all O O
four O B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
are O O
located O O
within O O
the O O
PAX6 O B_GENE/B_SEQUENCE[MEASURE]
paired O O
domain O B_LOCATION/B_GENE
and O O
affect O O
amino O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
acids O B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
which O O
are O O
highly O O
conserved O O
in O O
all O O
known O O
paired O O
domain O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Our O O
results O O
support O O
the O O
hypothesis O O
that O O
the O O
under O O
- O O
representation O O
of O O
missense O O
mutations O O
is O O
caused O O
by O O
ascertainment O O
bias O O
and O O
suggest O O
that O O
a O O
substantial O O
burden O O
of O O
PAX6 B B_DISEASE/B_MEASURE
- I I_DISEASE/I_MEASURE
related I I_DISEASE/I_MEASURE
disease I I_DISEASE/I_MEASURE
remains O O
to O O
be O O
uncovered O O
. O O
. O O

The O O
chromosomal O O
order O O
of O O
genes O O
controlling O O
the O O
major O O
histocompatibility O O
complex O O
, O O
properdin O O
factor O O
B O O
, O O
and O O
deficiency B B_GENE/B_DISEASE
of I I_GENE/I_DISEASE
the I I_GENE/I_DISEASE
second I I_GENE/I_DISEASE
component I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
complement I I_GENE/I_DISEASE
. O O

The O O
relationship O O
of O O
the O O
genes O O
coding O O
for O O
HLA O O
to O O
those O O
coding O O
for O O
properdin O O
Factor O O
B O O
allotypes O O
and O O
for O O
deficiency B B_GENE/B_DISEASE
of I I_GENE/I_DISEASE
the I I_GENE/I_DISEASE
second I I_GENE/I_DISEASE
component I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
complement I I_GENE/I_DISEASE
( O O
C2 O O
) O O
was O O
studied O O
in O O
families O O
of O O
patients O O
with O O
connective O O
tissue O O
disorders O O
. O O

Patients O O
were O O
selected O O
because O O
they O O
were O O
heterozygous O O
or O O
homozygous O O
for O O
C2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

12 O O
families O O
with O O
15 O O
matings O O
informative O O
for O O
C2 B B_DISEASE
deficiency I I_DISEASE
were O O
found O O
. O O

Of O O
57 O O
informative O O
meioses O O
, O O
two O O
crossovers O O
were O O
noted O O
between O O
the O O
C2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O O
and O O
the O O
HLA O O
- O O
B O O
gene O O
, O O
with O O
a O O
recombinant O O
fraction O O
of O O
0 O O
. O O

035 O B_NUMBER[MEASURE]
. O O

A O O
lod O O
score O O
of O O
13 O O
was O O
calculated O O
for O O
linkage O O
between O O
C2 B B_DISEASE/B_GENE
deficiency I I_DISEASE/I_GENE
and O O
HLA O O
- O O
B O O
at O O
a O O
maximum O O
likelihood O O
value O O
of O O
the O O
recombinant O O
fraction O O
of O O
0 O O
. O O

04 O B_NUMBER[MEASURE]
. O O

18 O B_PERSON/B_LOCATION
families O I_PERSON/I_LOCATION
with O O
21 O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
informative O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
matings O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O O
both O O
properdin O B_LOCATION/B_PERSON
Factor O I_LOCATION/I_PERSON
B O I_LOCATION/I_PERSON
allotype O I_LOCATION/I_PERSON
and O O
HLA O B_GENE/B_LOCATION
- O O
B O B_PROTEIN[GENE]/B_DISEASE
were O O
found O O
. O O

Of O O
72 O B_NUMBER[MEASURE]/B_PERSON
informative O B_NUMBER[MEASURE]/I_PERSON
meioses O B_NUMBER[MEASURE]/I_PERSON
, O O
three O B_MEASURE
recombinants O I_MEASURE
were O O
found O O
, O O
giving O O
a O O
recombinant O B_MEASURE/B_ENT
fraction O I_MEASURE/I_ENT
of O O
0 O B_NUMBER[MEASURE]/B_BIO
. O O

042 O B_NUMBER[MEASURE]
. O O

A O O
lod O B_MEASURE
score O I_MEASURE
of O O
16 O B_MEASURE
between O O
HLA O B_PROTEIN[GENE]/B_MEASURE
- O O
B O B_PROTEIN[GENE]/B_DISEASE
and O O
Factor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
allotypes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O O
calculated O O
at O O
a O O
maximum O B_MEASURE
likelihood O I_MEASURE
value O I_MEASURE
of O O
the O O
recombinant O B_MEASURE/B_LOCATION
fraction O I_MEASURE/I_LOCATION
of O O
0 O B_MEASURE/B_BIO
. O O

04 O B_NUMBER[MEASURE]
. O O

A O O
crossover O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
shown O O
to O O
have O O
occurred O O
between O O
genes O B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
Factor O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O O
HLA O B_GENE/B_MEASURE
- O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
in O O
which O O
HLA O B_PROTEIN[GENE]/B_LOCATION
- O O
D O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
segregared O O
with O O
HLA O B_GENE/B_MEASURE
- O O
A O B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
B O B_PROTEIN[GENE]/B_DISEASE
. O O

These O O
studies O O
suggest O O
that O O
the O O
genes O O
for O O
Factor O O
B O O
and O O
C2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O O
located O O
outside O O
those O O
for O O
HLA O O
, O O
that O O
the O O
order O O
of O O
genese O O
is O O
HLA O O
- O O
A O O
, O O
- O O
B O O
, O O
- O O
D O O
, O O
Factor O O
B O O
allotype O O
, O O
C2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
that O O
the O O
genes O O
coding O O
for O O
C2 B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O O
Factor O O
B O O
allotypes O O
are O O
approximately O O
3 O O
- O O
- O O
5 O O
centimorgans O O
from O O
the O O
HLA O O
- O O
A O O
and O O
HLA O O
- O O
B O O
loci O O
, O O
and O O
that O O
the O O
apparent O O
lack O O
of O O
recombinants O O
between O O
the O O
Factor O O
B O O
gene O O
and O O
C2 B B_PROTEIN[GENE]/B_LOCATION
deficiency I I_PROTEIN[GENE]/I_LOCATION
gene O O
suggests O O
that O O
these O O
two O O
genes O O
lie O O
in O O
close O O
proximity O O
to O O
one O O
another O O
. O O

Distribution O O
of O O
emerin O O
and O O
lamins O O
in O O
the O O
heart O O
and O O
implications O O
for O O
Emery B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Dreifuss I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
muscular I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Emerin O O
is O O
a O O
nuclear O O
membrane O O
protein O O
which O O
is O O
missing O O
or O O
defective O O
in O O
Emery B B_DISEASE
- I I_DISEASE
Dreifuss I I_DISEASE
muscular I I_DISEASE
dystrophy I I_DISEASE
( O O
EDMD B B_DISEASE/B_GENE
) O O
. O O

It O O
is O O
one O B_PERSON/B_MEASURE
member O I_PERSON/I_MEASURE
of O O
a O O
family O B_PERSON/B_LOCATION
of O O
lamina O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O O
associated O O
proteins O B_BIO/B_GENE
which O O
includes O O
LAP1 O B_GENE/B_DISEASE
, O O
LAP2 O B_GENE/B_DISEASE
and O O
lamin O B_GENE/B_LOCATION
B O I_GENE/I_LOCATION
receptor O I_GENE/I_LOCATION
( O O
LBR O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O O
. O O

A O O
panel O B_PERSON/B_LOCATION
of O O
16 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monoclonal O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O O
mAbs O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O O
has O O
been O O
mapped O O
to O O
six O B_LOCATION/B_BIO
specific O I_LOCATION/I_BIO
sites O I_LOCATION/I_BIO
throughout O O
the O O
emerin O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecule O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O O
phage O B_BACTERIUM[BIO]/B_GENE
- O O
displayed O O
peptide O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
libraries O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O O
has O O
been O O
used O O
to O O
localize O O
emerin O B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
human O B_SPECIES[BIO]
and O O
rabbit O B_SPECIES[BIO]
heart O I_SPECIES[BIO]
. O O

Several O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mAbs O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
against O O
different O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
emerin O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epitopes O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
did O O
not O O
recognize O O
intercalated O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
discs O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O O
though O O
they O O
recognized O O
cardiomyocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
strongly O O
, O O
both O O
at O O
the O O
rim O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O O
in O O
intranuclear O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spots O I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O O
channels O B_LOCATION
. O O

A O O
polyclonal O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rabbit O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antiserum O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
emerin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O O
recognize O O
both O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O O
intercalated O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
discs O B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
but O O
, O O
after O O
affinity O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O O
a O O
pure O B_DISEASE
- O O
emerin O B_PROTEIN[GENE]/B_BACTERIUM[BIO]
band O I_PROTEIN[GENE]/I_BACTERIUM[BIO]
on O O
a O O
western O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
stained O O
only O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
membrane O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O O

These O O
results O O
would O O
not O O
be O O
expected O O
if O O
immunostaining O O
at O O
intercalated O O
discs O O
were O O
due O O
to O O
a O O
product O O
of O O
the O O
emerin O O
gene O O
and O O
, O O
therefore O O
, O O
cast O O
some O O
doubt O O
upon O O
the O O
hypothesis O O
that O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
defects I I_DISEASE_ADJECTIVE[DISEASE]
in O O
EDMD B B_DISEASE/B_SPECIES[BIO]
are O O
caused O O
by O O
absence O O
of O O
emerin O O
from O O
intercalated O O
discs O O
. O O

Although O O
emerin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
abundant O B_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
membranes O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O O
cardiomyocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
it O O
was O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
many O B_DISEASE
non O I_DISEASE
- O O
myocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O O
the O O
heart O B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O O

This O O
distribution O O
of O O
emerin O O
was O O
similar O O
to O O
that O O
of O O
lamin O O
A O O
, O O
a O O
candidate O O
gene O O
for O O
an O O
autosomal O O
form O O
of O O
EDMD B B_DISEASE/B_GENE
. O O

In O O
contrast O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
lamin O B_GENE
B1 O I_GENE
was O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
cardiomyocyte O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O O
showing O O
that O O
lamin O B_GENE
B1 O I_GENE
is O O
not O O
essential O B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
localization O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O O
emerin O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
the O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
lamina O I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O O

Lamin O B_GENE
B1 O I_GENE
is O O
also O O
almost O O
completely O O
absent O B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
skeletal O B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
nuclei O I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O O

In O O
EDMD B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
additional O O
absence O O
of O O
lamin O O
B1 O O
from O O
heart O O
and O O
skeletal O O
muscle O O
nuclei O O
which O O
already O O
lack O O
emerin O O
may O O
offer O O
an O O
alternative O O
explanation O O
of O O
why O O
these O O
tissues O O
are O O
particularly O O
affected O O
. O O
. O O

Genetic O O
mapping O O
of O O
the O O
copper B B_DISEASE/B_GENE
toxicosis I B_DISEASE/I_GENE
locus O O
in O O
Bedlington O O
terriers O O
to O O
dog O O
chromosome O O
10 O O
, O O
in O O
a O O
region O O
syntenic O O
to O O
human O O
chromosome O O
region O O
2p13 O O
- O O
p16 O O
. O O

Abnormal O O
hepatic B B_DISEASE/B_ORGANISM_FUNCTION
copper I I_DISEASE/I_ORGANISM_FUNCTION
accumulation I I_DISEASE/I_ORGANISM_FUNCTION
is O O
recognized O O
as O O
an O O
inherited B B_DISEASE
disorder I I_DISEASE
in O O
man O O
, O O
mouse O O
, O O
rat O O
and O O
dog O O
. O O

The O O
major O O
cause O O
of O O
hepatic B B_DISEASE/B_GENE
copper I I_DISEASE/I_GENE
accumulation I I_DISEASE/I_GENE
in O O
man O O
is O O
a O O
dysfunctional O O
ATP7B O O
gene O O
, O O
causing O O
Wilson B B_DISEASE
disease I I_DISEASE
( O O
WD B B_PROTEIN[GENE]/B_DISEASE
) O O
. O O

Mutations O B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O O
the O O
ATP7B O B_GENE/B_LOCATION
genes O I_GENE/I_LOCATION
have O O
also O O
been O O
demonstrated O O
in O O
mouse O B_SPECIES[BIO]/B_DISEASE
and O O
rat O B_SPECIES[BIO]/B_GENE
. O O

The O O
ATP7B O O
gene O O
has O O
been O O
excluded O O
in O O
the O O
much O O
rarer O O
human O O
copper B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
overload I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease O O
non B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Indian I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
childhood I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cirrhosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
indicating O O
genetic O O
heterogeneity O O
. O O

By O O
investigating O O
the O O
common O O
autosomal O O
recessive O O
copper B B_DISEASE/B_GENE
toxicosis I I_DISEASE/I_GENE
( O O
CT B B_LOCATION/B_ORGANIZATION
) O O
in O O
Bedlington O O
terriers O O
, O O
we O O
have O O
identified O O
a O O
new O O
locus O O
involved O O
in O O
progressive O O
liver B B_DISEASE
disease I I_DISEASE
. O O

We O O
examined O O
whether O O
the O O
WD B B_DISEASE/B_PERSON
gene O O
ATP7B O O
was O O
also O O
causative O O
for O O
CT B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
investigating O O
the O O
chromosomal O O
co O O
- O O
localization O O
of O O
ATP7B O O
and O O
C04107 O O
, O O
using O O
fluorescence O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
. O O

C04107 O O
is O O
an O O
anonymous O O
microsatellite O O
marker O O
closely O O
linked O O
to O O
CT B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O O

However O O
, O O
BAC O O
clones O O
containing O O
ATP7B O O
and O O
C04107 O O
mapped O O
to O O
the O O
canine O O
chromosome O O
regions O O
CFA22q11 O O
and O O
CFA10q26 O O
, O O
respectively O O
, O O
demonstrating O O
that O O
WD B B_LOCATION/B_PERSON
cannot O O
be O O
homologous O O
to O O
CT B B_LOCATION/B_ORGANIZATION
. O O

The O O
copper O O
transport O O
genes O O
CTR1 O O
and O O
CTR2 O O
were O O
also O O
excluded O O
as O O
candidate O O
genes O O
for O O
CT B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
since O O
they O O
both O O
mapped O O
to O O
canine O O
chromosome O O
region O O
CFA11q22 O O
. O O

2 O O
- O O
22 O B_MEASURE
. O O

5 O B_NUMBER[MEASURE]
. O O

A O O
transcribed O B_GENE/B_MEASURE
sequence O I_GENE/I_MEASURE
identified O O
from O O
the O O
C04107 O B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O O
containing O O
BAC O B_GENE/B_DISEASE
was O O
found O O
to O O
be O O
homologous O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O O
a O O
gene O B_GENE/B_LOCATION
expressed O O
from O O
human O B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
chromosome O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2p13 O I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O O
p16 O B_MEASURE
, O O
a O O
region O B_LOCATION/B_PERSON
devoid O B_LOCATION/I_PERSON
of O O
any O O
positional O B_GENE
candidate O I_GENE
genes O I_GENE
. O O

Molecular O O
analysis O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
in O O
205 O O
families O O
: O O
extended O O
genotype O O
- O O
phenotype O O
correlations O O
in O O
FAP B B_DISEASE/B_PERSON
and O O
evidence O O
for O O
the O O
role O O
of O O
APC B B_MEASURE/B_BACTERIUM[BIO]
amino O O
acid O O
changes O O
in O O
colorectal B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
predisposition O O
. O O

BACKGROUND O O
/ O O
AIMS O O
The O O
development O O
of O O
colorectal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
a O O
variable O O
range O O
of O O
extracolonic O O
manifestations O O
in O O
familial B B_DISEASE
adenomatous I I_DISEASE
polyposis I I_DISEASE
( O O
FAP B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
the O O
result O O
of O O
the O O
dominant O O
inheritance O O
of O O
adenomatous B B_DISEASE/B_GENE
polyposis I B_DISEASE/I_GENE
coli I B_DISEASE/I_GENE
( O O
APC B B_GENE/B_BACTERIUM[BIO]
) O O
gene O O
mutations O O
. O O

In O O
this O O
study O O
, O O
direct O O
mutation O O
analysis O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
was O O
performed O O
to O O
determine O O
genotype O O
- O O
phenotype O O
correlations O O
for O O
nine O O
extracolonic O O
manifestations O O
and O O
to O O
investigate O O
the O O
incidence O O
of O O
APC B B_GENE/B_PERSON
mutations O O
in O O
non O O
- O O
FAP O O
colorectal B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
. O O

METHODS O O
The O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
was O O
analysed O O
in O O
190 O O
unrelated O O
FAP B B_DISEASE/B_PERSON
and O O
15 O O
non O O
- O O
FAP O O
colorectal B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
patients O O
using O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
, O O
the O O
protein O O
truncation O O
test O O
, O O
and O O
direct O O
sequencing O O
. O O

RESULTS O O
Chain O O
terminating O O
signals O O
were O O
only O O
identified O O
in O O
patients O O
belonging O O
to O O
the O O
FAP B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
( O O
105 O O
patients O O
) O O
. O O

Amino O O
acid O O
changes O O
were O O
identified O O
in O O
four O O
patients O O
, O O
three O O
of O O
whom O O
belonged O O
to O O
the O O
non O O
- O O
FAP O O
group O O
of O O
colorectal B B_DISEASE/B_NUMBER[MEASURE]
cancer I B_DISEASE/I_NUMBER[MEASURE]
patients O O
. O O

Genotype O O
- O O
phenotype O O
correlations O O
identified O O
significant O O
differences O O
in O O
the O O
nature O O
of O O
certain O O
extracolonic O O
manifestations O O
in O O
FAP B B_DISEASE/B_NUMBER[MEASURE]
patients O O
belonging O O
to O O
three O O
mutation O O
subgroups O O
. O O

CONCLUSIONS O B_MEASURE/B_PERSON
Extended O I_MEASURE
genotype O I_MEASURE
- O O
phenotype O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations O I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
made O O
in O O
this O O
study O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O O
have O O
the O O
potential O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O O
determine O O
the O O
most O O
appropriate O B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance O I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
prophylactic O B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimens O I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O O
those O O
patients O B_PERSON
with O O
mutations O B_DISEASE/B_GENE
associated O O
with O O
life O B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
threatening O O
conditions O B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

This O O
study O O
also O O
provided O O
evidence O O
for O O
the O O
pathological O O
nature O O
of O O
amino O O
acid O O
changes O O
in O O
APC O O
associated O O
with O O
both O O
FAP B B_DISEASE/B_GENE
and O O
non O O
- O O
FAP O O
colorectal B B_DISEASE
cancer I I_DISEASE
patients O O
. O O
. O O

Inherited B B_DISEASE
colorectal I I_DISEASE
polyposis I I_DISEASE
and O O
cancer B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
risk O O
of O O
the O O
APC O O
I1307K O O
polymorphism O O
. O O

Germ O O
- O O
line O O
and O O
somatic O O
truncating O O
mutations O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
are O O
thought O O
to O O
initiate O O
colorectal B B_DISEASE
tumor I I_DISEASE
formation O O
in O O
familial B B_DISEASE_ADJECTIVE[DISEASE]
adenomatous I I_DISEASE_ADJECTIVE[DISEASE]
polyposis I I_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]
and O O
sporadic O O
colorectal O O
carcinogenesis O O
, O O
respectively O O
. O O

Recently O O
, O O
an O O
isoleucine O O
- O O
- O O
> O O
lysine O O
polymorphism O O
at O O
codon O O
1307 O O
( O O
I1307K O O
) O O
of O O
the O O
APC B B_GENE/B_BACTERIUM[BIO]
gene O O
has O O
been O O
identified O O
in O O
6 O O
% O O
- O O
7 O O
% O O
of O O
the O O
Ashkenazi O O
Jewish O O
population O O
. O O

To O O
assess O O
the O O
risk O O
of O O
this O O
common O O
APC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allelic O O
variant O O
in O O
colorectal O O
carcinogenesis O O
, O O
we O O
have O O
analyzed O O
a O O
large O O
cohort O O
of O O
unselected O O
Ashkenazi O O
Jewish O O
subjects O O
with O O
adenomatous B B_DISEASE/B_GENE
polyps I I_DISEASE/I_GENE
and O O
. O O
or O O
colorectal B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
APC O O
I1307K O O
polymorphism O O
. O O

The O O
APC O B_DISEASE
I1307K O I_DISEASE
allele O I_DISEASE
was O O
identified O O
in O O
48 O B_MEASURE
( O O
10 O B_MEASURE
. O O
1 O B_MEASURE
% O I_MEASURE
) O O
of O O
476 O B_PERSON/B_BIO
patients O I_PERSON/I_BIO
. O O

Compared O O
with O O
the O O
frequency O B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
two O B_PERSON/B_BIO
separate O I_PERSON/I_BIO
population O I_PERSON/I_BIO
control O I_PERSON/I_BIO
groups O I_PERSON/I_BIO
, O O
the O O
APC O B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
I1307K O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
allele O I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O O
associated O O
with O O
an O O
estimated O O
relative O B_MEASURE/B_DISEASE
risk O I_MEASURE/I_DISEASE
of O O
1 O B_TIME[MEASURE]/B_DISEASE
. O O

5 O O
- O O
1 O B_MEASURE
. O O

7 O O
for O O
colorectal B B_PERSON/B_MEASURE
neoplasia I I_PERSON/I_MEASURE
( O O
both O O
P O O
= O O
. O O
01 O O
) O O
. O O

Furthermore O O
, O O
compared O O
with O O
noncarriers O O
, O O
APC O O
I1307K O O
carriers O O
had O O
increased O O
numbers O O
of O O
adenomas B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
colorectal B B_DISEASE
cancers I I_DISEASE
per O O
patient O O
( O O
P O O
= O O
. O O
03 O O
) O O
, O O
as O O
well O O
as O O
a O O
younger O O
age O O
at O O
diagnosis O O
. O O

We O O
conclude O O
that O O
the O O
APC O O
I1307K O O
variant O O
leads O O
to O O
increased O O
adenoma B B_DISEASE
formation O O
and O O
directly O O
contributes O O
to O O
3 O O
% O O
- O O
4 O O
% O O
of O O
all O O
Ashkenazi O O
Jewish O O
colorectal B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
. O O

The O O
estimated O O
relative O O
risk O O
for O O
carriers O O
may O O
justify O O
specific O O
clinical O O
screening O O
for O O
the O O
360 O O
, O O
000 O O
Americans O O
expected O O
to O O
harbor O O
this O O
allele O O
, O O
and O O
genetic O O
testing O O
in O O
the O O
setting O O
of O O
long O O
- O O
term O O
- O O
outcome O O
studies O O
may O O
impact O O
significantly O O
on O O
colorectal B B_DISEASE
cancer I I_DISEASE
prevention O O
in O O
this O O
population O O
. O O

Localization O O
of O O
human O O
BRCA1 O O
and O O
its O O
loss O O
in O O
high O O
- O O
grade O O
, O O
non B B_DISEASE
- I I_DISEASE
inherited I I_DISEASE
breast I I_DISEASE
carcinomas I I_DISEASE
. O O

Although O O
the O O
link O O
between O O
the O O
BRCA1 O O
tumour B B_DISEASE
- O O
suppressor O O
gene O O
and O O
hereditary B B_DISEASE
breast I I_DISEASE
and I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
is O O
established O O
, O O
the O O
role O O
, O O
if O O
any O O
, O O
of O O
BRCA1 O O
in O O
non B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
familial I I_DISEASE/I_ORGANISM_FUNCTION
cancers I I_DISEASE/I_ORGANISM_FUNCTION
is O O
unclear O O
. O O

BRCA1 O O
mutations O O
are O O
rare O O
in O O
sporadic B B_DISEASE/B_PERSON
cancers I I_DISEASE/I_PERSON
, O O
but O O
loss O O
of O O
BRCA1 O O
resulting O O
from O O
reduced O O
expression O O
or O O
incorrect O O
subcellular O O
localization O O
is O O
postulated O O
to O O
be O O
important O O
in O O
non B B_DISEASE
- I I_DISEASE
familial I I_DISEASE
breast I I_DISEASE
and I I_DISEASE
ovarian I I_DISEASE
cancers I I_DISEASE
. O O

Epigenetic O B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
loss O B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
however O O
, O O
has O O
not O O
received O O
general O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acceptance O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due O O
to O O
controversy O B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O O
the O O
subcellular O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization O I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O O
BRCA1 O B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins O I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O O
reports O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O O
which O O
have O O
ranged O O
from O O
exclusively O O
nuclear O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O O
to O O
conditionally O O
nuclear O O
, O O
to O O
the O O
ER O B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
/ O O
golgi O B_LOCATION/B_PERSON
, O O
to O O
cytoplasmic O B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
invaginations O I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
into O O
the O O
nucleus O B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O O

In O O
an O O
attempt O B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O O
resolve O O
this O O
issue O B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O O
we O O
have O O
comprehensively O O
characterized O O
19 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O O
BRCA1 O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antibodies O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O O

These O O
reagents O O
detect O O
a O O
220 O O
- O O
kD O O
protein O O
localized O O
in O O
discrete O O
nuclear O O
foci O O
in O O
all O O
epithelial O O
cell O O
lines O O
, O O
including O O
those O O
derived O O
from O O
breast B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
malignancies I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Immunohistochemical O O
staining O O
of O O
human O O
breast O O
specimens O O
also O O
revealed O O
BRCA1 O O
nuclear O O
foci O O
in O O
benign O O
breast O O
, O O
invasive B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lobular I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
low B B_DISEASE
- I I_DISEASE
grade I I_DISEASE
ductal I I_DISEASE
carcinomas I I_DISEASE
. O O

Conversely O O
, O O
BRCA1 O O
expression O O
was O O
reduced O O
or O O
undetectable O O
in O O
the O O
majority O O
of O O
high O O
- O O
grade O O
, O O
ductal B B_DISEASE/B_PERSON
carcinomas I I_DISEASE/I_PERSON
, O O
suggesting O O
that O O
absence O O
of O O
BRCA1 O O
may O O
contribute O O
to O O
the O O
pathogenesis O O
of O O
a O O
significant O O
percentage O O
of O O
sporadic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
breast I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O
. O O

